GLP‑1 news from 2026
1054 dated, sourced GLP-1 developments from 2026: approvals, trial results, prices, lawsuits, compounding and culture.
- Safety
Rule 702 general causation hearing opens in MDL 3094
Judge Marston opened a multi-day hearing on whether plaintiffs' general causation experts may testify, alongside defense motions for summary judgment on multiple injury categories. The Eastern District of Pennsylvania's MDL 3094 page states the hearing runs from September 14, 2026 through September 18, 2026. It is the pivotal event in the litigation to date: without admissible general causation evidence, claims cannot reach a jury. As of September 14, 2026 no ruling had issued.
- Prices
Status check: the two Medicare prices for semaglutide in 2027 still have not been reconciled
Two different government prices for semaglutide are scheduled to apply in 2027 and CMS has not publicly resolved which governs. The Inflation Reduction Act negotiation set a maximum fair price of about $274 for the Ozempic, Rybelsus and Wegovy group effective January 1, 2027, with $276.78 on commonly used Ozempic and Rybelsus presentations and $385.63 on the highest Wegovy dose. The separate most-favored-nation agreement set $245 for Medicare and Medicaid. Analysts have said publicly it is unclear which price is the real one.
- Safety
Still no NAION warning on any US tirzepatide label
As of this refresh, full-text search of the current Mounjaro and Zepbound prescribing information returns no occurrence of 'NAION' or 'optic neuropathy', 21 months after the FDA first listed NAION as a class potential signal naming both products, and 15 months after European regulators added it to semaglutide labeling. No FDA statement explaining the divergence was located.
- Safety
Australian regulator finds eight times the approved semaglutide dose in a product sold as retatrutide
Australia's Therapeutic Goods Administration published a safety alert on September 14 after laboratory testing of a product sold as retatrutide, obtained in its original unmarked vial, found no retatrutide at all but undeclared semaglutide at roughly eight times the level in approved semaglutide products. The consumer who used it vomited uncontrollably, tore an esophagus and required hospital treatment. The TGA said retatrutide is unapproved by any comparable regulator, that any retatrutide obtained outside a clinical trial may be counterfeit, and that it has not located the source; penalties reach A$1.82 million per breach for individuals and seven years imprisonment.
- Safety
Court weighs expert evidence in the GLP-1 stomach injury MDL
A hearing on the admissibility of plaintiffs' expert evidence under Rule 702 in MDL 3094 was scheduled for mid-September 2026, the litigation's biggest test so far. Litigation trackers give the window variously as September 10 to 18 and September 14 to 18; the exact start date is unconfirmed against the court docket. The rulings will decide what scientific testimony reaches bellwether juries.
- Research
EASD 2026 in Milan sets up the next round of competitor data
The 62nd annual meeting of the European Association for the Study of Diabetes runs September 28 to October 2 at the Milan Convention Centre, with a scientific program from September 29. Expected obesity and incretin presentations include Eli Lilly's eloralintide plus tirzepatide Phase 2 data on September 30, SYNCHRONIZE-2 results for Boehringer Ingelheim's survodutide in obesity with type 2 diabetes, AstraZeneca's AZD6234 amylin data, and additional Hengrui ribupatide results. Roche's Pharma Day on September 28 falls in the same window.
- Business
Generic liraglutide cash prices run three to eleven times below the weekly brands, depending on the dose
GoodRx cash prices captured on 2026-09-14 show generic liraglutide at $112.19 with a coupon for a two-pen diabetes carton (retail $615.85) and $372.45 for a five-pen weight-management carton (retail $717.63), against listings above $1,200 for Ozempic and Mounjaro on the same site. That is roughly an eleven-fold gap at the 1.8 mg diabetes dose but only about a three-fold gap at the 3 mg weight-management dose, where generic competition is thinner. Nine companies list a Victoza-referenced product and four a Saxenda-referenced product in the FDA drug code directory; those thirteen labels sit on eight generic applications plus one authorized generic.
- Research
Label check: what the current Zepbound prescribing information actually says about dosing
The Zepbound US prescribing information, revised 08/2026 and read in full on this date, lists four presentations: single-dose pen, single-dose vial, multi-dose vial and single-patient-use KwikPen, with the multi-dose vial and KwikPen each holding four doses of one strength. The recommended starting dosage is 2.5 mg weekly for 4 weeks; recommended maintenance dosages are 5, 10 or 15 mg for weight reduction and 10 or 15 mg for obstructive sleep apnea, with a 15 mg maximum. Recent Major Changes include a never-share KwikPen warning (01/2026), a severe gastrointestinal adverse reactions update (02/2026), removal of the suicidal behavior and ideation warning (02/2026), and a diabetic retinopathy complications update (08/2026). SURMOUNT-MAINTAIN is not yet reflected in the label, which still cites the SURMOUNT-4 randomized withdrawal trial.
- Business
Novo Nordisk rebrands as 'Novo' and introduces 'The Novo Way'
One week before its Capital Markets Day, the company adopted the single name 'Novo' for day-to-day use with the tagline 'Lasting Health Starts Now', keeping Novo Nordisk A/S as its legal name and the Apis bull logo in updated form. It also launched a cultural framework built on customer obsession, competitiveness, clarity, and care and integrity. Product brand names were unchanged.
- Competition
Roche heads into Pharma Day with three obesity mechanisms in hand
Roche's September 28 Pharma Day is expected to cover Phase 2 results for enicepatide in obesity with type 2 diabetes, whose companion study carries a September 24 completion date, plus updates on the once-daily oral CT-996, the antibody emugrobart in combination with tirzepatide, and petrelintide with partner Zealand Pharma. Roche has said it wants to be a top-three obesity player and has pointed to enicepatide, which produced 22.5 percent placebo-adjusted weight loss at 48 weeks in Phase 2, as a potential best-in-class asset. The August Hanmi license added a third non-incretin mechanism alongside amylin.
- Prices
Semaglutide cash prices settle into a $149 to $499 band while list prices stay above $1,000
As of mid-September 2026 the cheapest branded route is the Wegovy or Ozempic pill at $149 a month, the pens run $199 introductory and $349 standard, Wegovy HD is $399 and Ozempic 2 mg is $499, all against list prices of $1,027.51 for Ozempic and $1,349.02 for Wegovy.
- Competition
Sixteen challenger programs are now in Phase 3, and none reads out before 2027
Recruiting Phase 3 obesity programs in the United States as of September 2026 include aleniglipron with ACCOMPLISH-1 and -2, eloralintide across five ENLIGHTEN trials, enicepatide in three trials, elecoglipron in nine, AZD6234 in three SELENE trials, ribupatide in three KaiNETIC trials, berobenatide, ASC30 with AURORA-1 and -2, and several MariTide outcomes and extension studies. Earliest primary completions cluster in 2028, with MariTide's January 2027 dates the nearest exception. The practical consequence is that the branded market stays a two-company market through 2027 whatever the pipeline looks like on paper.
- Policy
Status check: BALANCE state window closes January 1 with one committed state and no CMS participant count
With 109 days left in the state Medicaid application window that closes January 1, 2027, CMS has still not published a participant count for the BALANCE model, and only Indiana has been publicly identified as committing. CMS delayed the Medicare Part D half of BALANCE indefinitely in April after insufficient plan interest and extended the Bridge through December 2027 instead. Nothing has been announced about what covers Medicare obesity prescriptions in 2028.
- Prices
Status check: Bridge copays are excluded from every Part D affordability mechanism
Because the Medicare GLP-1 Bridge operates outside the Part D benefit, the $50 monthly copay does not count toward the Part D deductible or the $2,100 annual out-of-pocket cap in 2026, cannot be reduced by Extra Help, and cannot be spread across the year through the Medicare Prescription Payment Plan. Twelve months of Bridge copays comes to $600 in spending that does nothing to move a beneficiary toward catastrophic coverage on their other medications.
- Policy
Status check: no state has been named as a BALANCE participant and Medicare coverage after 2027 remains undecided
Two coverage questions that shape 2028 for US GLP-1 patients are open as of mid-September. CMS has not named a single participating state under BALANCE, the model intended to replace the Bridge in Medicaid, and has announced no successor arrangement for Medicare obesity coverage when the Bridge expires December 31, 2027. The Treat and Reduce Obesity Act, which would lift the statutory Part D exclusion, has 51 House and 19 Senate cosponsors and has not moved.
- Prices
Status check: Novo Nordisk's $675 list price still lands well above every negotiated and cash price
Novo Nordisk's announced reduction takes the US list price of Wegovy, Ozempic and Rybelsus to $675 a month on January 1, 2027, a cut of roughly 50 percent for Wegovy and 35 percent for Ozempic. That figure sits far above the $245 most-favored-nation price, the roughly $274 Inflation Reduction Act maximum fair price, and NovoCare cash prices of $349 for the pen and $149 to $299 for the pill. The cut matters mainly for patients on coinsurance or inside a deductible, not for cash payers.
- Prices
Status check: the Zepbound formulary class action against CVS Caremark remains live as restoration nears
The class action challenging CVS Caremark's July 2025 removal of Zepbound from its largest commercial templates survived a motion to dismiss in late August and remains active as the October 1 restoration approaches. Caremark's May 28 announcement returns Zepbound as an additional preferred option on formularies covering an estimated 25 million to 30 million people, but employers still decide whether to cover weight-management drugs at all, so formulary placement does not by itself restore any individual's coverage.
- Science
The lean-mass race now spans a dozen programs and one approved drug
Preserving muscle during incretin-driven weight loss has become its own competitive lane, with Eli Lilly's bimagrumab, Scholar Rock's apitegromab, Regeneron's trevogrumab with garetosmab, and Veru's oral enobosarm all in mid-stage testing alongside GLP-1 therapy, and Roche holding two non-incretin bets in petrelintide and the newly licensed HM17321. Published Phase 2 work reported that apitegromab with tirzepatide gave 54.9 percent greater relative lean-mass retention than tirzepatide alone, and that bimagrumab plus semaglutide produced roughly 22 percent weight loss with about 92 percent of it from fat. Scholar Rock's September 11 approval in spinal muscular atrophy is the first regulatory validation of the underlying mechanism, though none of these agents is approved for use with obesity drugs.
- Research
Tirzepatide evidence base: what has reported and what has not
As of this date, tirzepatide has published results across SURPASS 1-6, SURPASS J-mono, J-combo, AP-Combo, PEDS, SWITCH, EARLY, CN-MONO and CVOT; SURMOUNT 1-5, OSA, J, CN and MAINTAIN; SUMMIT; and SYNERGY-NASH. Still unreported: SURMOUNT-MMO (estimated October 2027), SURPASS-T1D-1 and -2 (estimated November 2026), TRIUMPH-5 (estimated November 2026), TREASURE-CKD (completed, unreported) and SURPASS-CN-INS (completed, unpublished).
- Business
Where semaglutide stands in September 2026
As of mid-September 2026 semaglutide is sold as Ozempic injection and tablets, Wegovy injection, Wegovy HD and the Wegovy pill, covering diabetes, heart, kidney, weight and liver indications. Novo Nordisk faces a December CagriSema decision, an expanding generic threat abroad and a US market where Eli Lilly leads on prescriptions.
- Prices
Aetna posts a Standard Control Choice formulary addition for Zepbound effective October 1
Aetna's formulary update documents list Zepbound as an addition to the Standard Control Formulary Choice in the Endocrine and Metabolic, Antiobesity class effective October 1, 2026, the operational reflection of the Caremark decision inside a CVS Health-owned carrier. The listing is the first plan-level confirmation that the restoration is being implemented rather than merely announced, though exclusions, precertification, quantity limits and step therapy still apply and remain subject to change.
- Research
Amgen's MariTide readouts now sit outside the 2026 window
MariTide, a peptide-antibody conjugate that activates the GLP-1 receptor while blocking the GIP receptor, is in nine global Phase 3 studies across obesity, obstructive sleep apnea, cardiovascular disease and heart failure, with the primary readout for MARITIME-1 guided to early 2027 and MARITIME-1 and MARITIME-2 carrying primary completion dates of January 21, 2027. Phase 2 reported roughly 20 percent average weight loss at 52 weeks on the efficacy estimand without a plateau, and 12.3 to 16.2 percent on the treatment-policy estimand, alongside high discontinuation and vomiting rates that led Amgen to slow Phase 3 dose escalation. A Phase 3 switch study is enrolling patients moving off weekly tirzepatide or semaglutide.
- Research
AstraZeneca's obesity case rests on two readouts due this fall
AstraZeneca started three Phase 3 SELENE trials of the amylin analog AZD6234 in August 2026 with primary completion in August 2028, one of them testing the drug as an add-on for people already on an incretin, and moved the oral GLP-1 elecoglipron into Phase 3 in obesity and type 2 diabetes with readouts analysts place in 2027 or 2028. Nearer term, the company is expected to present AZD6234 data at EASD, plus Phase 2 results in participants on stable background GLP-1 therapy and from the Phase 2b ASCEND study of the GLP-1/glucagon dual agonist AZD9550 combined with AZD6234. Detailed Phase 2 numbers for AZD6234 have not been published.
- Search trends
Baseline keyword and SERP landscape captured for semaglutides.org
A dedicated tirzepatide pass harvested 13,213 clean US queries from Google and DuckDuckGo autocomplete across 86 seeds, clustered them into 38 topic clusters, probed 75 competitor URLs for live status, and sampled r/Zepbound, r/Mounjaro and r/compoundedtirzepatide. The first pass had tracked 67 Mounjaro and 88 Zepbound queries; this pass raises tirzepatide coverage to 1,213 tracked queries and adds root-level Mounjaro, Zepbound and tirzepatide hubs to the site architecture.
- Compounding
Branded tirzepatide self-pay prices sit far below the shortage-era gap
A price index covering 14 telehealth providers recorded a median first-month price of $197 for compounded semaglutide and $299 for compounded tirzepatide as of September 3, 2026, against $199 to $349 for the Wegovy pen and $299 to $449 for Zepbound before membership fees. Noom's brand-medication track was listed at $39 for the first month then $129 a month, and WW Med+ at $25 a month for an introductory period, as read from company sites on September 5. The persistence of the gap is why the compounded market survives enforcement that has removed its main legal footing.
- FDA & regulation
China's semaglutide generics remain stuck behind data exclusivity
Semaglutide's Chinese patent has lapsed, but generic approvals from Hangzhou Jiuyuan Gene Engineering, Livzon Pharmaceutical Group and The United Laboratories remain suspended rather than rejected while regulators work through a data exclusivity period tied to the China-Switzerland free trade agreement. Jiuyuan's Jikeqin, a generic referencing Wegovy, was accepted for review in February 2026; Huadong Medicine and CSPC have filings of their own. Eleven or more Chinese programs are in late-stage development, so the queue behind the exclusivity question is long.
- Business
Chinese licensing keeps setting the price of entry into obesity
Deal trackers covering 2026 put AstraZeneca's obesity and diabetes collaboration with CSPC at the top of the year's licensing table at up to $18.5 billion with $1.2 billion up front, ahead of Bristol Myers Squibb with Hengrui at up to $15.2 billion and Pfizer with Innovent at up to $10.5 billion. Menarini's September deal for Gan & Lee's bofanglutide and Genentech's August license for Hanmi's HM17321 extend the pattern into Europe and Korea. More than 100 China-origin licensing deals have been signed since the start of 2025, with the quarterly peak in the first three months of 2026.
- Policy
CMS has not yet published the 2027 Medicare Advantage and Part D landscape a month before open enrollment
CMS finalized 2027 Medicare Advantage and Part D rules and payment policies but said the finalized plan landscape, average premiums and county-level plan details would be released in mid-to-late September, ahead of the annual enrollment period running October 15 to December 7. Because the Medicare GLP-1 Bridge operates outside Part D, plan choice does not determine Bridge eligibility, but it does determine cost sharing for anyone routed back to Part D by a diabetes, sleep apnea or MASH diagnosis.
- Research
Corbus reports 5 percent weight loss for its peripheral CB1 pill in Phase 1b
Corbus Pharmaceuticals announced positive topline data from CANYON-1, a Phase 1b study of the once-daily oral CB1 inverse agonist CRB-913 in obesity, reporting statistically significant mean weight loss of 5.0 percent at the 60 mg dose after 12 weeks against 0.0 percent on placebo, with 44.4 percent of participants losing at least 5 percent and no plateau observed. The company plans a Phase 2 obesity study in 2027 and will present full data in a late-breaking session at ObesityWeek in November. CRB-913 is designed to be far less brain-penetrant than earlier CB1 drugs, the class withdrawn for neuropsychiatric harm.
- Prices
India's generic semaglutide market settles into a price war six months on
Six months after India's semaglutide patent lapsed on March 20, 2026, more than 40 approved generic brands are in circulation and pricing has compressed sharply: Dr. Reddy's launched Obeda at about 4,200 rupees a month while rivals including Sun Pharmaceutical, Lupin, Natco and Mankind launched on the same day at prices reported as low as 325 to 750 rupees per weekly injection. Novo Nordisk has cut its own Indian prices in response, from a starting point of roughly 8,800 to 10,000 rupees a month. Dr. Reddy's has said it is targeting 87 countries in 2026, with Canada and Brazil already approving generics.
- FDA & regulation
Mazdutide's US path stays theoretical as Lilly publishes a Phase 2
Mazdutide remains approved only in China, for chronic weight management since June 2025 and for type 2 diabetes glycemic control since September 2025, and is not approved or under review by the FDA. Eli Lilly, which originated the molecule and holds rights outside China, published a 179-participant US Phase 2 in The Lancet Diabetes and Endocrinology on August 21, 2026 but has announced no Phase 3 program or FDA filing. Lilly's stated US obesity priorities remain tirzepatide, orforglipron and retatrutide.
- Competition
Pfizer's obesity case now rests on a single monthly injectable
After cutting MET-224o and PF-07976016 in August, Pfizer's obesity portfolio centers on berobenatide, the ultra-long-acting GLP-1 formerly known as MET-097i, with three Phase 3 trials already running, VESPER-4, VESPER-5 and VESPER-6, and a plan to advance ten Phase 3 studies during 2026 including a switch trial from approved weekly therapies to monthly dosing. Phase 2b data showed placebo-corrected weight loss of up to 12.3 percent at 28 weeks on the medium Phase 3 monthly dose, and about 16 percent mean loss over 32 weeks at the high weekly dose. Leerink has said the asset's value hinges on Phase 3 results in 2028.
- FDA & regulation
Status check: GLOBE and GUARD drug-pricing model rules remain unfinalized nine months after proposal
CMS proposed two Innovation Center payment models on December 23, 2025 that would change how inflation rebates are calculated using international price benchmarks: GLOBE for certain Part B drugs and GUARD for certain Part D drugs. Comments closed February 23, 2026 and neither rule has been finalized. The American Hospital Association warned that manufacturers would likely adjust list prices to reduce GLOBE rebates, with knock-on effects for Average Manufacturer Price and therefore Medicaid rebate math on drugs including GLP-1s.
- Policy
Status check: Marketplace plans remain the weakest GLP-1 coverage channel heading into 2027
Obesity medications are not an essential health benefit under the Affordable Care Act, so Marketplace carriers are not required to cover them. A Leverage|Axiaci review of all 300 carriers offering 2026 individual and family plans found only 26 covering GLP-1s for obesity, concentrated in nine states, with all but four restricting coverage to a BMI of 40 or above. Enrollment with any such coverage fell from 3.6 million in 2024 to 2.8 million in 2026, and 2027 benchmark premiums are rising again.
- Policy
Status check: PBM delinking under the 2026 appropriations law does not bite until 2028
The Consolidated Appropriations Act, 2026 introduced delinking in Medicare Part D, limiting pharmacy benefit manager compensation to bona fide service fees unconnected to drug price or rebate volume, and required standardized transparency and full rebate pass-through for ERISA plans. Most provisions do not take effect until August 2028, with some in January 2029. For GLP-1 formulary decisions through 2027, the rebate-driven economics that produced the Caremark exclusion and its reversal remain in place.
- Research
Survodutide heads to EASD without a filing date
Boehringer Ingelheim has not published a US filing date or expected launch for survodutide despite reporting up to 16.6 percent average weight loss at 76 weeks in the pivotal SYNCHRONIZE-1 trial in April 2026, with about 85 percent of participants losing at least 5 percent. SYNCHRONIZE-2 results in participants with type 2 diabetes are expected at EASD at the end of September. The GLP-1/glucagon dual agonist holds FDA breakthrough therapy designation in MASH, with two Phase 3 liver trials under way and a cardiovascular outcomes trial running.
- Compounding
The compounding fight has moved from courtrooms to dockets and ad panels
As of mid-September 2026 the litigation track that defined 2025 has largely resolved against compounders: the Fifth Circuit upheld both shortage delistings, a federal judge dismissed the Strive antitrust suit with prejudice, and Lilly's cases against telehealth platforms survive in narrowed form. What remains open sits in administrative and self-regulatory channels: the unfinalized 503B bulks exclusion, Novo's demonstrable-difficulties nomination, the 503A peptide bulks rulemaking, and ten National Advertising Division cases. The Seventh Circuit argument on retatrutide's classification on September 24 is the next scheduled decision point.
- Research
Viking's VK2735 maintenance data remains the quarter's outstanding small-cap readout
Viking Therapeutics has guided data from a Phase 1 maintenance-dosing study of subcutaneous VK2735 to the third quarter of 2026, testing whether patients can hold weight loss on monthly injections or oral regimens after weekly induction, and the company has said patients retained most of their loss four weeks after the final dose. Phase 3 VANQUISH-1 and VANQUISH-2 are fully enrolled, and a Phase 3 of the oral formulation is guided to start in the fourth quarter. Viking closed the second quarter with $502 million in cash after a July follow-on raise of about $159.6 million.
- Culture
AI analysis of 400,000 Reddit posts surfaces side effects that rarely reach trials
Coverage of a Penn AI study analyzing roughly 400,000 GLP-1 Reddit posts highlighted symptom clusters users discuss heavily but that appear little in trial adverse event tables, including taste changes, altered alcohol response and sleep effects. Social-media mining cannot establish incidence or causation and skews toward people with problems or enthusiasm. It is being used as a hypothesis generator for formal pharmacovigilance.
- Business
Analysts size retatrutide at up to $30 billion by 2031 ahead of a Q1 2027 filing
Clarivate projections circulated in September put retatrutide at roughly $30 billion of revenue by 2031, split about $10 billion in obesity and $20 billion in diabetes, with a Biologics License Application planned for the first quarter of 2027 and a 2028 launch window. The same analysis put Foundayo at about $16 billion by 2031. Lilly's capital expenditure reached $9.9 billion over the trailing twelve months, largely to build the capacity those forecasts assume.
- Business
Citi raises its Lilly price target to $1,600 after a month of share weakness
Citi analyst Geoff Meacham raised his Lilly price target from $1,500 to $1,600 with a Buy rating, framing the incretin franchise as a structural multi-year story even as the shares fell about 16% over the preceding month on pricing headlines. The bull case rests on tirzepatide holding roughly six of ten US obesity prescriptions and about seven of ten injectable ones, Foundayo's prescriber expansion, and a retatrutide filing in the first quarter of 2027. The bear case is that the 9% US price decline excluding rebate adjustments marks the start of a margin unwind.
- Business
Doustdar's case: obesity will not be a winner-takes-all market
Across an August Reuters interview, a Yahoo Finance sit-down and the September rebrand, chief executive Mike Doustdar has pressed one argument: obesity treatment will not produce a single winner, because growth comes from expanding the treated population, new formulations and new indications rather than from share stealing. He has put the US obesity population near 110 million with only about 15 to 20 million on any GLP-1, branded or compounded. It is the framing Novo Nordisk will carry into its Capital Markets Day.
- Science
Eloralintide moves into Phase 3 alone and in combination with tirzepatide
A September review of the amylin class confirmed that Lilly's selective amylin receptor agonist eloralintide is now in Phase 3 after Phase 2 results of up to 20% weight reduction at the 9 mg dose, and that Lilly is separately testing it in combination with tirzepatide. ENLIGHTEN-1 and ENLIGHTEN-6 both began in February 2026 and were still recruiting in September, with primary results not expected before 2028. Competing amylin programs from Novo Nordisk, Zealand and Roche are running on overlapping timelines.
- Business
Kailera trades below its April IPO price as data slips to 2027 and beyond
Kailera Therapeutics closed recently at $18.51 with a market capitalization of about $2.40 billion, down roughly 29 percent since shares began trading in April, against $1.17 billion in cash and marketable securities and runway into mid-2028. Its catalysts sit further out than most of the challenger field: Phase 2b ribupatide injection data mid-2027, KAI-7535 Phase 2 and KAI-4729 Phase 1 in 2027, and the global Phase 3 KaiNETIC readout in 2028. The company is a test case for whether public markets will fund a China-origin obesity franchise through a long data gap.
- Research
ObesityWeek 2026 late-breakers start to surface
ObesityWeek runs November 14 to 17 in Washington, DC, and several competitor programs have already confirmed late-breaking slots: Corbus will present full CANYON-1 data for CRB-913, Biomed Industries has a Phase 2 abstract for the quadruple receptor agonist NA-931 reporting weight loss with lean-mass preservation, and MannKind and Rose Pharma have an accepted abstract on patient preference for a rapid-acting, short-duration GLP-1. The late-breaking abstract deadline closed on July 22. The meeting is the last major US stage of 2026 for pipeline data.
- Compounding
Telehealth platforms that still offer compounded GLP-1s narrow to a patient-specific pathway
Provider comparisons published in late summer show which platforms still route patients to compounded GLP-1s under the narrow patient-specific pathway, including Mochi Health, Ivim Health, Eden, Zealthy, Noom Med and Found, while the largest platforms have moved to branded product. U.S. News published its first ratings of GLP-1 telehealth platforms on August 12, naming Amazon One Medical best for insurance support, Found best for clinical support, Noom best for supplemental support and Ro best for customer satisfaction. Several compounded-pathway providers have received FDA warning letters or are defendants in manufacturer lawsuits.
- Business
Lilly presents at the Morgan Stanley Global Healthcare Conference
Lilly appeared at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14, 2026, one of the few scheduled venues between second-quarter earnings and the third-quarter report where the company addresses pipeline, pricing and commercialization questions publicly. Investors were looking for updates on Foundayo's ramp, the pending type 2 diabetes decision and retatrutide's filing timing. The company paid its regular quarterly dividend earlier in the week.
- Prices
Canadian grocers report generic semaglutide lifting pharmacy volumes
Canadian Press reporting on grocery-chain pharmacy units found generic semaglutide driving higher prescription volumes even as price deflation pressures same-store sales measured in dollars, with Metro's early experience cited as evidence that access gains can offset part of the revenue hit. Health Canada has approved three generic semaglutide products and continues to review more, making Canada the first G7 country to authorize them. Canada remains the clearest real-world test of what generic semaglutide does to a developed-market branded franchise.
- Science
GLP-1 use linked to fewer psychiatric hospitalizations in bipolar disorder
Researchers reported that people with bipolar disorder had significantly lower rates of psychiatric hospitalization during periods when they were taking GLP-1 medicines than when they were not. The analysis is observational and no GLP-1 is approved for psychiatric conditions.
- Prices
Novo Nordisk aligns Ozempic pricing with generics in Canada as Apotex begins shipping
Novo Nordisk cut Ozempic pricing for uninsured Canadians through its savings card as Apotex started shipping its generic semaglutide and Dr. Reddy's widened distribution. The company is also running consumer advertising in Canada urging patients to ask for brand-name Ozempic. It is the clearest live test anywhere of whether a GLP-1 originator can hold volume through generic entry by matching price rather than ceding the market.
- Competition
Novo's Wegovy pill still outruns Foundayo roughly four to one
Commentary on the oral GLP-1 race noted that Novo Nordisk's Wegovy pill retains a lead of more than four to one over Foundayo on weekly prescriptions, and that Novo describes it as the strongest US GLP-1 volume launch to date. One structural advantage cited is brand familiarity: the Wegovy pill carries a name prescribers already know, while Foundayo is a new brand for a new molecule. Foundayo is growing faster on a percentage basis and matches the Wegovy pill's $149 entry self-pay price.
- Safety
Ukraine charges 27 in a falsified tirzepatide manufacturing ring
Prosecutors in Dnipropetrovsk and the Security Service of Ukraine served notices of suspicion on 27 people over the illegal manufacture and sale of a falsified weight-loss drug marketed as "Biopatid" across Ukraine. The active ingredient, tirzepatide of unknown origin, was imported from China and declared to customs as a food additive through a controlled broker. More than 250 authorized searches were conducted at manufacturing, storage and sales sites as well as hospitals and cosmetology offices, seizing underground laboratory equipment, packaging and about 15 million hryvnias in cash.
- Culture
Largest musculoskeletal synthesis to date: no bone or joint effect, low-certainty lean-mass reduction
A meta-analysis in Drugs pooling 60 articles and 1,250,717 individuals found no effect of GLP-1 receptor agonists on bone outcomes, no significant change on joint measures, and reductions in lean body mass and fat-free mass at low certainty of evidence — concluding that the clinical significance of the muscle changes is still unresolved.
- Research
Musculoskeletal meta-analysis of 1.25 million people finds lean mass loss but no fracture signal
Drugs published a systematic review and meta-analysis of 60 studies covering 1,250,717 people. GLP-1 drugs consistently reduced lean body mass (standardized mean difference -0.52, low certainty) but showed no effect on bone mineral density or fractures, and the authors noted that almost no study measured strength or physical performance.
- Research
Meta-analysis links GLP-1 drugs to lean mass loss but not bone loss
A systematic review and meta-analysis in Drugs pooling 60 studies and more than 1.25 million people finds no effect of GLP-1 receptor agonists on bone mineral density, fractures or osteoarthritis measures, but a consistent reduction in lean body mass and fat-free mass driven mainly by liraglutide and semaglutide, at low certainty.
- Culture
Penn researchers publish an AI study of 400,000 GLP-1 Reddit posts
The Nature Health paper drew on nearly 70,000 users across more than five years, finding gastrointestinal symptoms most common and surfacing less-discussed reports of menstrual irregularity and temperature changes.
- FDA & regulation
Tally counts 32 FDA warning letters on GLP-1s and peptides since December 2024
A register of FDA warning letters on GLP-1s and peptides counts 32 letters since December 2024, arriving in batches rather than continuously. The targets split three ways: 17 telehealth and compounding businesses, 12 research-peptide sellers, and 3 to manufacturers of the approved drugs themselves. The largest coordinated action was 13 letters in a single day on June 8, 2026, and the August 2026 wave is legally different because it charges unapproved new drug violations rather than misbranding by compounders.
- Business
Hims margin reset passes its first anniversary with 2027 the test
Analysis of Hims & Hers one year after the FDA removed semaglutide from the shortage list finds gross margin down from 76 to 64 percent and adjusted EBITDA margin compressed to 8 percent, with 38 percent revenue growth in the second quarter but a widened adjusted loss of $0.10 a share. The company raised full-year 2026 revenue guidance to $3.2 billion while cutting its EBITDA forecast to $275 to $325 million. Whether the margin reset was temporary depends on execution through 2027, when net profitability is supposed to arrive.
- Research
Review consolidates the case for GLP-1 drugs in psoriasis
A review summarized randomized and cohort data showing PASI improvements with liraglutide and semaglutide alongside falling interleukin-6, interleukin-17, interleukin-23, tumor necrosis factor alpha and C-reactive protein, with effects that appear at least partly independent of weight loss.
- FDA & regulation
FDA approves Scholar Rock's apitegromab, the first muscle-targeted drug to reach market
The FDA approved Isembyld (apitegromab-mstn) for spinal muscular atrophy in adults and children aged two and older, the first therapy that directly targets muscle loss rather than the underlying disease. Scholar Rock shares rose about 12 percent, and analysts forecast worldwide peak sales above $2 billion by 2035. The approval matters to the obesity field because Scholar Rock is testing the same myostatin inhibitor for lean-mass preservation alongside GLP-1 therapy, where it competes with more than a dozen programs including Lilly's bimagrumab, Regeneron's trevogrumab and Veru's enobosarm.
- Competition
Lilly's tirzepatide reaches about 57% of the US GLP-1 market
IQVIA data cited by Citi put tirzepatide at nearly 57% of total US GLP-1 prescriptions, up from about 49.5% a year earlier, while Novo Nordisk's semaglutide held roughly flat at 37%. Total GLP-1 prescriptions grew 5.4% over four weeks versus a 6.8% decline the prior year.
- Safety
Pharmacovigilance study flags Wernicke encephalopathy with semaglutide and tirzepatide
Israeli researchers reviewing 195,979 adverse event cases identified 15 of Wernicke encephalopathy, a thiamine-deficiency brain disorder, and found it disproportionately associated with GLP-1 drugs, with most cases involving semaglutide or tirzepatide. Nearly all affected patients had gastrointestinal problems, vomiting, appetite loss or malnutrition, and only two showed the classic diagnostic triad, which the authors say makes the condition easy to miss. Wernicke encephalopathy is fatal in up to 20% of untreated cases but reversible with prompt intravenous thiamine; disproportionality analyses cannot establish causation or incidence.
- Policy
Review finds most-favored-nation drugmakers now hold Section 232 tariff relief, with Novo Nordisk exempt until 2029
A trade-press review found that manufacturers accounting for 89 percent of branded pharmaceuticals are covered by most-favored-nation pricing agreements and will not face Section 232 tariffs until 2029, naming Novo Nordisk and Sanofi among companies carrying both pricing and onshoring commitments. The finding means the tariff regime that took effect July 31 for unprotected companies has largely bypassed the GLP-1 manufacturers, removing a cost pressure that analysts had expected to reach US list prices.
- Prices
AARP tells members the Bridge is delivering major savings as open enrollment approaches
AARP's weekly member briefing led with Medicare GLP-1 Bridge savings, reflecting White House figures reported August 31 that more than 500,000 beneficiaries had enrolled and saved $216 million, with CMS Administrator Mehmet Oz citing 600,000. AARP's prescription drug policy principal said continued growth is plausible because the program sits outside Part D coverage and requires beneficiaries to work through their prescriber rather than their plan, a structure many enrollees are still learning.
- Science
FDA approves the first myostatin inhibitor, a class GLP-1 muscle research has been watching
The FDA approved Scholar Rock's ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy in patients aged two and older already on an SMN2-targeted therapy, the first approval for a myostatin-targeting drug after decades of failures in the class. The approval is for SMA, not obesity, but apitegromab is the same molecule that preserved 54.9% more relative lean mass alongside tirzepatide in the phase 2 EMBRAZE trial. It establishes regulatory precedent for a mechanism several companies are pursuing as a GLP-1 add-on.
- Policy
MedWatch reports state pushback on Novo Nordisk's most-favored-nation deal
MedWatch reported that Novo Nordisk's most-favored-nation agreement with the US administration could reach millions of patients on paper but is running into state-level resistance, echoing POLITICO's finding that most Medicaid programs are declining the offered pricing. The gap between the announced deal and actual uptake is now the central question about what the MFN framework delivers. Novo Nordisk has said it expects only a slight 2026 sales impact from the arrangement.
- Competition
Weekly tracking shows both obesity pills still climbing, with Novo ahead
Prescription tracking for early September showed Foundayo and the Wegovy pill both growing, with Novo Nordisk holding the lead it built during its three-month head start.
- Competition
Wegovy pill and Foundayo both hit record weekly prescriptions
The Wegovy pill reached about 183,000 weekly prescriptions and Foundayo climbed nearly 8% to about 47,500, narrowing but not closing the gap between the two oral GLP-1 launches.
- Culture
Danone reports a US yogurt sales surge among GLP-1 users
Danone said high-protein yogurt sales rose notably among US consumers using GLP-1 drugs, one of the few company-reported figures isolating GLP-1 users as a distinct buying cohort. The result supports the emerging split in food-industry outcomes between indulgence categories and protein-forward ones. The company did not publish the underlying panel methodology.
- Safety
Health Canada warns on counterfeit and unauthorized Ozempic and Mounjaro sellers
Health Canada issued advisory RA-81518 flagging unauthorized and counterfeit GLP-1 products sold by retailers and online, and urged Canadians to buy only from licensed pharmacies. The warning lands as brand and generic semaglutide compete openly in Canada for the first time, giving counterfeiters a plausible cover story about price. Canada is the second country worldwide, and the first in the G7, to authorize generic semaglutide.
- Business
Lilly begins selling Foundayo in Israel
Lilly started selling Foundayo in Israel, adding another market to the oral GLP-1's rollout after the UK launch in late August. The company has said orforglipron was submitted for approval in more than 40 countries for weight management and, in some cases, type 2 diabetes, with launches following each approval. Israeli pricing and reimbursement terms were not detailed in the initial coverage.
- Research
Lilly's tirzepatide chronic kidney disease Phase 2 closes out
Eli Lilly's Phase 2 study of tirzepatide in participants with overweight or obesity and chronic kidney disease, with or without type 2 diabetes, changed from active, not recruiting to completed, with the primary completion date pulled back to July 6, 2026 and enrollment revised from 140 to 134 participants. Kidney outcomes are the next contested indication in the class after cardiovascular disease and sleep apnea. Novo's REMODEL findings in August had already suggested kidney protection is not diabetes-specific.
- Business
Novo schedules a staff town hall ahead of an investor update
Novo Nordisk set a September 15, 2026 employee town hall ahead of an investor event, drawing attention after a year of restructuring, guidance swings and pipeline setbacks. The company did not preview the content.
- Business
Virginia regulators approve a $98 million power project for Lilly's Goochland County campus
The State Corporation Commission approved construction of an electric substation and a 7-mile transmission line to serve Lilly's planned $5 billion manufacturing campus in the West Creek Business Park in Goochland County, Virginia, over an objection from a developer whose land the route crosses. Lilly bought more than 200 acres at the site for $38 million earlier in the summer and has not yet broken ground, though a spokesperson said construction is expected to start soon. The Virginia site is designated for antibody drug conjugates and monoclonal antibodies rather than incretins.
- FDA & regulation
China approves Wegovy for MASH, the first GLP-1 cleared for the liver disease there
China's National Medical Products Administration approved semaglutide injection for metabolic dysfunction-associated steatohepatitis in non-cirrhotic adults with moderate to advanced fibrosis, stages F2 to F3, making Wegovy the first and only GLP-1 receptor agonist approved for MASH in China. Novo Nordisk said the clearance extends the semaglutide evidence base from weight and cardiovascular health into liver health. The company disclosed no Chinese launch date, price or reimbursement plan.
- FDA & regulation
Seventh Circuit set to hear Lilly's retatrutide classification appeal on September 24
A legal analysis published September 10 previews oral argument in Eli Lilly and Company v. Robert F. Kennedy, Jr., scheduled for September 24 before the Seventh Circuit, on whether retatrutide is a biologic or a conventional drug. Lilly argues its 39-amino-acid backbone plus a two-amino-acid side chain totals 41 and meets the protein definition, and that the FDA blew a statutory deadline after remand; the FDA says the deadline applies only to the original designation request. The Outsourcing Facilities Association backed the FDA and called the appeal a money grab. The piece notes Novo Nordisk's chief executive estimates 1.5 million U.S. patients still get tirzepatide or semaglutide through compounders.
- Science
A modeling study estimates how fast weight returns after stopping either drug
Researchers projected the trajectory of regain after semaglutide or tirzepatide is stopped, reinforcing that both are chronic treatments rather than courses.
- Business
Bloomberg reports Lilly will steer GLP-1 profits into women's health
Bloomberg reported that Lilly plans a larger push into women's health funded by the cash its incretin franchise is generating. The move continues a pattern in which tirzepatide revenue underwrites acquisitions and programs outside obesity and diabetes, following the Merida Biosciences and AtaiBeckley deals. Lilly did not publish specific targets or timelines with the report.
- Science
Cell Reports study identifies an 'obesity memory' in fat cells that drives regain
A Cleveland team reported in Cell Reports that obesity leaves a lasting epigenetic change in fat cells that keeps the hunger hormone asprosin elevated even after weight is lost, a state they call obesity memory. Blocking the asprosin pathway prevented weight regain in their model and also prevented transmission of obesity risk from mother to offspring before birth. The authors argue this explains why patients regain weight after stopping GLP-1 drugs, which suppress appetite without erasing the underlying memory; the work is preclinical.
- Culture
Current Obesity Reports names engagement as the unsolved problem in digital obesity care
A review found digital tools increase access, enable personalization and reduce the burden of self-monitoring, while stating that low engagement remains a persistent problem with digitally delivered interventions — the neutral backdrop for a commercial GLP-1 app category with no published randomized trials of its own features.
- Business
Foundayo's prescriber base expanded from about 8,000 to 36,000 in a single quarter
Analyst coverage of Lilly's second-quarter disclosures reported that the number of clinicians writing Foundayo grew from roughly 8,000 to about 36,000 prescribers in one quarter, with an international rollout planned for 2027. The expansion tracks Lilly's argument that oral dosing pushes obesity treatment into primary care rather than specialist clinics. Prescriber counts are a leading indicator; they do not by themselves establish prescription volume.
- Compounding
Lilly says it has referred more than 200 entities to regulators and law enforcement
Alongside the six retatrutide lawsuits filed August 12, Eli Lilly said it had referred more than 200 entities and individuals selling or advertising research-use-only retatrutide to regulatory and law enforcement agencies. The referral count is a larger number than the litigation docket and signals that the company is treating the gray market as an enforcement problem rather than only a civil one. Compounded GLP-1s currently run roughly $150 to $200 a month against $299 to $449 self-pay for the highest doses of branded products, the price gap that sustains the market.
- Science
Review argues GLP-1 eye risk is not a class effect
A review in Frontiers in Medicine, accepted September 10, proposed a pharmacological heterogeneity framework for GLP-1 ocular safety, arguing that longer-acting semaglutide carries the NAION and diabetic retinopathy signals while shorter-acting agents such as liraglutide and exenatide show much weaker associations. The authors tie the difference to duration of receptor engagement and speed of glycemic correction rather than a uniform class mechanism. The paper is a narrative review, not new primary data.
- Research
Umbrella review quantifies GLP-1 drugs as insulin adjuncts in type 1 diabetes
Diabetes, Obesity and Metabolism published an overlap-informed umbrella review of 18 systematic reviews covering 56 unique primary studies. Reanalysis found adjunctive GLP-1 therapy reduced HbA1c by 0.23 percentage points and body weight by 3.93 kg, with very high overlap between reviews driven by the ADJUNCT ONE and ADJUNCT TWO liraglutide trials.
- Research
A Chinese biotech registers a semaglutide-to-zovaglutide switching trial
Beijing QL Biopharmaceutical registered HORIZON-SWITCH-SZ, a 210-participant Phase 2 study evaluating safety and tolerability of switching adults with obesity from semaglutide to zovaglutide, listed as not yet recruiting. Zovaglutide is a once-monthly GLP-1 peptide already in Phase 3 in China, and QL Biopharm raised more than $72 million around the program. Switching studies are becoming a standard competitive tool as long-interval dosing candidates try to pull patients off weekly incretins.
- Business
Huntsville advances a $230 million tax district to support Lilly's $6 billion Alabama plant
Huntsville officials held a public hearing on a 9,000-acre tax increment financing district covering the site of Lilly's planned $6 billion Alabama campus, with about $230 million of mostly infrastructure spending planned across 11 projects. The city's economic development director said the district was drawn years ago but would not be moving forward without Lilly's investment, the largest capital project in Alabama history. The city council plans to vote on October 8, after a Limestone County Commission vote scheduled for October 5.
- Research
Novo Nordisk registers a CagriSema trial in painful diabetic neuropathy
Novo Nordisk disclosed a study of CagriSema in painful diabetic peripheral neuropathy, testing whether the amylin-GLP-1 combination reduces weekly pain intensity scores against placebo. It is a comorbidity indication rather than a weight or glucose endpoint, and it follows the pattern of expanding incretin franchises into complications of metabolic disease. No results are expected for years.
- Research
Review raises an untested question about tirzepatide and oral progestogens
A hypothesis-generating review in Maturitas asked whether the gastric-emptying effect behind tirzepatide's labeled oral contraceptive warning might also alter oral progestogens used for endometrial protection during menopausal hormone therapy or for gynecologic disease control. It restated the original interaction data and made two careful points: a fall in peak concentration is not the same as reduced efficacy, and the effect is largest after the first dose and diminishes with continued treatment, so any risk concentrates during initiation and dose escalation. No equivalent data exist for therapeutic progestogens.
- Research
Weekly basal insulin plus semaglutide shows benefit in type 2 diabetes
New data reported a once-weekly basal insulin combined with semaglutide improving glycemic control in type 2 diabetes, pointing toward a weekly-injection regimen covering both agents. The combination would simplify dosing for patients already on both. Results are from a controlled study reported in conference and journal formats and have not changed labeling.
- FDA & regulation
China's NMPA accepts Hengrui's ribupatide filing for type 2 diabetes
China's National Medical Products Administration accepted Hengrui Pharma's new drug application for ribupatide injection, a dual GLP-1/GIP receptor agonist, for glycemic control in adults with type 2 diabetes, putting the molecule into formal review. Hengrui granted Kailera Therapeutics exclusive rights outside Greater China in May 2024; Kailera is running the global Phase 3 KaiNETIC program in obesity and plans a global Phase 3 of the oral formulation in the first half of 2027. An approval would make ribupatide the first domestically developed dual agonist cleared in China.
- Science
Endocrine Society publishes an obesity research roadmap and launches a Center on Obesity
The Endocrine Society released 'Obesity Science, Research Gaps, and Opportunities in the New Era of Obesity Medicines' in Endocrine Reviews, a statement led by Daniel Drucker summarizing more than 200 recent publications and naming six priority areas: obesity pathophysiology and defended fat mass, heterogeneity of treatment response, treatment targets beyond percent weight lost, the physiology of plateau and maintenance, health outcomes from pharmacotherapy, and long-term safety. It was timed with the launch of the society's new Center on Obesity. The statement argues treatment goals should extend past the scale to sleep apnea, liver disease and cardiovascular risk.
- Science
Analysis puts tirzepatide at nearly two-thirds of Lilly's quarterly revenue
A pipeline review notes Mounjaro and Zepbound together now account for close to two-thirds of Lilly's quarterly revenue, funding an expanding portfolio that includes the approved oral GLP-1 Foundayo and retatrutide, with a US retatrutide filing planned for the first quarter of 2027.
- Research
Comparative review: tirzepatide wins on weight, not on tolerability
A comparative synthesis reported that tirzepatide produces greater weight loss than semaglutide but does not show a safety or tolerability advantage, with gastrointestinal adverse events broadly similar or higher. The framing matters as payers increasingly force switching between the two molecules. Differences in trial design and dose escalation complicate direct comparison.
- Policy
Forbes argues the administration's drug-pricing push has left pharmacy benefit managers largely untouched
A Forbes analysis argued that while the administration has pressed manufacturers into most-favored-nation agreements and tariff-linked commitments, it has taken comparatively little action against pharmacy benefit managers, which control about 80 percent of US prescriptions and have faced longstanding scrutiny over opaque rebates and spread pricing. The piece landed three weeks after PBMs volunteered to display TrumpRx cash prices in their benefit tools, a commitment that imposes no change to rebate economics.
- Compounding
Law firm guidance says the Fifth Circuit ruling closes the shortage defense for tirzepatide compounders
A Clark Hill client alert on the August 27 and September 1 Fifth Circuit decisions concluded that compounders can no longer rely on the former tirzepatide and semaglutide shortages to justify routine large-scale production of essentially copies of the approved products. The opinion in the tirzepatide case noted that the FDA discounted access reports collected through a Hims & Hers website because they did not reliably establish when or where the reported problem occurred. Section 503A patient-specific compounding survives on a narrower footing, and both opinions were issued unpublished.
- Business
Morgan Stanley downgrades Novo Nordisk over growth and the patent cliff
Morgan Stanley cut its rating on Novo Nordisk, noting semaglutide accounted for 75% of 2026 sales and faces loss of exclusivity across Europe and the US in the early-to-mid 2030s. The bank forecast a $10 billion oral obesity franchise by 2031 but said it would not offset pricing and competitive headwinds.
- Business
Novo Nordisk's third-quarter impairment from ziltivekimab comes into view
With HERMES and ATHENA now halted alongside the failed ZEUS trial, analysts began sizing the non-cash impairment Novo Nordisk had already flagged for the third quarter of 2026 against a franchise some had modeled at blockbuster scale. The company has said the ZEUS outcome does not change its adjusted operating profit outlook for the year, because the charge is non-cash and sits outside the adjusted measure. Only ARTEMIS, reading out in the first half of 2027, remains.
- Competition
Physicians say Mounjaro's cardiovascular approval matters more than expected
A survey of prescribers found the new indication was likely to shift prescribing in type 2 diabetes, because it removes the argument that only semaglutide had proven heart benefit.
- Research
Zealand's ZUPREME-2 petrelintide trial is marked completed
The registry record for ZUPREME-2, Zealand Pharma's Phase 2 trial of petrelintide in participants with overweight or obesity and type 2 diabetes, changed from active, not recruiting to completed. Zealand has guided topline results to the second half of 2026, and the completion marks the last operational step before that readout. The trial is the second of the two Phase 2 studies that will inform the registrational design Zealand and Roche have said they will start this half.
- Culture
Investigation finds a fake GLP-1 market on TikTok aimed at women
A Stacker investigation documented TikTok sellers marketing counterfeit or non-existent GLP-1 products to women seeking weight loss, using influencer formats and direct-message sales to evade platform moderation. The reporting follows FDA import alerts and warning letters to online peptide sellers through August and September. Platform enforcement has not kept pace with the volume.
- Compounding
Law firm guidance says compounders must now justify every GLP-1 prescription individually
A client alert on the two Fifth Circuit decisions tells compounding pharmacies, telehealth companies, med spas and weight-loss businesses that the shortage exception can no longer support routine large-scale production of copies of the approved GLP-1s. It advises organizations that expanded during the shortages to review whether their products, production practices and distribution models satisfy the requirements now in force, and to evaluate whether their compounding is genuinely patient-specific. The FDA's shortage determinations remain in place following the appeals.
- Business
MannKind licenses its inhaled delivery platform for a short-acting GLP-1
MannKind and Rose Pharma entered a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere, an inhaled rapid-acting, short-duration GLP-1 receptor agonist for weight management. MannKind takes an equity stake in Rose Pharma, a board seat and royalties on future sales, and will support formulation development through Phase 1b; Rose Pharma keeps clinical development, regulatory strategy and commercialization. Financial terms were not disclosed, and MannKind had abandoned its own inhaled GLP-1 after Phase 1 more than 16 years ago.
- Research
Novo opens a pediatric CagriSema trial in type 2 diabetes
A Novo Nordisk Phase 3 study measuring how much CagriSema lowers blood sugar and body weight against placebo in children and adolescents with type 2 diabetes moved from not yet recruiting to recruiting. The trial extends the combination's program into a population where no GLP-1/amylin combination has been tested and where labels remain narrow. A US decision on CagriSema in adults is expected in the fourth quarter of 2026.
- Business
WeightWatchers names Stephen Bye chief executive
WW International appointed Stephen Bye as president and chief executive and a member of its board, effective this fall. Bye most recently led Ookla, the connectivity intelligence company behind Speedtest and Downdetector, and has no prior pharmaceutical or telehealth operating background. He inherits a company whose behavioral business is in structural decline and whose growth now depends on a clinical segment built around GLP-1 prescribing partnerships.
- Culture
WeightWatchers launches a GLP-1 culture podcast with Dear Media
WW International and Dear Media launched "The Weigh In," a weekly podcast about GLP-1 use, framed by the company as an attempt to reduce stigma around weight-loss medication. It is WeightWatchers' first podcast dedicated to GLP-1s and its most visible consumer-media push since the clinical pivot. The launch sits alongside the LillyDirect partnership as part of a broader repositioning from diet program to medication-adjacent brand.
- Prices
Truveta data show a 19 percent jump in GLP-1 prescribing among adults 65 and older after the Bridge launch
Truveta reported that the share of adults aged 65 and older with a GLP-1 prescription rose 19 percent from June to July 2026, the largest month-to-month increase in seven years of the company's data. Tirzepatide prescriptions showed an 80 percent relative increase and semaglutide 40.9 percent; orforglipron volume was too small to measure. Truveta cautioned that the data do not establish causation but said the timing points to how quickly removing a financial barrier changes medication access.
- FDA & regulation
Aleniglipron open-label extension reports 16.2% weight loss at 72 weeks
Structure Therapeutics reported up to 16.2% average weight loss at 72 weeks on the 180 mg dose with no plateau and fewer than 5% of participants discontinuing for adverse events. Analysts called the efficacy in line with the Wegovy pill (16.6% at 64 weeks) and better than Foundayo (12.4% at 72 weeks).
- Policy
CMS says most Bridge prior authorizations clear in under 12 hours and confirms there is no formal appeal
CMS officials told AARP that the Bridge has generally beaten its 72-hour prior authorization target, with most determinations completed in under 12 hours, and that most requests arrive electronically rather than by fax. A CMS official also confirmed there is no formal appeals process for a Bridge denial: a prescriber can correct and resubmit a request with accurate or new information, but beneficiaries have appeal rights only for GLP-1 coverage decisions issued under the Part D benefit.
- Research
ERS 2026: semaglutide tied to about 40 percent fewer asthma attacks
A large real-world study presented in Barcelona of UK electronic health records found people with chronic airway disease on GLP-1 drugs had fewer exacerbations than comparable patients prescribed sulfonylureas, with semaglutide showing roughly a 38 to 40 percent reduction in asthma attacks and about 20 percent fewer COPD flare-ups. Investigators urged no change in practice without trials.
- Compounding
Judge trims Lilly's conspiracy claims in the Mochi Health compounded tirzepatide suit
Judge Jacqueline Scott Corley in the Northern District of California partially granted a motion to dismiss in Eli Lilly and Company v. Mochi Health Corp., dismissing Lanham Act conspiracy claims against both the Mochi medical defendants and the supplying pharmacy while allowing California Unfair Competition Law conspiracy claims to proceed against Aequita Pharmacy and its parent. The court found Lilly had plausibly alleged that Mochi's chief executive exercised significant control over Aequita's prescription-filling procedures and that Aequita had significant financial motivation to participate. The Lanham Act claims were dismissed without leave to amend unless discovery produces supporting facts.
- Research
Novo shuts two more ziltivekimab heart trials, and analysts write off IL-6
Novo Nordisk closed two additional cardiovascular studies of ziltivekimab, following the drug's failure to reduce major adverse cardiovascular events in the Phase 3 ZEUS trial on July 31, with analysts describing IL-6 as an invalid target. The retreat removes Novo's clearest route to a cardiometabolic franchise that does not depend on GLP-1 and leaves the company's next-generation case resting on CagriSema, zenagamtide and cagrilintide. Roughly $30 billion of market value evaporated on the original ZEUS readout.
- Research
Novo takes amycretin into late-stage trials in both pill and injection form
Novo Nordisk confirmed that both oral and subcutaneous amycretin, a single molecule targeting GLP-1 and amylin receptors, had moved into phase 3 after positive regulatory feedback. Phase 2 data showed about 22% weight loss over 36 weeks with the injection.
- Business
Sandoz aims for a Canadian generic semaglutide launch this year and excludes GLP-1s from its 2035 plan
Sandoz told investors it received Brazilian approval for its generic semaglutide in July and is eyeing a Canadian launch this year for patients with diabetes, while stating that its 2025-to-2035 net sales targets exclude any contribution from generic GLP-1 drugs. The company plans to grow its biosimilars portfolio from 13 to 100 products by 2040 and named $650 billion of branded products losing exclusivity over the next decade. Excluding GLP-1 generics from the plan is a statement about how uncertain the legal and pricing path still is outside a handful of markets.
- Business
Analysts set out what Novo Nordisk has to show at its Capital Markets Day
Previews from MedWatch, TIKR and Danish outlet Økonomisk Ugebrev converged on the same checklist for the September 21 investor day in London: credible long-term sales and margin targets, a pipeline story that survives the ziltivekimab collapse, manufacturing capacity plans that do not repeat the Wegovy supply failure, and a defense of semaglutide economics into the 2030s patent cliff. It is the first Capital Markets Day under Mike Doustdar. Novo Nordisk had already said it would give a full review of strategy, operations and financial targets.
- Business
Analysts size the obesity market at roughly 27% annual growth
Market forecasts published in September 2026 projected the obesity drug market expanding at about 27% a year through 2036 as oral GLP-1s and pipeline innovation broadened access. IQVIA counted about 190 obesity-related products in development.
- Policy
CMS says it kept Bridge outreach deliberately limited while manufacturers advertised the program
A CMS official told a press briefing that the agency did limited public outreach ahead of the July launch because beneficiaries act on information when they can actually use it, and that more promotion would follow as the program matured. In the meantime Eli Lilly and Novo Nordisk ran their own Bridge promotions, including social video and television commercials for Foundayo and Zepbound, while a Wegovy commercial cited the $50 price without naming the program. The Patient Advocate Foundation promoted an explainer to a newsletter reaching nearly 400,000 people.
- FDA & regulation
Eight more generic semaglutide files sit under Health Canada review
Health Canada was reviewing eight additional generic semaglutide submissions beyond the authorizations already granted to Dr. Reddy's on April 28, 2026 and Apotex, with Apotex offering full SKU parity to Ozempic. Under Canada's pan-Canadian pricing tiers, a first generic prices at 75% to 85% of brand, two at 50%, and three or more at 35%, so the third approval is the one that moves the market. University of Toronto researcher Mina Tadrous has estimated out-of-pocket costs near C$100 a month once three generics are selling.
- Culture
Gallup revises its 2026 GLP-1 and obesity estimates
Gallup updated its July 2026 release after changing its weighting criteria, publishing an adult obesity rate of 36.8% for 2026 and confirming 11% current GLP-1 use for weight loss and 90% public awareness of the drugs.
- Culture
Household data show one GLP-1 user changes what the whole household eats
eMarketer reported that GLP-1 use reshapes purchasing for entire households rather than just the person taking the drug, with spillover into shared meals, snacks and beverage choices. The effect amplifies the market impact of a user base that Gallup now puts at 11% of US adults for weight loss. The analysis is panel-based consumer data, not a controlled study.
- Business
Moonwalk raises $70 million, with Lilly investing, for an adipose-targeted RNAi obesity drug
Moonwalk Biosciences closed an oversubscribed $70 million Series B co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly, Gaorong Ventures, ARCH Venture Partners, Khosla Ventures and Future Ventures. Proceeds fund IND-enabling work on MW101, an adipose-selective small interfering RNA licensed in part from a Chinese drugmaker, toward first-in-human studies in late 2027. In preclinical work MW101 produced weight and fat loss while maintaining muscle mass.
- Research
Peer-reviewed Zepbound cost-offset numbers published in Diabetes, Obesity and Metabolism
The Lilly-funded matched-cohort study of 15,843 tirzepatide initiators over age 55 reported monthly costs staying near baseline in the treated group, moving from $1,061 to $955 over 18 months, while untreated controls rose from $1,031 to $1,244. The differences were $145 per person per month at 6 to 12 months and $319 at 12 to 18 months, both statistically significant. The analysis excluded the cost of tirzepatide itself and could not observe net price, so it measures offsets elsewhere in care rather than net cost.
- Research
PeerJ meta-analysis confirms regain after withdrawal and improvement in side effects
PeerJ published a systematic review and meta-analysis of weight change and adverse reactions in adults with overweight or obesity after GLP-1 withdrawal. It confirmed the regain pattern established by the randomized trials and documented that gastrointestinal adverse effects generally improve after stopping, which is a fact patients frequently ask about and which the withdrawal trials rarely report as a headline result.
- Competition
Structure Therapeutics reports first clinical data for an oral small-molecule amylin agonist
ACCG-2671 became the first oral small-molecule amylin receptor agonist with reported clinical data, alongside reaffirmed aleniglipron results supporting the ongoing Phase 3 program.
- Competition
Three guided third-quarter obesity milestones are still unannounced with weeks to go
As of September 8, three dated commitments across the challenger field remained open: Structure Therapeutics' guided Phase 3 start for aleniglipron, Viking Therapeutics' guided VANQUISH-2 topline in participants with type 2 diabetes, and Zealand Pharma and Roche's guided start of registrational Phase 3 trials of petrelintide monotherapy. Twenty-two days remained in the quarter. Ascletis, which dosed the first patient in its global Phase 3 on August 30, was the only company in the group to have met its window.
- Research
STEP Young: 40 percent of children aged 6 to 11 fall below the obesity threshold
Novo Nordisk reported first results from STEP Young, a phase 3 trial of once-weekly semaglutide in 165 children aged 6 to under 12 with obesity; both arms also received a reduced-calorie diet and more physical activity. After 68 weeks, 40.4% of children on semaglutide were no longer classified as having obesity versus none (0%) on placebo, a figure that assumes full adherence to treatment. Novo reported no new safety concerns and none identified for growth or pubertal development.
- Business
Lilly's US manufacturing commitment passes $50 billion across four new sites
Lilly's domestic manufacturing program now exceeds $50 billion since 2020, more than double the $23 billion committed between 2020 and 2024, built around four new US sites. Three of the four are dedicated to active pharmaceutical ingredient manufacturing and the fourth expands parenteral capacity. The program is projected to create more than 3,000 permanent jobs and nearly 10,000 construction jobs.
- Research
New analysis finds semaglutide and tirzepatide produce similar weight loss in type 2 diabetes
Researchers reported that in patients with type 2 diabetes the two drugs delivered comparable weight reduction, narrowing a gap that is consistently wide in obesity trials without diabetes. The result matters for formulary and step-therapy decisions where tirzepatide's obesity-trial advantage has driven preference. Trial populations and durations differ, and the finding does not extend to people without diabetes.
- FDA & regulation
No final FDA determination on the 503B bulks exclusion as of early September
A status check against the Federal Register and FDA dockets confirms the agency has not issued a final determination on its April 30, 2026 proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List. The Federal Register notice published May 1, 2026 at 91 Fed. Reg. 23431; the comment period was extended once by a June 26 notice and closed July 30, 2026. Analysts note the practical effect of finalization would be to make a closed door permanent, since none of the three is currently on the list and the shortage pathway ended in 2025; liraglutide injection remains on the shortage list and is the one conditional exception.
- Prices
North Carolina confirms no restoration of state-employee GLP-1 coverage
Reporting confirmed the budget signed in July 2026 contained no provision restoring State Health Plan coverage of GLP-1s for weight loss, with officials saying current prices remain unaffordable. In the same period, NC Medicaid recorded more than $47 million in weight-loss GLP-1 claims in June alone across more than 34,500 beneficiaries.
- Safety
Case report: a pen-handling error delivered four weekly semaglutide doses at once
Clinicians described a patient who received four weekly semaglutide doses in a single administration because of a pen-handling mistake, reporting dysesthesia rather than the expected severe nausea. The report is a single case and cannot be generalized, but it adds to a small literature on accidental overdose as self-administration spreads. Device handling errors are a recognized reporting category in adverse event databases.
- Research
GLP-1 drugs linked to fewer nerve complications than DPP-4 inhibitors in diabetes
A comparative analysis reported lower rates of diabetic neuropathy complications among GLP-1 users than among patients on DPP-4 inhibitors. Neuropathy has been a relatively under-studied endpoint for the class compared with cardiovascular and kidney outcomes. The study is observational and the comparator is a weight-neutral drug class, so weight loss remains a plausible mediator.
- Research
Head-to-head asthma analysis finds no advantage for tirzepatide over semaglutide
In 8,176 matched pairs of adults with asthma and type 2 diabetes, the risk of an asthma exacerbation over 12 months was essentially identical between tirzepatide and semaglutide (11.0 versus 11.1 percent). Tirzepatide users needed slightly fewer rescue inhaler prescriptions. The result checks the claim that dual GIP/GLP-1 agonism brings extra respiratory benefit.
- Business
Lilly says international incretin growth ran at 136% and flags generic supply constraints in Canada
Recapping Lilly's second-quarter call, chief financial officer Lucas Montarce said US revenue rose 48% while rest-of-world revenue grew 136%, driven by Mounjaro in Latin America and Asia. Lilly International president Patrik Jonsson said the company was 'pleasantly surprised' by its Canadian performance and that generic semaglutide entrants there have had significant supply constraints. Both Lilly tirzepatide products remain under patent protection in Canada, so the generic pressure is on the semaglutide market rather than tirzepatide.
- Business
Novo Nordisk's buyback reaches DKK 9.0 billion of a DKK 15 billion program
Novo Nordisk disclosed that as of September 4, 2026 it had repurchased 32,034,179 B shares since February 4 at an average price of DKK 281.63, for DKK 9,021,774,283 of the DKK 15 billion twelve-month program. Daily purchases through late August and early September ran at DKK 291.92 to DKK 305.35 per share. The buyback is the clearest signal of how management intends to support the stock while the pipeline narrative is under repair.
- Business
Novo shares slip even on positive pediatric data
Novo Nordisk stock dipped on the day it reported the STEP Young results, a reminder of how much investor attention has shifted to pricing and competition rather than trial outcomes. Analysts called the pediatric opportunity meaningful but not transformative on its own.
- Policy
Medicare's second negotiation round trims 15 drugs including Ozempic, saving about $685 million
Reporting on the second cycle of Medicare drug price negotiation put total 2027 enrollee out-of-pocket savings across the 15 selected drugs at roughly $685 million, with the semaglutide products among the largest contributors by volume. Ozempic, Wegovy and Rybelsus all move to a $274 maximum fair price on January 1, 2027. What an individual pays still depends on their Part D plan's benefit design.
- Business
Lilly's own employee pharmacy benefit sits with Rightway, not CVS Caremark
A policy analysis noted that Lilly replaced CVS Caremark with Rightway as the pharmacy benefit manager for its own employees effective January 1, 2026, several months after Caremark removed Zepbound from its standard commercial formulary in favor of Wegovy. Lilly has not said the formulary decision prompted the switch. Caremark announced in May 2026 that Zepbound returns to its commercial formularies as an additional preferred option on October 1, 2026, and Lilly has not indicated whether that changes its Rightway arrangement.
- FDA & regulation
Lilly moves against imports of counterfeit Mounjaro
UNVERIFIED: trade press reportedly described suits against pharmacies over counterfeit Mounjaro entering the United States, but the cited article could not be retrieved during the 2026-09-14 fact-check and the claim is not independently confirmed.
- Policy
Medicaid obesity coverage count stands at 12 states and is set to fall again on October 1
A state-by-state review put the count of Medicaid fee-for-service programs covering GLP-1s for obesity at 12 as of early September, down from KFF's January 2026 count of 13 after MassHealth stopped paying for obesity-only prescriptions on July 1. Rhode Island's elimination of weight-management coverage takes effect October 1, which would bring the count to 11. Every state continues to cover tirzepatide for type 2 diabetes because federal law only permits the weight-loss carve-out.
- Prices
Hims & Hers opens a waitlist for $149 Wegovy and Ozempic under the Novo deal
Hims & Hers launched a waitlist for branded Wegovy and Ozempic at $149 a month through its Novo Nordisk partnership, the lowest self-pay price the platform has offered for branded semaglutide. The offer extends the March 2026 pivot from compounded to branded medication, a shift the company has said compressed gross margin by roughly 12 points to 64 percent while expanding its addressable market. Hims reported filling more than 125,000 Wegovy shipments within six weeks of that launch.
- Prices
LillyDirect self-pay ladder confirmed at $299 to $449 with a refill condition, and $499 to $699 without
A pricing review corrected earlier reporting and confirmed that LillyDirect 2026 self-pay prices for Zepbound are $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 to 15 mg when the patient refills within 45 days, rising to $499 for 7.5 mg and $699 for 10 to 15 mg otherwise. The refill-timing condition is the detail most often dropped in secondary coverage and changes the effective price by hundreds of dollars a month at maintenance doses.
- Business
WeightWatchers partners with LillyDirect to expand Med+ nationwide
WW International expanded its Med+ clinical program nationwide through a partnership with LillyDirect, Eli Lilly's direct-to-consumer pharmacy channel. The deal is part of a post-bankruptcy pivot in which the legacy behavioral business is shrinking, with second-quarter 2026 revenue down 22.7 percent year over year, while the clinical segment built around GLP-1 medication grows. WW's Med+ membership was priced at $25 a month for the first period as of early September.
- Prices
Zepbound savings card terms confirmed at $25 with tighter 2026 caps than 2025
A pricing review confirmed the 2026 Zepbound Savings Card gives commercially insured patients whose plan covers the drug a $25 price, with the card paying up to $100 per one-month fill and $1,300 per calendar year across 13 fills, down from $150 and $1,950 in 2025. Commercially insured patients whose plan does not cover Zepbound pay $499 for a one-month single-dose pen fill or $299 for the 2.5 mg KwikPen. The card expires December 31, 2026.
- Business
WeightWatchers extends its UK partnership with CheqUp
WW International expanded its UK partnership with CheqUp to deliver integrated weight-health services combining medication access with behavioral coaching. The move mirrors the company's US clinical pivot, licensing prescribing infrastructure rather than building it, and comes as UK GLP-1 clinics proliferate. It extends WW's model of pairing an established behavior-change brand with third-party prescribing rails.
- Research
Novo Nordisk halts the HERMES and ATHENA ziltivekimab heart failure trials for futility
Novo Nordisk told investigators on September 4, 2026 that it was ending the Phase 3 HERMES and ATHENA studies of ziltivekimab early after an independent data monitoring committee concluded they were unlikely to succeed. HERMES measured time to first cardiovascular death or heart failure hospitalization and urgent visit; ATHENA measured quality-of-life endpoints in the same population. The halt follows the July 31 ZEUS failure and leaves ARTEMIS, in post-heart-attack patients, as the only remaining Phase 3 for the IL-6 antibody, reading out in the first half of 2027.
- Business
Foundayo reaches about 44,000 weekly scripts as oral GLP-1s expand the market
Both oral GLP-1s hit record weekly prescriptions on the IQVIA panel cited by Citi: roughly 181,000 for the Wegovy pill (up about 3%) and about 44,000 for Foundayo (up about 8%). Citi credited the oral launches with swinging total GLP-1 prescription growth from a 6.8% decline a year earlier to a 5.4% four-week increase. CORRECTED 2026-09-14: an earlier version dated this event September 11 and gave 183,000 and 47,500; those figures could not be reproduced from the cited Fierce Pharma tracker, whose verifiable latest update is September 4.
- Safety
Investigation ties three patient injury cases to pharmacies in Mochi Health's supplier network
An investigation published September 4 documents three patients in three states who suffered serious medical emergencies after using compounded GLP-1s from pharmacies that have at various times supplied Mochi Health. A Texas wrongful-death suit filed by Don Rhodes alleges his daughter died after 29 days in critical illness following a dose increase of compounded semaglutide from Empower Pharmacy; a Kentucky suit by Jimmie Wilson alleges liver failure requiring transplant after compounded tirzepatide from Lexington Compounding Pharmacy; an Illinois Mochi customer reports four hospitalizations. Both pharmacies deny causation and Empower has moved to dismiss.
- Research
Off-label GLP-1 prescribing to US children under 12 rises more than 300-fold since 2019
A study in Pediatrics covering more than 3.5 million children aged 8 to 11 with obesity and without diabetes found GLP-1 weight-loss prescribing rose from 0.03% in 2019 to 9.3% by June 2026, a more than 300-fold increase, with 20,282 children treated over the period. None of these drugs is FDA-approved under age 12, though clinical guidelines permit use from age 8 in some cases. Wegovy was the most common, and 94% of those prescribed had severe obesity. Children in higher-income communities were 55% more likely to receive a prescription.
- Science
Retatrutide reports up to 30.3% average weight loss in TRIUMPH-1
Eli Lilly's triple GIP/GLP-1/glucagon agonist met primary and key secondary endpoints across 4, 9 and 12 mg doses in a 2,339-participant Phase 3 trial, with average weight loss reported up to 30.3% - the largest figure yet reported from a Phase 3 obesity trial.
- Compounding
Washington State shut down Mochi's in-house compounder over illegally imported GLP-1 powder
Reporting on Mochi Health's supply chain details Washington State inspectors raiding and shutting down Aequita Pharmacy in Kirkland, citing what regulators described as a serious risk to patients. Inspection findings included workers whose licensing was questioned, expired medications, and GLP-1 base powder that state officials said had been imported illegally from overseas. Aequita had been Mochi's in-house source for compounded GLP-1s, and its closure pushed the company to contract with Empower Pharmacy, which already carried three FDA warning letters since 2022, investigations by 15 state pharmacy boards and a $65,000 DEA fine in 2024.
- Compounding
Lilly details the scale of its retatrutide enforcement campaign
The Indianapolis Business Journal reported that Lilly has referred more than 200 people and entities to the FDA, the Department of Justice, state attorneys general and law enforcement, and has reported more than 14,000 websites, advertisements, social media posts and product listings marketing retatrutide across more than 100 countries. The complaints name Striker Pharmacy near Houston, Sacramento medical spa chain Aesthetic Envy and online sellers Astra Peptides, Texas Peptides, Lone Star Peptide and Legendary Peptides. Lilly argues the gray market will force it to rehabilitate the molecule's reputation before launch.
- Research
Novo begins a Phase 3 comparing two injectable cagrilintide presentations
A Novo Nordisk Phase 3 study comparing two different versions of injectable cagrilintide against placebo in people with excess body weight moved from not yet recruiting to recruiting. Cagrilintide monotherapy produced 11.8 percent average weight loss against 2.3 percent on placebo over 68 weeks in a REDEFINE 1 sub-analysis, and Novo has said it will start Phase 3 trials of a high-dose cagrilintide by the end of 2026. The amylin analog is Novo's hedge against the possibility that CagriSema alone will not close the gap with tirzepatide.
- Research
Lilly registers a phase 1 gastric emptying study of tirzepatide in type 1 diabetes
A single-dose, blinded, randomized phase 1 study (NCT07803744) using oral acetaminophen to track gastric emptying in adults with type 1 diabetes and overweight was first posted on 2026-09-04 as not yet recruiting, alongside the two ongoing SURPASS-T1D phase 3 trials. Tirzepatide is not approved for type 1 diabetes.
- Culture
Medscape reframes 'easy way out' stigma as a clinical problem
A Medscape feature gathered clinician perspectives on the persistent belief that GLP-1 use is an easy way out, arguing the framing suppresses disclosure and drives patients toward unsupervised sourcing. It follows peer-reviewed work in August naming GLP-1 treatment stigma as distinct from weight stigma. The article is commentary and review, not new data.
- Research
Novo Nordisk advances a new injectable obesity candidate into Phase 3
Novo Nordisk disclosed a new Phase 3 program for an injectable obesity candidate, part of a pipeline push it has promised to detail at its September 21 Capital Markets Day. The company has publicly flagged a high-dose CagriSema study pairing cagrilintide 2.4 mg with Wegovy HD semaglutide 7.2 mg for the second half of 2026, plus the REDEFINE 11 long-term study reading out in the first half of 2027. Investors have signaled that new late-stage starts, not existing readouts, are what the stock needs.
- Safety
Pharmacists call on state boards to act against illegal retatrutide
A pharmacy trade publication argued that state licensing boards, not federal regulators, are the only bodies able to discipline the clinicians prescribing an unapproved drug.
- Compounding
Strive Pharmacy says it is pre-sourcing peptide ingredients ahead of any 503A rule
Strive Pharmacy co-founder and chief executive Nate Hill told Pharmaceutical Executive that the compounder is pre-sourcing active pharmaceutical ingredients and running stability, potency and sterility testing on a limited set of higher-demand peptide products while the FDA decides whether to add peptides to the 503A Bulks List. Hill was explicit that preparation is not production: "we're not going to produce them until it is moved over to category one." No proposed rule has published, none of the six peptides the July advisory committee recommended is on the list, and none is lawfully compoundable today.
- Research
Veru's enobosarm GLP-1 muscle study closes enrollment above target
Veru's proof-of-concept study of enobosarm in patients on a GLP-1 receptor agonist moved from recruiting to active, not recruiting, with enrollment revised upward from 200 to 239 participants. Enobosarm is an oral selective androgen receptor modulator positioned to shift weight loss toward fat and away from lean tissue. Veru reported in January that enobosarm helped older patients lose 71 percent less muscle when taken with semaglutide in a 168-person trial.
- Business
California SB 1089 sent to the Governor
The Preventive Treatment Health Care Act, which would direct California to seek manufacturing partnerships to lower GLP-1 prices under the CalRx program and let employers with 100 or more workers negotiate discounts directly, was enrolled and presented to the Governor eight months after California cut Medicaid obesity coverage.
- Research
Novo and United Laboratories report 19.7 percent weight loss for triple agonist UBT251
United Laboratories and Novo Nordisk announced positive topline results from a Chinese Phase 2 trial of UBT251, a once-weekly GLP-1/GIP/glucagon triple receptor agonist, showing 19.7 percent mean weight loss and a 17.5 kg reduction at 24 weeks on the 6 mg dose against 2.0 percent on placebo. The randomized, double-blind study enrolled 205 participants with obesity or overweight plus at least one weight-related comorbidity and reported improvements in waist circumference, blood glucose and blood pressure. Novo licensed UBT251 outside Greater China in March 2025 and has said a type 2 diabetes Phase 2 will start in the second half of 2026.
- Science
NYU study finds the first genetic link between GLP-1 receptor activity and male pattern hair loss
Published online September 3 in the Journal of Investigative Dermatology, an NYU Langone team used GLP1R variants as a proxy for GLP-1 receptor activity across genetic databases covering more than 200,000 people and found men with higher predicted activity had a 7% increased risk of androgenetic alopecia. The association held after adjusting for hypertension, insulin resistance and lower testosterone. Senior investigator Lynn Petukhova called it the first genetic evidence for a link long suspected but never demonstrated; the study does not show how GLP-1 activity affects follicles, and the analysis was limited to men.
- Research
EASO issues a position statement on integrating incretin therapies into obesity care
The European Association for the Study of Obesity published a position statement in The Lancet Regional Health Europe setting out how incretin-based medicines should sit within comprehensive obesity management rather than replacing it. The statement addresses nutrition, physical activity, psychological support and long-term follow-up alongside pharmacotherapy. It is guidance for European practice and carries no regulatory force in the United States.
- Business
FDA shortage record still lists liraglutide in shortage while most suppliers report available
Hikma updated its entry on 2026-09-03 reporting both presentations available, and Meitheal did the same on 2026-08-27, while the active ingredient remained listed as Currently in Shortage from a 2023 posting. Brand Victoza and Saxenda stayed at Limited Availability.
- Business
Menarini licenses Gan & Lee's every-two-weeks GLP-1 for Europe
Italy's Menarini Group agreed to pay Gan & Lee Pharmaceuticals EUR 62 million up front, up to EUR 664 million in milestones and double-digit royalties for European rights to bofanglutide, a long-acting GLP-1 dosed once every two weeks, across 39 markets. Bofanglutide met its primary endpoints in a Chinese Phase 3 and a US Phase 2 in obesity and overweight, and Gan & Lee plans a global Phase 3 to support European registration. The deal is a license to a late-stage development program, not a launch-ready product.
- Compounding
Novo Nordisk wins a false-advertising ruling against an Ozempic copycat pharmacy
A federal court ruled for Novo Nordisk in a Lanham Act case against a compounding pharmacy that marketed knockoff semaglutide, and follow-on reporting described an injunction covering claims about Ozempic and Wegovy. The orders in this line of cases typically bar defendants from suggesting their compounded products are FDA-approved, genuine or therapeutically equivalent, and often require corrective disclosures. Novo Nordisk has said courts have entered dozens of permanent injunctions on those terms.
- FDA & regulation
State licensing boards issue warning notices on research-use-only peptides
State medical, nursing and pharmacy boards have issued a wave of warning notices to licensees over clinical use of peptides, most aimed at research-use-only products but some sweeping in all non-FDA-approved peptides as "unapproved substances" whose administration constitutes unprofessional conduct. Several notices state that delegating to nurse practitioners or physician assistants does not cure the problem and that patient waivers do not shift responsibility. States that have issued warnings or taken a more restrictive posture include Alabama, California, Connecticut, Louisiana, Mississippi, New Jersey, Ohio and South Carolina, with licenses suspended in some cases.
- Research
Ildong sets September 29 for topline Phase 1 data on a Korean oral GLP-1
Ildong Pharmaceutical said it will present topline Phase 1 results for ID110521156, an oral GLP-1 receptor agonist developed by its affiliate Yunovia, at an investor briefing in Seoul on September 29. Interim data presented at the American Diabetes Association meeting in June reported average weight reduction of 6.9 percent and a maximum of 11.9 percent over four weeks in the 100 mg cohort. The topline will add high-dose weight-loss results plus safety and tolerability.
- Business
Lilly's African partner forecasts more than $124 million of Mounjaro sales in 2027
Aspen Pharmacare, which markets tirzepatide across sub-Saharan Africa under license, gave the first public revenue estimate for the region and said it was pursuing approvals in more countries.
- Science
Structural work on GLP-1 signaling aims at brain-disease applications
Korean researchers described new structural detail of GLP-1 receptor signaling, presented as a step toward designing agents that act on the central nervous system rather than only on metabolism. The work is basic science with no clinical candidate attached. It lands in a year when the EVOKE Alzheimer's failure has pushed neurodegeneration interest toward mechanism rather than repurposing.
- Business
Superluminal raises $60 million to take an MC4R obesity drug into the clinic
Superluminal Medicines closed an oversubscribed $60 million Series B to advance a selective, biased MC4R agonist for rare genetic forms of obesity and hypothalamic obesity, with a Phase 1 trial expected to begin by the end of 2026. The company applies AI, protein dynamics and structural biology to G protein-coupled receptor targets. The program follows the path Rhythm Pharmaceuticals opened with setmelanotide, aiming for greater receptor selectivity.
- Research
Tirzepatide reported to help post-bariatric hypoglycemia in three cases
A case series in JCEM Case Reports described three patients with symptomatic post-bariatric hypoglycemia after Roux-en-Y gastric bypass whose episodes had responded only partially to diet change, acarbose and other drugs. On tirzepatide, all three had more time in glucose range, fewer and less severe hypoglycemic episodes, and less glucose variability. The proposed mechanism is slower gastric emptying blunting the post-meal glucose spike. The authors state that efficacy needs confirmation and that optimal dosing is unknown.
- Policy
Only Indiana has committed to the BALANCE Medicaid pricing model while 29 states have declined
The Public Sector Healthcare Roundtable reported that nine months after CMS introduced the BALANCE model, which lets states buy GLP-1s at negotiated prices through Medicaid, Indiana is the only state that has committed to participate and 29 state Medicaid programs have declined. States cited cost concerns, budget constraints and doubts about the model's long-term financial sustainability. CMS's own model page still lists the number of participants as not applicable.
- Prices
Modern Healthcare documents the employer retreat: Cigna and PwC out this year, PepsiCo and Starbucks in October
Modern Healthcare reported that employers are cutting GLP-1 weight-loss coverage as a primary way to trim benefit budgets, naming Cigna Group and PricewaterhouseCoopers as having eliminated coverage during 2026 and PepsiCo and Starbucks as following in October. The reporting drew on Business Group on Health data showing large-employer coverage of GLP-1s for weight loss at 60 percent this year, down from 72 percent in 2025.
- Science
Nature reports late-life semaglutide extended lifespan 12% in female mice
An NIH-funded team at UC Berkeley led by Danica Chen reported in Nature that starting semaglutide in 20-month-old female mice, roughly equivalent to a woman in her sixties, raised median lifespan from 742 to 834 days, about 12%. Treated animals showed better muscle and cognitive function, improved glucose control and reductions in aging hallmarks including inflammation, cellular senescence and stem cell attrition, with the drug behaving as a calorie-restriction mimetic. The authors are explicit that nothing about human aging follows without long-term clinical studies in older adults.
- Prices
Starbucks confirms it will end employer-sponsored GLP-1 weight-loss coverage in October
Starbucks confirmed it will stop covering GLP-1 medications when prescribed for weight loss, effective October 2026, as part of a wider round of benefit reductions ahead of the 2027 renewal cycle that also saw Disney end spousal coverage for workers with access to other employer coverage and Bloomberg LP introduce employee premium contributions for the first time. Diabetes coverage is unaffected by the Starbucks change.
- Policy
Analyst says the Medicare GLP-1 Bridge could become a blockbuster revenue line for Lilly
Fierce Pharma reported an analyst view that the latest White House update on the Medicare GLP-1 Bridge implies blockbuster annual sales for Lilly from the program. The Bridge launched July 1, 2026, reimburses at $245 per monthly supply against a $50 beneficiary copay and runs through December 31, 2027. Enrollment passed 500,000 people in its first two months.
- Safety
FDA screens GLP-1 ingredients at the border and flags vials labeled with pharmacies that do not exist
The FDA expanded import screening of GLP-1 active ingredients and warned that vials circulating in the US carry labels naming pharmacies with no corresponding registration. Poison control centers separately reported a surge in calls involving unapproved GLP-1 products, including dosing errors from self-drawn vials. The actions extend an enforcement campaign that has already produced batches of warning letters to online peptide sellers.
- Culture
Obesity Action Coalition presses PepsiCo and Starbucks to keep GLP-1 coverage
The Obesity Action Coalition launched public campaigns urging PepsiCo to reverse a reported decision to end GLP-1 obesity coverage for some employees from October and urging Starbucks to abandon a similar cut. The group noted PepsiCo is simultaneously developing products such as Propel Clear Protein aimed at GLP-1 users. Cigna and PricewaterhouseCoopers dropped weight-loss GLP-1 coverage earlier in 2026, part of a fall from 72% to 60% coverage among large employers.
- Safety
Poison control centers report a surge in calls tied to unapproved GLP-1 products
Reporting on the FDA's updated warning described a rising volume of poison control calls and safe-medicine complaints involving unapproved GLP-1 products bought online. The agency reiterated that unapproved versions do not undergo review for safety, effectiveness or quality, and that it has publicly warned telehealth companies for claiming compounded drugs are the same as FDA-approved products. Dosing errors with compounded injectable semaglutide have produced adverse events serious enough to require hospitalization, including cases where clinicians miscalculated doses.
- Prices
September pricing snapshot: LillyDirect self-pay is now identical for Zepbound pens and vials
A September 2 pricing review recorded that LillyDirect self-pay prices are the same for Zepbound KwikPens and single-dose vials, at $299 for 2.5 mg, $399 for 5 mg and $449 from 7.5 mg upward when refilled within 45 days, against regular prices of $599 to $1,049. Foundayo self-pay runs $149 at 0.8 mg and, temporarily through December 31, 2026, at 2.5 mg, $199 at 5.5 mg and $299 at the three top doses. TrumpRx.gov listed four GLP-1s that day and did not list Foundayo or Mounjaro; its Zepbound page routes buyers to LillyDirect.
- Business
Upper Macungie grants final land development approval for Lilly's Fogelsville plant
Upper Macungie Township supervisors unanimously approved the Final Land Development Plan and Sewage Planning Module for Lilly's Lehigh Valley manufacturing facility on September 2, 2026, conditioned on binding traffic mitigation. Lilly told the board that peak construction runs from the fourth quarter of 2027 through the first quarter of 2029, with as many as 1,500 workers on site. The company has secured 600 off-site parking spaces and plans a traffic signal and Main Street widening in 2027.
- Culture
EDO finds pharma NFL ads about twice as effective as prime-time averages
EDO's fourth annual NFL TV Outcomes Report found pharma ads in 2025-26 regular season games were about 104% more effective than average pharma ads on prime-time broadcast and cable, with Lilly and Zepbound among the standouts.
- Safety
FDA updates its unapproved GLP-1 guidance with compounded tirzepatide adverse event counts
The agency's standing page reported that as of May 31, 2026 it had received more than 730 adverse event reports associated with compounded tirzepatide and 990 associated with compounded semaglutide, and said both figures are likely undercounts because state-licensed pharmacies that are not outsourcing facilities are not required to report. It also described fraudulent compounded products carrying labels naming pharmacies that do not exist.
- Safety
GLP-1 injury dockets reach 4,022 and 216 pending cases
The JPML's monthly statistics showed 4,022 actions pending in MDL 3094 (4,056 filed to date) and 216 pending in the newer NAION docket MDL 3163, both before Judge Karen S. Marston in the Eastern District of Pennsylvania.
- Safety
FDA adds a border screen and a fraudulent-label warning to its unapproved GLP-1 guidance
The FDA's updated page on unapproved GLP-1 drugs describes a green-list import alert covering GLP-1 active pharmaceutical ingredients with potential quality concerns, designed to keep them out of the U.S. supply chain while allowing imports from manufacturers that appear to meet manufacturing standards. The update also flags fraudulent compounded semaglutide and tirzepatide carrying false label information: in some cases the compounding pharmacy named does not exist, and in others a real licensed pharmacy did not make the product. The agency cites one adverse event involving a product labeled as compounded tirzepatide from a pharmacy that did not compound it.
- Compounding
FDA posts a new batch of warning letters to online peptide sellers
Letters dated August 24, 2026 went to sellers listing retatrutide, semaglutide, tirzepatide, elamipretide and tesamorelin alongside bacteriostatic water, with FDA again rejecting research-use-only labeling as a defense.
- FDA & regulation
Fifth Circuit issues its companion semaglutide opinion upholding the FDA delisting
The Fifth Circuit filed its decision in Outsourcing Facilities Association v. FDA, No. 25-10758, on September 1, affirming summary judgment for the agency in the semaglutide shortage-delisting challenge. The panel held that any failure to use notice-and-comment procedures was harmless because affected parties had actual notice and repeated chances to submit information, and that the FDA reasonably relied on Novo Nordisk's supply, inventory and demand data. The opinion is the companion to No. 25-10600, the tirzepatide case decided August 27, and like it is unpublished.
- Safety
GLP-1 injury litigation tops 4,000 cases with vision claims growing
By September 2026 there were 4,022 cases pending in the gastrointestinal MDL 3094 and about 200 in the NAION vision-loss MDL 3163, both before Judge Karen S. Marston in Philadelphia. No trials had been held and no global settlement announced.
- Safety
JPML count: 4,022 pending in MDL 3094 and 216 in MDL 3163
The Judicial Panel's monthly statistics report showed MDL 3094 at 4,022 pending actions out of 4,056 filed, and MDL 3163 at 216 pending out of 216 filed. Both proceedings remain before Judge Karen S. Marston in the Eastern District of Pennsylvania, with Eli Lilly and Novo Nordisk as the manufacturer defendants. No settlement exists in either.
- Prices
KFF polling finds only about a third of drug users have heard of TrumpRx and most doubt the policies will lower costs
KFF survey work released around September 1 found that only 35 percent of prescription drug users reported knowing about TrumpRx, roughly seven months after its launch, and that 72 percent of adults said the government is not doing enough on drug pricing. Fifty-nine percent doubted current policies would meaningfully lower costs, and 66 percent of Americans taking medications reported cost concerns. Separately, KFF tracking found about 18 percent of adults have ever used a GLP-1 and 12 percent currently do.
- Business
Lilly cuts Foundayo self-pay prices on two doses through year end
Lilly's terms page shows the 2.5 mg self-pay price temporarily reduced from $199 to $149 a month and the 5.5 mg price from $299 to $199, 'for a limited time, through December 31, 2026.' Lilly publishes no start date and gave no public reason. Patients in the r/FoundayoPill community reported the new prices appearing on September 1, some saying LillyDirect texted customers that day, and several who had filled days earlier reported refunds of the difference after contacting LillyDirect. The September 1 date and the refunds are consumer reports, not stated Lilly policy. Nothing has been published about 2027 prices.
- Business
More than 20 drugmakers have announced US drug-pricing agreements
Reuters counted more than 20 companies with publicly announced most-favored-nation pricing deals, following a second wave in late August 2026 that added nine mostly smaller firms offering Medicaid MFN pricing, with about $19.6 billion in additional US manufacturing commitments reported.
- Business
Novo Nordisk launches the Wegovy pill in Germany, its first European market
Oral semaglutide 25 mg went on sale in German pharmacies on September 1, 2026, the first European launch following the European Commission approval on July 15. Novo Nordisk told Reuters that retail pharmacy prices will vary by dose and sit roughly in line with the Wegovy pen, which currently runs about €170 to €280 in Germany. Unlike the injection, which is approved from age 12 in the EU, the tablet is licensed for adults only.
- Business
Securities class action filed against Hims & Hers over privacy disclosures
Velanki v. Hims & Hers Health, Inc., No. 26-cv-09313, was filed in the Northern District of California on behalf of investors who bought HIMS securities between August 4, 2025 and July 29, 2026. The complaint alleges the company failed to disclose that it shared consumer health information with advertising platforms and charged customers for prescriptions almost immediately after intake, conduct that exposed it to regulatory scrutiny and penalties. The lead-plaintiff deadline is November 2, 2026; the stock fell $4.32, or 14.73 percent, to $25.00 on the day the FTC complaint became public.
- Prices
UnitedHealthcare's updated weight-loss prior authorization program takes effect
Program 2026 P 1114-22 became effective, covering phentermine, Contrave, Qsymia, Saxenda, Xenical, Wegovy injection and tablet, Wegovy HD, Zepbound and Foundayo. It confirms a BMI 30 threshold (or 27 with a comorbidity), no BMI requirement for the MASH indication, 5-month initial approvals for Wegovy and 6-month approvals for Zepbound and Foundayo, and 12-month renewals conditioned on at least 5 percent weight loss.
- Business
Analysts say the Mounjaro heart label helps diabetes reimbursement, not obesity coverage
Commentary on the August 28 approval argued that the new cardiovascular risk-reduction indication gives Lilly medical-necessity language for the diabetes patients most exposed to a cost review, but does not touch Zepbound's obesity label, which is where employer coverage is actually being cut. Employer GLP-1 coverage for weight loss fell from 72% in 2025 to 60% in 2026, with roughly 14% of surveyed employers having dropped or planning to drop the drugs for 2027. A label expansion does not compel any payer to cover anything.
- FDA & regulation
BMJ reporting traces Canada's generic semaglutide to an unpaid C$250 patent fee
The BMJ detailed how Novo Nordisk stopped paying a C$250 annual maintenance fee on its Canadian semaglutide patent starting in 2018, a lapse that under Canada's Patent Act cannot be revived and that, alongside data protection expiring on January 5, 2026, opened the door to generics. Novo Nordisk would only say that intellectual property decisions are considered at a global level, and told the BBC the situation is localized and does not affect intact US exclusivity. I-MAK's Tahir Amin said the Canadian patent could have run to 2028.
- Research
ESC 2026 data show a lower maintenance dose keeps cardiometabolic gains
Results presented at the European Society of Cardiology meeting showed that people maintained on 5 mg tirzepatide held improvements in blood pressure and other markers, supporting a step-down strategy after the weight comes off.
- Safety
Higher semaglutide doses tied to fewer neuropsychiatric events, independent of weight lost
A study published September 1 in npj Metabolic Health and Disease reported that among roughly 63,000 semaglutide patients, higher doses were associated with lower incidence of new mood, anxiety and substance-use diagnoses, and that the association did not track with how much weight patients lost. The authors position the finding against mixed prior literature, including a Lancet Psychiatry Swedish cohort that found worsening mental illness in some depressed and anxious patients. The design is observational and cannot establish a protective effect.
- Research
MASH outcomes master protocol including tirzepatide begins recruiting
A phase 3 master protocol with a target enrollment of 4,500 and a major adverse liver outcomes primary endpoint is recruiting, with estimated primary completion in August 2030. It is the outcomes-level liver study that the phase 2 SYNERGY-NASH trial could not provide.
- Business
Novo Nordisk names Bayer's Andrea Haegebarth head of global research
Novo Nordisk announced that Andrea Haegebarth, most recently Bayer's global head of research and early development for precision medicine, will join as senior vice president of global research effective October 1, 2026. Jacob Petersen, who held the research role, moves to a new position as head of R&D external innovation after more than 25 years at the company. Chief scientific officer Martin Holst Lange described the two roles as complementary, one strengthening internal discovery and the other widening the company's reach into outside science.
- Research
Pfizer starts the first of its September berobenatide Phase 3 trials
A Pfizer Phase 3 study of berobenatide carries a start date of September 1, 2026, with VESPER-6, a placebo-controlled trial of once-monthly PF-08653944 in adults with overweight or obesity, listed as recruiting on September 4. Two further Phase 3 registrations in Japan and China show start dates of September 28. Pfizer told investors it plans to advance ten berobenatide Phase 3 studies in 2026 and targets a first approval in 2028.
- Prices
Reuters publishes a company-by-company reference to the GLP-1 terms inside the drug-pricing deals
Reuters compiled the terms of the drug-pricing agreements struck with more than 20 manufacturers. For GLP-1s, Novo Nordisk agreed to sell Ozempic and Wegovy at $350 a month through TrumpRx, down from list prices of about $1,000 and $1,350, and to supply NovoLog and Tresiba insulins at $35. Eli Lilly agreed to offer Zepbound and Foundayo to Medicare beneficiaries at no more than $50 a month, with the Zepbound multidose pen at $299 rising to $449 by dose and Foundayo starting at $149 through LillyDirect.
- Prices
Time reports that most-favored-nation Medicaid pricing has not translated into the lowest TrumpRx prices for consumers
Reviewing the latest round of agreements, Time noted that the deals bind Medicaid to prices paid primarily in Europe while consumer-facing TrumpRx prices remain higher than what patients pay abroad, citing earlier New York Times reporting. Analysts quoted in the piece described most-favored-nation deals as an administratively easier path than lowering prices for all payers, and cautioned that direct-to-consumer discounts are not always the cheapest route for a given patient.
- Culture
Virtual GLP-1 program with strength coaching improves both quantity and quality of weight loss
A quasi-experimental evaluation of 245 adults found a 12-week virtual program with strength-focused activity coaching produced 6.0% adjusted weight loss versus 3.3% with usual care, with greater fat loss (-3.3% vs -1.6%) and better muscle preservation (+0.6% vs +0.2%).
- Competition
CSPC registers a Phase 2 of its own incretin candidate in type 2 diabetes
CSPC Ouyi Pharmaceutical registered a 240-participant Phase 2 study of SYH2069 in people with type 2 diabetes not controlled by diet and exercise alone or by metformin, listed as not yet recruiting. CSPC is AstraZeneca's partner on an obesity and diabetes collaboration announced in March 2026 with $1.2 billion upfront and potential payments of about $18.5 billion, the largest China-origin licensing structure of the year. The registration shows CSPC continuing to build its own metabolic pipeline alongside the partnership.
- Science
Lancet Diabetes & Endocrinology editorializes on soaring GLP-1 use
The journal published an editorial on the scale and speed of global GLP-1 receptor agonist uptake, raising questions about equity of access, unmonitored use and the thinness of long-term safety data relative to the size of the exposed population. It is an editorial position rather than new evidence. The framing echoes concerns raised in the Endocrine Society's scientific statement a week later.
- Research
Regeneron pushes back the readout on its muscle-preservation combination
The primary completion date for Regeneron's Phase 2 study of trevogrumab, alone or with garetosmab, added to semaglutide for weight loss, fat loss and lean-mass preservation moved from May 6 to June 16, 2026 in a registry update. Earlier COURAGE data reported that trevogrumab roughly halved semaglutide-induced lean-mass loss, with the garetosmab combination cutting it further. Regeneron is one of more than a dozen companies now working on lean-mass preservation alongside incretins.
- Business
Solera adds Noom to its employer and health plan weight management network
Solera Health added Noom to its curated weight management network, giving health plan and employer members access to Noom Weight, a CDC Full Plus-recognized diabetes prevention program, and a GLP-1 Companion program at no extra cost. The deal routes Noom through the benefits channel rather than direct-to-consumer subscriptions, a shift several GLP-1 adjacent companies are making as cash-pay competition intensifies. It also positions Noom's behavior-change content as a wrapper around medication rather than a substitute for it.
- Business
The New York Times profiles Doustdar a year into the Novo Nordisk turnaround
In a long profile reported from New York and from Clayton and Durham, North Carolina, the Times laid out chief executive Mike Doustdar's argument that investors are fixated on the Eli Lilly rivalry and are underestimating the breadth of Novo Nordisk's portfolio and pipeline. The piece framed pills as the company's likely second act after the Ozempic injection. It also captured the investor anxiety underneath: the key US semaglutide patent expires early in the next decade.
- Research
TREASURE-CKD reaches estimated primary completion with no results yet public
Lilly's phase 2b mechanistic kidney trial of tirzepatide in 140 adults with chronic kidney disease and overweight or obesity was scheduled to reach primary completion in September 2026. Its primary endpoint is the change in renal sinus fat on MRI at 52 weeks, with kidney oxygenation and measured filtration rate among the secondary measures. No results had been published as of 2026-09-14.
- Safety
Rule 702 expert hearing tests whether GLP-1 drugs can cause gastroparesis
The admissibility hearing in MDL 3094 is the pivotal moment of the gastrointestinal litigation. If plaintiffs' general causation experts are excluded, thousands of claims collapse; if they survive, the case moves toward bellwether trials expected in late 2026 or 2027.
- Science
Five semaglutide presentations now on the US market at once
As of September 2026 the US has Ozempic injection, Ozempic tablets, Rybelsus tablets, Wegovy injection including the 7.2 mg high dose, and Wegovy tablets - five presentations of one molecule with different strengths, indications and dosing rules.
- Business
Generic liraglutide undercuts every branded GLP-1 on acquisition cost
By September 2026 the FDA lists liraglutide products from nine manufacturers. The national average acquisition cost for a generic liraglutide 3-pack is about $32.00 per mL effective 2026-08-19 against $87.81 for brand Victoza, roughly 64 percent lower, and far below Trulicity at about $487 per mL and the Ozempic pen at about $332 per mL. Liraglutide injection nonetheless remains on the FDA shortage list.
- Science
Semaglutide's label now spans six approved uses
Across its brands semaglutide is approved for type 2 diabetes, cardiovascular risk reduction in diabetes, chronic kidney disease in diabetes, chronic weight management, cardiovascular risk reduction in obesity or overweight, and noncirrhotic MASH with moderate to advanced fibrosis. No other GLP-1 carries that range.
- Prices
Wegovy self-pay prices settle at $349 for pens and $399 for the high dose
After introductory offers expire, Novo Nordisk's published self-pay prices are $349 a month for Wegovy 0.25 mg through 2.4 mg pens and $399 for Wegovy HD 7.2 mg, with tablets at $149 to $299 by dose. Commercially insured patients can pay as little as $25 a month with the savings offer.
- FDA & regulation
Appeals court sets a September date in Lilly's fight with the FDA over retatrutide's drug class
The Seventh Circuit scheduled oral arguments for September 24, 2026 in Eli Lilly's appeal against the FDA's determination that retatrutide is neither a protein nor a biological product. The outcome decides whether the drug gets five or twelve years of market exclusivity.
- Compounding
Compounded semaglutide still undercuts branded cash prices
Price trackers in late 2026 listed compounded semaglutide between roughly $178 and $299 a month, against $149 for the starter dose of the Wegovy pill and $349 for the injection. The price gap is why compounding has not disappeared despite the enforcement push.
- Safety
GLP-1 gastrointestinal MDL passes 4,000 with no trial date set
MDL 3094 reached 4,022 pending cases, with 4,056 filed in total, and continued to add hundreds of filings a month. The figure comes from a litigation tracker following the Judicial Panel on Multidistrict Litigation's monthly statistics; the JPML's own August 1, 2026 report put the count at 3,928. Bellwether trial selection remained tied to the outcome of the expert evidence rulings.
- Safety
JAMA Pediatrics reports elevated biliary event risk in youth on GLP-1 drugs
Using the TriNetX network, researchers matched 18,759 patients aged 12 to 21 treated with GLP-1 receptor agonists to an equal number of non-users and found significantly elevated rates of cholecystitis, biliary colic and cholecystectomy. Elevated event rates persisted in the subgroup with class I or II obesity. Gallbladder disease is already a labeled risk for the class in adults, but pediatric data have been scarce as prescribing to minors climbs.
- Safety
Legal analysts estimate GLP-1 liability could top $2 billion
Observers of MDL 3094 and MDL 3163 estimated combined potential liability above $2 billion across gastrointestinal and vision-loss claims, while cautioning that no case had been tried. Mass settlements were viewed as unlikely before late 2027.
- Science
MASH remains a semaglutide-only indication among GLP-1 drugs
As of September 2026, Wegovy was still the only GLP-1 carrying an approved MASH indication. Tirzepatide showed 73.3% MASH resolution at 15 mg in the phase 2 SYNERGY-NASH study and is in phase 3, so prescribing it for MASH remains off-label.
- Competition
Corbus expects topline Phase 1b results for its peripheral CB1 drug CRB-913
The 240-participant CANYON-1 study completed its final patient visit in August 2026, with results due in September, a key test of whether CB1 can be revived as an obesity target without central nervous system side effects.
- Culture
GLP-1 waste and packaging draw environmental criticism
Commentators began raising the environmental cost of tens of millions of single-use injector pens and cold-chain shipping. The arrival of daily tablets removes the refrigeration and needle-disposal burden for a growing share of patients.
- Safety
Multi-state Medicaid cohort examines GLP-1 use and new depression diagnoses
A multi-state Medicaid cohort study compared baseline GLP-1 receptor agonist use with newly documented depression diagnoses among adults with type 2 diabetes, covering dulaglutide, exenatide, liraglutide, semaglutide and tirzepatide. The analysis follows the FDA's 2026 drug safety communication asking manufacturers to remove the suicidal behavior and ideation warning from the class. Claims-based mental health outcomes are sensitive to diagnostic coding and care access.
- Policy
NICE appraisal of the obesity pill stays open in the UK
Britain's National Institute for Health and Care Excellence asked Eli Lilly for more information after its first committee meeting on orforglipron and has not set a second review date. The appraisal listing carries an expected publication date of November 18, 2026.
- Safety
Optometry guidance tells clinicians how to counsel GLP-1 patients on NAION
A September clinical briefing walked optometrists through the NAION evidence, including a retrospective cohort of 710 patients with type 2 diabetes in which 17 semaglutide users developed NAION compared with matched controls. The guidance advises documenting disc-at-risk anatomy and counseling on sudden painless vision loss rather than withholding treatment. It reflects a professional shift from debating the signal to managing it.
- Research
Post hoc analysis examines orforglipron in adults 65 and older
Obesity Pillars published a post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials looking at orforglipron in participants aged 65 and older with and without type 2 diabetes. Older adults are a group where lean mass loss and fracture risk raise the stakes of obesity pharmacotherapy but where trial representation has been thin. Post hoc subgroups are hypothesis-generating and were not powered endpoints.
- Prices
Brazil clears two more synthetic semaglutide pens as interchangeable
Brazil's health regulator ANVISA approved an EMS generic and Germed's Semaclique as interchangeable substitutes for Ozivy, the first synthetic semaglutide pen it cleared in May 2026. The approvals bring the number of post-patent semaglutide registrations in Brazil to at least seven within five months of patent expiry, following Sun Pharmaceutical's July approval and launch with Hypera Pharma. Brazil accounted for about 60 percent of South American GLP-1 revenue in 2025, making it the largest live test of what generic pricing does to a branded semaglutide market.
- Safety
Guardian reports patients buying gray-market retatrutide despite no approval anywhere
The Guardian documented people sourcing retatrutide from online sellers, reconstituting vials at home and dosing from instructions supplied by vendors, months before Lilly plans to file the drug with the FDA. Lilly says it has reported more than 14,000 listings across more than 100 countries and that patients have been hospitalized after using black-market product; that harm claim comes from the company. No regulator has reviewed any of the products for identity, purity or sterility.
- Policy
Most-favored-nation agreements reach 26 manufacturers covering 89 percent of the branded drug market
With nine more companies signing on August 31, including Astellas, BeOne Medicines, BridgeBio, CSL, Sun Pharmaceutical, Teva and UCB, the administration counted 26 manufacturers with most-favored-nation pricing agreements, covering 89 percent of the branded drug market by its own tally. The White House Council of Economic Advisers raised its estimate of ten-year savings to roughly $600 billion and said TrumpRx had produced more than $700 million in patient savings since February.
- Research
ADJUST-T1D extension shows glycemic gains fade after stopping semaglutide
Diabetes, Obesity and Metabolism published a 12-week extension following 16 people with type 1 diabetes who stopped semaglutide and 22 placebo participants. Those who stopped had a greater decline in time in range (median -3.6 percent versus +1.5 percent) and greater glucose variability, with no significant differences in hypoglycemia metrics.
- Safety
Brazil seizures of smuggled GLP-1s nearly triple as black market grows
Reuters reported that Brazilian customs seized more than 76,000 pens, vials and other weight-loss products containing semaglutide and tirzepatide in the first half of 2026, nearly three times the total confiscated in all of 2025, with Federal Police counting 165,589 units through June against 60,865 for all of last year. Smuggled product from Paraguay has been found hidden in jars of dulce de leche aboard a tourist bus, under shoe insoles and inside vehicle compartments. The scale matters to U.S. readers because the same unregulated supply chains feed online sellers shipping into the United States.
- Business
Hims & Hers begins selling branded GLP-1s in Australia
Hims & Hers said on August 31 that it has begun offering branded GLP-1 weight-loss drugs and men's health treatments in Australia, its first Asia-Pacific market, following the acquisition of Eucalyptus and its Pilot and Juniper brands. The rollout rebrands Pilot under the Hims umbrella and extends care-team access to 24 hours a day, with women's health services planned later in the year. The expansion moves growth offshore while the company's U.S. GLP-1 business runs on lower-margin branded resale after its exit from compounded semaglutide.
- Business
Lilly begins Foundayo's first big consumer ad campaign, fronted by Martha Stewart
Foundayo direct-to-consumer advertising went wide in late August 2026 with Martha Stewart as the face of the campaign, drawing immediate criticism in consumer forums because Stewart reportedly does not take a GLP-1 herself. Lilly's leadership had told analysts that broad DTC marketing would only start once commercial access across the three major PBMs was in place, which happened in June 2026.
- Research
Lilly registers a 2,001-patient Phase 3 of orforglipron in people who are only overweight
Eli Lilly registered a Phase 3 trial of orforglipron in 2,001 participants with overweight who are at risk of developing obesity-related complications or of progressing to class 1 obesity, listed as not yet recruiting. The design pushes the oral GLP-1 toward a prevention framing rather than treatment of established obesity. If it succeeds, it would widen the eligible population well beyond current labels and sharpen the coverage fight with payers.
- Research
One-year data confirm the Taltz plus Zepbound combination in psoriatic disease
Follow-up from the phase 3b trial showed the improvement held at 12 months, strengthening the case for treating obesity as part of inflammatory disease care.
- Safety
Penn study links GLP-1 use to higher male pattern hair loss risk
Penn Medicine researchers reported that patients with diabetes taking GLP-1 receptor agonists, a class that includes tirzepatide, had a higher risk of androgenetic alopecia than patients on other diabetes drugs. The analysis used electronic health record data and is observational. It follows a July BMJ analysis that flagged a hair-loss signal across the class and adds a male-specific finding.
- Culture
Reuters documents a booming Brazilian black market in Wegovy and Mounjaro
Reuters reported record seizures of smuggled weight-loss injections in Brazil, hidden in motorcycle exhaust pipes and false shoe soles, as the country became one of the world's hottest GLP-1 markets. A high-dose 2.4 mg Wegovy box sells for close to $340 online through a patient support program, against roughly $290 for the lowest Mounjaro dose. Anvisa approved Ozivy, Brazil's first domestic semaglutide alternative, in May 2026 and has since cleared others, betting that cheaper regulated supply will pull buyers away from smuggled product.
- Research
Reuters reports GLP-1 drugs work even at low starter doses
Reuters covered research finding that patients on low starter doses of GLP-1 and dual-agonist drugs achieved meaningful weight loss, complicating the assumption that titration to maximum doses is always necessary. The finding has direct cost implications for tirzepatide, where LillyDirect self-pay pricing steps from $299 at 2.5 mg to $449 at 7.5 mg and above. The work is observational and does not establish that low doses match high doses for every patient.
- Research
Sciwind opens a Phase 3 of ecnoglutide in knee osteoarthritis
Hangzhou Sciwind Biosciences moved a Phase 3 study of ecnoglutide in participants with obesity and knee osteoarthritis from not yet recruiting to recruiting. Ecnoglutide is already approved in China for type 2 diabetes and chronic weight management, and Pfizer holds Chinese commercialization rights under a deal worth up to $495 million struck in February 2026. The osteoarthritis indication puts Sciwind on the same comorbidity ground Lilly has staked out with retatrutide's TRIUMPH-4 knee trial.
- Policy
Sun Pharma secures more than two years of Section 232 tariff relief in its US pricing agreement
Sun Pharmaceutical said its agreement with the US government to supply affordable medicines carried more than two years of relief from Section 232 pharmaceutical tariffs, giving the company cost certainty for its innovative portfolio. The arrangement follows the pattern set for Eli Lilly and Novo Nordisk, whose November 2025 GLP-1 pricing deals carried a three-year tariff exemption, and illustrates how tariff relief has become the main lever pulling manufacturers into most-favored-nation pricing.
- FDA & regulation
Zepbound label revision keeps dual weight and sleep apnea indications with different dose floors
The revised Zepbound prescribing information maintains two indications with different maintenance requirements: 5 mg, 10 mg or 15 mg for weight reduction, but 10 mg or 15 mg for moderate to severe obstructive sleep apnea. It restates that the 2.5 mg starting dosage is for initiation only and is not approved as a maintenance dosage, and that safety and effectiveness have not been established in pediatric patients.
- Research
Altimmune's PERFORMA appears on the registry as an 1,800-patient Phase 3
Altimmune's Phase 3 study of the efficacy, safety and clinical outcomes of pemvidutide in MASH was registered with an enrollment target of 1,800 participants and a status of recruiting. The scale puts pemvidutide's liver program in the same weight class as the incretin MASH trials now running from Novo Nordisk and Eli Lilly. Altimmune has said its cash funds the program through the 52-week readout expected in 2029.
- Culture
Boston Globe documents a double bind: shamed for using a GLP-1, shamed for not
A Boston Globe feature described users caught between fat stigma and drug stigma, with people reporting judgment for taking a GLP-1 and equal judgment for staying heavy without one. The reporting draws on interviews rather than survey data. It follows peer-reviewed August work naming GLP-1 treatment stigma as a distinct phenomenon from weight stigma.
- Compounding
Counsel warns telehealth advertisers that compounded-drug marketing is the enforcement target
A compliance alert traced the FDA's escalating scrutiny of compounded-drug advertising, noting the March 3, 2026 announcement of 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products, a second coordinated wave after the 2025 letters. The guidance argues that enforcement now turns on claims of equivalence to approved drugs, implied FDA approval and implied in-house manufacturing rather than on the act of compounding itself. It urges platforms to audit landing pages, affiliate copy and influencer material.
- Research
Innovent's 9 mg mazdutide Phase 3 record flips to unknown status
The registry entry for Innovent Biologics' Phase 3 study of IBI362 9 mg in Chinese adults with obesity changed from active, not recruiting to unknown, meaning the sponsor has not verified the record within the registry's expected window. The 9 mg dose produced up to 20.1 percent average weight loss over 60 weeks in the GLORY-2 trial. A status change of this kind is an administrative signal, not a clinical one, but it is the sort of change that disappears from the public record once overwritten.
- Research
Meta-analysis quantifies weight loss with newer GLP-1 agents in adults without diabetes
A systematic review pooled trials of newer GLP-1 and multi-agonist agents in adults with overweight or obesity but without diabetes, confirming substantially larger weight reductions than older agents. The synthesis reinforces the widening efficacy gap between first-generation GLP-1s such as liraglutide and current agents. Heterogeneity across trial designs and durations limits direct head-to-head inference.
- Safety
Penn's hair loss findings break into mainstream coverage, and its authors push back on the weight-loss explanation
Penn Medicine publicized its target trial emulation showing GLP-1 users were 37% more likely than SGLT2 inhibitor users and 68% more likely than DPP-4 inhibitor users to develop hair loss, triggering a wave of national coverage through early September. Co-author George Cotsarelis said that while weight loss is a known cause of shedding, there is a chance the drug causes hair loss through a different mechanism that needs to be explored. The underlying study was published in The BMJ on July 22, 2026; the news cycle, not the data, is what is new here.
- Research
Pooled analysis of 6,239 adults reports semaglutide benefits beyond weight itself
An analysis covering 6,239 adults reported improvements across cardiometabolic measures that the authors argue are not fully explained by the amount of weight lost. The work belongs to a 2026 line of research trying to separate drug effects from weight effects, a distinction that matters for how broadly these drugs should be prescribed. As a pooled analysis it cannot establish causation for individual endpoints.
- Prices
White House announces most-favored-nation deals with nine more manufacturers
The latest round further expanded the drugs carried on TrumpRx beyond the original GLP-1 and fertility categories.
- Research
Ascletis doses the first patient in a global Phase 3 of oral small-molecule GLP-1 ASC30
Ascletis Pharma dosed the first participant in the global Phase 3 program for ASC30, a once-daily oral small-molecule GLP-1 receptor agonist, under registrations AURORA-1 and AURORA-2. The program covers roughly 4,600 participants at sites in the United States, Europe and Canada, testing 20 mg, 40 mg and 60 mg maintenance doses over 72 weeks. Guided topline is the third quarter of 2028, with an FDA submission targeted by the end of 2028; the company positions ASC30 as a candidate to be the second oral small-molecule GLP-1 rather than a near-term rival to orforglipron.
- Culture
Researchers describe GLP-1s reopening 'cultural body trauma' for women
Reporting on Australian research described women experiencing the GLP-1 boom as a revival of earlier diet-culture harms, with participants recounting renewed body surveillance and shame. The framing treats the drug class as a cultural event layered on decades of prior weight-loss messaging. The underlying work is qualitative.
- Research
ESC's new heart failure guideline recommends semaglutide and tirzepatide for HFpEF with obesity
At its 2026 Congress in Munich, the European Society of Cardiology released updated heart failure guidelines that recommend semaglutide and tirzepatide for patients with heart failure with preserved ejection fraction and obesity, reflecting the STEP-HFpEF and SUMMIT programs and supporting real-world data. The same update backed mineralocorticoid receptor antagonists across the ejection fraction spectrum and revised the definition of myocardial infarction. The US labels still carry no HFpEF indication, so the guideline and the American regulatory position have now diverged.
- Research
Large US cohort compares GLP-1 drugs with spironolactone in resistant hypertension
A retrospective multicenter cohort study in EClinicalMedicine used the TriNetX US Collaborative Network across 67 healthcare organizations to compare adults with overweight or obesity and resistant hypertension who started semaglutide or tirzepatide against those who started a mineralocorticoid receptor antagonist as fourth-line therapy. The pool contained 213,309 eligible patients before propensity matching, with major adverse cardiovascular events over two years as the primary outcome. Semaglutide and tirzepatide were analyzed together, and confounding by indication remains the central limitation.
- Science
Novo Nordisk brings oral semaglutide cardiovascular data to ESC 2026 in Munich
At the European Society of Cardiology Congress in Munich from August 28 to 31, Novo Nordisk presented SOUL analyses of oral semaglutide cardiovascular outcomes by baseline blood pressure control, real-world data on oral semaglutide and inflammatory markers, and a symposium on cardiovascular inflammation chaired with Paul Ridker. Company medical affairs framed the program around organ protection rather than glucose or weight control. Mediation analyses presented there argued that weight loss explains only part of semaglutide's cardiovascular benefit.
- FDA & regulation
Lilly announces the first cardiovascular indication for a dual GIP/GLP-1 agonist
Announced during the European Society of Cardiology congress, the approval makes Mounjaro the first and only GIP and GLP-1 receptor agonist with a cardiovascular risk-reduction claim. Commentators stressed that the trial showed non-inferiority to dulaglutide, not superiority.
- FDA & regulation
Lilly announces the Mounjaro heart indication, built on a head-to-head trial
SURPASS-CVOT randomized 13,299 adults across 640 sites in 30 countries to tirzepatide or dulaglutide rather than placebo. Over a median 210.1 weeks the MACE-3 hazard ratio was 0.92 (95.3% CI 0.83-1.01), meeting non-inferiority at p=0.007. Superiority was not established. All-cause death was 8.5% versus 10.1%, hazard ratio 0.84.
- Business
Mounjaro approved to reduce cardiovascular risk in type 2 diabetes
Eli Lilly's pending indication for Mounjaro to reduce major adverse cardiovascular events is supported by SURPASS-CVOT, which showed an 8% reduction versus dulaglutide and met non-inferiority rather than superiority. An FDA decision was expected in the third quarter of 2026.
- Business
Foundayo passes 40,000 weekly US prescriptions
Twenty weeks into launch, IQVIA data cited by Citi put Foundayo at 40,862 weekly total prescriptions, its first week above 40,000. For comparison, Novo Nordisk's Wegovy pill had reached roughly 57,000 by week 6 of its own launch.
- Search trends
Google updates site reputation abuse guidance on editorially overseen affiliate content
Updated guidance indicated Google is unlikely to act against affiliate content written by a freelancer where the publisher exercises editorial oversight and the content is created specifically for that publication. This defines the operating model an affiliate health site should be able to demonstrate.
- Competition
India's cheap generic semaglutide struggles to crack the market
Bloomberg reported that the flood of cheaper copycat semaglutide released by India's March patent expiry had not displaced branded products as quickly as expected. Distribution, pen supply and physician habits slowed adoption.
- Prices
Canada's pCPA tiers spell out how far generic semaglutide prices will fall
Analysis of Canada's pan-Canadian Pharmaceutical Alliance pricing framework laid out the step-down schedule for generic semaglutide: the first entrant prices at 75% to 85% of brand, the second at about 50%, and three or more at 35%. Applied to current Canadian brand prices, which run from about C$86 to C$663 for Ozempic and C$270 to C$550 for Wegovy, that points to roughly C$100 a month out of pocket once three generics are selling. The schedule is automatic and does not require a negotiation for each product.
- Culture
Food-centered communities start reckoning with what GLP-1s do to shared meals
A Hadassah Magazine essay examined what widespread GLP-1 use means for a culture organized around holiday meals, hosting and abundance, from Shabbat tables to shiva platters. It is part of a broader late-summer genre treating appetite suppression as a social event rather than a private medical one. The piece is reported commentary, not survey data.
- FDA & regulation
FDA approves the Mounjaro cardiovascular indication
Supplements S-044 (new indication) and S-045 (new dosing regimen) were actioned. S-044 added reduction of major adverse cardiovascular events in adults with type 2 diabetes at high risk. S-045 is the quieter and more practical change: FDA's approval letter describes it as updating the Mounjaro prescribing information to indicate that the 2.5 mg dose of tirzepatide can be used for ongoing glycemic control in patients with type 2 diabetes. The label's previous sentence, "The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control," is gone from the 8/2026 revision, and Mounjaro's dosing section no longer directs an automatic increase to 5 mg after four weeks. The parallel restriction in the Zepbound label is unchanged.
- Compounding
Fifth Circuit upholds FDA's removal of tirzepatide from the shortage list
An unpublished per curiam panel opinion in No. 25-10600 affirms the district court, holding that any failure to use notice-and-comment rulemaking was harmless and that FDA's determination was not arbitrary. A companion opinion resolves the semaglutide appeal the same day. This closes the compounders' main route back to shortage-based mass compounding of tirzepatide.
- Prices
Novo Nordisk confirms it will cut US list prices for Wegovy, Ozempic and Rybelsus in 2027
Novo Nordisk reiterated that US list prices for its semaglutide medicines will fall on January 1, 2027, with Wegovy and Ozempic moving to a stated $675 per month from figures above $1,000. The move flows from the most-favored-nation pricing agreement the company signed with the White House in late 2025 and from the Medicare negotiated price taking effect the same day. List price is not what most patients pay, but it resets deductible math, coinsurance and cash-price benchmarks across the market.
- Research
Researchers propose an 'adaptive maintenance' framework beyond continue-or-stop
Obesity Pillars published a review arguing that care after incretin-induced weight loss should move beyond a binary choice between indefinite maximum-dose medication and discontinuation. It set out five strategies for formal study: continued medication, monitored dose reduction with pre-specified re-escalation criteria, switching to an oral agent, reduced-frequency dosing, and intermittent rescue therapy, and suggested early appetite and satiety changes may flag relapse before the scale does. It is the clearest published statement of the field's research agenda.
- Competition
William Blair maps the rest of 2026 for everyone chasing third place in obesity
A William Blair review circulated after second-quarter earnings set out the remaining 2026 catalysts across the obesity field: Roche's September 28 Pharma Day and a Phase 2 enicepatide readout in type 2 diabetes, AstraZeneca's AZD6234 amylin data at EASD, Pfizer's plan to advance ten berobenatide Phase 3 trials, Novo's Phase 3 starts for zenagamtide and high-dose cagrilintide, and a fourth-quarter CagriSema decision. Obesity therapeutics reached $66 billion in sales in 2025 and IQVIA projects $105 billion to $200 billion by 2027 and beyond.
- FDA & regulation
China's drug regulator accepts Novo Nordisk's filing for the Wegovy pill
China's National Medical Products Administration accepted Novo Nordisk's marketing application for oral semaglutide 25 mg for weight management, starting the formal review clock in the world's second-largest pharmaceutical market. Acceptance is not approval, and no decision timeline was disclosed. The filing lands as Chinese generic semaglutide injections reach the market following the March 20, 2026 patent expiry there.
- Business
EudraVigilance analysis compares suicide and self-injury reports across GLP-1 drugs
A Frontiers in Pharmacology study of 42,941 European adverse event reports from 2021 to 2025 finds 37 suicide or self-injury cases for liraglutide, 141 for semaglutide and 47 for tirzepatide. Reporting odds ratios versus tirzepatide were 2.54 for liraglutide and 2.69 for semaglutide. The authors state the findings do not establish causation and do not contradict regulatory conclusions.
- FDA & regulation
Fifth Circuit record puts Lilly's shortage-era capacity spending at about $23 billion
The Fifth Circuit's opinion in Outsourcing Facilities Association v. FDA records that Lilly spent roughly $23 billion building, expanding and acquiring manufacturing capacity in the US and Europe while Mounjaro and Zepbound sat on the shortage list, and won approval to sell single-dose vials alongside the original pens. The court found the FDA reasonably concluded that supply would meet or exceed projected demand. The opinion also notes Lilly's five-year new chemical entity exclusivity for tirzepatide runs to 2027.
- Culture
Arla Foods Ingredients credits GLP-1 nutrition demand for a 19.3% revenue jump
Arla Foods Ingredients reported revenue up 19.3%, attributing part of the gain to whey protein pricing and demand from products formulated for GLP-1 users. It is one of the first ingredient-supplier results to name the drug class directly as a growth driver. The figure is company-reported and not broken out by end market.
- Business
Deutsche Bank downgrades Novo Nordisk and the shares slip about 3%
Deutsche Bank cut its rating on Novo Nordisk, sending the stock down roughly 2.9% on growth concerns as the ziltivekimab failure and CagriSema's mixed record narrowed the visible pipeline. The downgrade came three weeks before the company's Capital Markets Day in London, where management was expected to reset long-term targets. Analyst consensus on the stock had already drifted to hold.
- Research
Lilly registers a Chinese Phase 3 of orforglipron in obesity
Eli Lilly registered a 192-participant Phase 3 trial of orforglipron in Chinese adults with obesity or overweight and weight-related health problems, listed as not yet recruiting. The filing extends the oral GLP-1's late-stage program into the market where Novo Nordisk, Innovent, Hengrui and Sciwind are all competing on price and access. Regulatory reviews for the pill were under way in more than 40 markets as of August.
- Research
Novo Nordisk opens a Korean Phase 3 trial of CagriSema
Novo Nordisk began enrolling Korean sites in a Phase 3 study of CagriSema, the fixed-dose weekly combination of cagrilintide 2.4 mg and semaglutide 2.4 mg. The expansion adds Asian data to a program whose US decision is expected in the fourth quarter of 2026 based on REDEFINE 1 and REDEFINE 2. CagriSema failed to demonstrate non-inferiority to tirzepatide 15 mg in the open-label REDEFINE 4 head-to-head reported in February 2026.
- Safety
Both tirzepatide labels updated on the basis of SURPASS-CVOT
Mounjaro gained an indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk, and both labels had their Diabetic Retinopathy Complications warning updated. The FDA approval letter for Zepbound supplement 041 states plainly that the retinopathy change was based on the SURPASS-CVOT trial.
- Prices
Court lets the Zepbound formulary lawsuit against CVS Caremark proceed
Judge Louis L. Stanton denied Caremark's motion to compel arbitration and granted its motion to dismiss only in part, allowing the ERISA duty-of-loyalty and denial-of-benefits claims to move forward on the theory that coverage decisions were driven by Caremark's own rebate interests. An amended complaint was due September 25, 2026.
- Prices
CVS and Walgreens each report about 100,000 Medicare Bridge prescriptions filled in under two months
CVS and Walgreens each told NPR they had filled roughly 100,000 Medicare GLP-1 Bridge prescriptions less than two months after the program's July 1 launch. Walmart did not give a number but said Bridge prescriptions were growing week over week and had been processed at more than 5,000 Walmart and Sam's Club pharmacies. A USC Schaeffer Institute scholar estimated the visible volume represented 5 to 10 percent of the roughly 4 million eligible beneficiaries within weeks of launch.
- Prices
KFF puts the 18-month cost of the Medicare GLP-1 Bridge between $1.3 billion and $10 billion
With CMS declining to publish a cost estimate, KFF modeled the Bridge demonstration at between $1.3 billion and $10 billion over its 18 months, depending on how many of the roughly 4 million eligible beneficiaries participate. For scale, KFF noted that Medicare Part D spending on prescription drugs was $181 billion in 2025. CMS has said the Bridge is intended in part to generate utilization data to inform later Medicare policy.
- Competition
Real-world analysis finds gray-market retatrutide underperforms and raises cardiovascular symptoms
An nference electronic-health-record analysis reports a 1.8-fold increase per quarter in retatrutide mentions from October 2023 through March 2026, with confirmed exposure in 652 of 983 patients whose notes mentioned the drug. Patients using non-trial products showed weaker weight loss and increased cardiovascular symptoms compared with the clinical trial program. Reported as a preprint at the time of coverage.
- Competition
AbbVie starts Phase 2 of its amylin analog ABBV-295
Gubra announced it had earned a milestone payment after AbbVie initiated the Phase 2 trial, confirming the accelerated timeline flagged on AbbVie's first-quarter call.
- Culture
Clinicians say GLP-1 uptake forces obesity and eating disorder care together
Researchers argued that the rapid spread of GLP-1 medicines has collapsed the traditional separation between obesity treatment and eating disorder treatment, since the same patients now move between both. They called for routine eating disorder screening before and during GLP-1 therapy and for shared care pathways. No guideline body has yet mandated such screening.
- Business
Construction tracker sizes the GLP-1 building boom around Lilly's sites
Industrial Info Resources reported that Lilly is investing more than $13 billion at its Lebanon, Indiana complex and tracked $3.2 billion of Lilly international construction underway with a further $3.7 billion in planning. Orforglipron-linked projects include the Houston API campus, a Puerto Rico building addition expected to contribute to oral-dose production in 2029 and the $6 billion Huntsville, Alabama campus. The tracker also flagged a planned oral GLP-1 plant in the Netherlands with an initial budget near $1.5 billion.
- Culture
Digital engagement linked to persistence, and persistence to results
A 48-week study of 191 adults with severe obesity starting semaglutide found persistence rose with platform engagement (59.5%, 71.9%, 79.5%), mean weight loss reached 14.6% among persistent participants, and persistence explained about 69% of the association between engagement and weight loss.
- FDA & regulation
FTC complaint names at least fifteen advertising platforms on the Hims site
A close reading of the FTC complaint found tracking code from at least fifteen advertising platforms running on Hims & Hers' website, including Meta, Snap, TikTok, Google, Microsoft, X, Pinterest, Reddit, Criteo and The Trade Desk. The complaint sets that against marketing language promising a "100% online, private, and secure process" and health information "only accessed by the medical providers managing your care." Three of the nine counts are ROSCA claims unrelated to data, alleging Hims charged people before any provider consultation and buried the cancel button inside an "add/remove items from order" menu.
- Research
JAMA Psychiatry links GLP-1 use to lower mortality in serious mental illness
A study in JAMA Psychiatry examined mortality and cardiovascular outcomes among people with serious mental illness who were prescribed GLP-1 receptor agonists, a group with sharply elevated cardiometabolic death rates and historically poor access to obesity treatment. The analysis is observational and subject to confounding by indication. It adds to a 2026 run of work on GLP-1s in psychiatric populations, where prescribing has lagged despite high antipsychotic-associated weight gain.
- Research
Meta-analysis pools real-world incretin results after bariatric surgery
Frontiers in Endocrinology published a systematic review of 27 papers, 19 in the meta-analysis, in adults treated at least one year after metabolic bariatric surgery. Twelve-month total weight loss pooled to 9.22 percent with liraglutide and 9.02 percent with semaglutide, well below the randomized BARI-STEP figure, with a 4.23 percentage point tirzepatide advantage at 6 months.
- Policy
Obesity Action Coalition publishes its first assessment of the Bridge's opening weeks
The Obesity Action Coalition, which has campaigned for Medicare coverage of obesity treatment for years, published an assessment of the Bridge's first two months, calling the July 1 launch an important policy step while noting that it does not solve every access problem or provide comprehensive obesity care. The group emphasized CMS's stated intent to use Bridge utilization data to inform future Medicare policy, and separately reported that the Treat and Reduce Obesity Act had reached 51 House and 19 Senate cosponsors.
- Prices
Walgreens says about half of its Bridge patients had never taken a GLP-1 before
Walgreens chief pharmacy officer Rick Gates told NPR that roughly half of the patients the chain has served through the Medicare GLP-1 Bridge had never taken a GLP-1 previously, and that uptake exceeded the company's own expectations despite stores stocking extra Wegovy, Zepbound and Foundayo ahead of the July launch. Gates said no supply issues had emerged and flagged early side-effect management as the main retention risk for a treatment-naive population.
- Policy
White House prepares a new round of Medicaid most-favored-nation deals with midsize biotechs
Reuters, citing Bloomberg News, reported that the administration planned to announce drug-pricing agreements with several midsize biotech companies the following Monday. Under the voluntary deals, participating companies would discount outpatient drugs for state Medicaid programs so that state prices align with what the companies charge abroad. Participation by state Medicaid programs remains optional, and the administration had previously projected $64.3 billion in combined federal and state Medicaid savings over ten years from the framework.
- Research
Pfizer files a Japanese Phase 3 of monthly berobenatide
Pfizer submitted VESPER-JM, a Phase 3 randomized, double-blind, placebo-controlled study of once-monthly berobenatide in Japanese adults with obesity disease, with a listed start date of September 28, 2026. A companion Japanese study, VESPER-JW, tests the once-weekly regimen. Participants remain on treatment and follow-up for roughly 22 months, placing topline data years out even as the program moves into its pivotal stage.
- Business
FDA records Novo Nordisk notice that Saxenda will be discontinued in January 2027
The FDA drug shortage and discontinuation databases record a Novo Nordisk notice for Saxenda NDC 0169-2800-15 stating the product will be available until discontinuation in January 2027, with the reason given as discontinuation of the manufacture of the drug. The same update lists both Victoza package sizes as having Limited Availability due to a shipping delay. No matching Novo Nordisk press release appeared in the company's US news archive as of 2026-09-14.
- Prices
KFF Health News documents the Medicare Bridge's biggest catch: sicker patients are routed out of the $50 price
A KFF Health News investigation found that an estimated 5.9 million Medicare enrollees are excluded from the Bridge's $50 monthly price because they carry a diagnosis the FDA has already approved GLP-1s to treat, such as type 2 diabetes or moderate-to-severe obstructive sleep apnea. Those beneficiaries are routed back to their Part D plan, where copays can run $200 to $600 a month. KFF's Juliette Cubanski estimated 3.8 million people qualify for the Bridge and that Medicare costs would run roughly $3.3 billion if a quarter enroll for the full 18 months and about $10 billion if three-quarters do.
- Prices
Business Group on Health survey finds 14 percent of employers have dropped or plan to drop GLP-1 coverage in 2027
A Business Group on Health survey released August 25 found that about 14 percent of US employers have already dropped or plan to drop GLP-1 coverage in 2027. Employers said healthcare costs would rise 9.2 percent in 2027 without intervention, up from 8.5 percent in 2026, and two-thirds reported rising utilization of the drugs. Pharmacy costs made up 25 percent of employer healthcare spending and are expected to rise 12 percent in 2027.
- Culture
Chipotle, Shake Shack and Smoothie King run "GLP-1 friendly" menus
ABC News documented national chains marketing menu items explicitly to GLP-1 users, and reported National Restaurant Association survey data showing GLP-1 users buy restaurant food 7.6 times a week versus 5.1 for non-users.
- FDA & regulation
Four GLP-1 FDA decisions line up for late 2026
Pharmacy benefit manager Prime Therapeutics listed four pending decisions: Mounjaro's cardiovascular indication in the third quarter, Foundayo for type 2 diabetes and the Ozempic 25 mg tablet in the fourth quarter, and CagriSema for weight management in December. The CagriSema decision is the largest single catalyst left in the year.
- Culture
Large-employer GLP-1 coverage falls to 60% from 72%
Business Group on Health's 2027 Employer Healthcare Strategy Survey found the share of large employers covering GLP-1s for weight management falling to 60% in 2026 from 72% in 2025, with 14% saying they have eliminated the coverage or plan to in 2027 - the first measured reversal of the employer coverage expansion. KFF Health News reported the finding on September 8, 2026.
- Prices
PepsiCo tells employees it will stop covering weight-loss drugs in October
Bloomberg reported that some PepsiCo employees were notified that weight-loss medications will no longer be covered by company health insurance as of October 2026. An internal email said prescription weight-loss medications had become one of the fastest-growing costs in PepsiCo's plans and that removing coverage would keep the healthcare program sustainable. Eli Lilly chief executive David Ricks responded publicly that employers already pay for obesity whether or not they cover the drugs.
- Research
VA/DoD guideline discourages stopping an effective obesity medication
Annals of Internal Medicine published a synopsis of the 2025 VA/DoD clinical practice guideline for adult overweight and obesity management. It discourages discontinuation of effective medications to prevent weight regain, and found insufficient evidence to recommend delaying pharmacotherapy relative to comprehensive lifestyle intervention, with no requirement to complete a lifestyle program first. It placed a large federal health system alongside the obesity societies on the continue-versus-stop question.
- Competition
Genentech licenses Hanmi's obesity candidate in a $2.3 billion deal
Genentech licensed Hanmi Pharmaceutical's UCN2-based obesity candidate in a deal worth up to $2.3 billion, another sign that large drugmakers are paying up for non-GLP-1 mechanisms. Deal-making around obesity assets remained heavy through 2026.
- FDA & regulation
Pipeline tracker sets a fourth-quarter 2026 window for the Foundayo type 2 diabetes decision
Prime Therapeutics' August GLP-1 pipeline update reported that Lilly submitted orforglipron for type 2 diabetes during the second quarter of 2026 under the Commissioner's National Priority Voucher pilot, making an approval possible in the fourth quarter of 2026. The same update placed the Mounjaro cardiovascular indication in the third quarter, which the FDA subsequently granted on August 27. Voucher-based timelines are estimates, not published PDUFA dates.
- Business
Business Post tallies Novo Nordisk's written-off acquisitions
An analysis of Novo Nordisk's deal record catalogued billions of dollars in acquisitions that have been impaired or written down, including the company's legal action against KBP Biosciences, and set that history against the ziltivekimab failure in ZEUS on July 31. The piece lands as Novo's non-GLP-1 diversification strategy comes under renewed scrutiny. Novo's obesity franchise is recovering while its attempt to build a second cardiometabolic leg has stalled.
- Research
Commentary sets research priorities for tirzepatide in youth with type 2 diabetes
A review of the SURPASS-PEDS program argued that pediatric tirzepatide data show clinical promise but leave open questions about growth, puberty, bone accrual and long-term adherence in adolescents. The authors called for dedicated safety follow-up rather than extrapolation from adult trials. Tirzepatide is not approved for type 2 diabetes in children in the United States.
- Culture
The GLP-1 'companion nutrition' race draws in Nestle, supplement makers and pharma
NutraIngredients reported an accelerating scramble to sell products positioned alongside GLP-1 therapy, spanning high-protein foods, micronutrient supplements, fiber and muscle-support formulations. Companies are targeting the practical consequences of eating far less: protein shortfalls, constipation and nutrient gaps. None of these products has been shown in randomized trials to change GLP-1 outcomes.
- Culture
The Guardian asks how people are supposed to talk about bodies in the Ozempic era
A Guardian feature canvassed clinicians, eating disorder specialists and etiquette researchers on how to discuss visible weight change now that a large share of it is pharmacological. The consensus reported was to stop commenting on bodies entirely, including compliments, because the speaker cannot know whether the change is wanted, medical or a relapse signal. It is one of several late-August pieces treating GLP-1-driven body change as a social-norms problem rather than a medical one.
- Compounding
FDA tallies more than 1,700 adverse event reports naming compounded GLP-1s
Reporting put FDA's count at about 990 for compounded semaglutide and more than 730 for compounded tirzepatide through May 31, 2026, with the agency noting the totals are likely undercounts because 503A pharmacies are not required to report.
- Compounding
Lilly and Novo take the copycat fight to the National Advertising Division
Bloomberg Law reported that Eli Lilly and Novo Nordisk have filed ten cases over the past year with BBB National Programs' National Advertising Division, a self-regulatory body, as a faster alternative to litigation against compounders and telehealth platforms. Novo says it has filed 130 federal lawsuits and five NAD challenges; Lilly has filed dozens of federal suits and at least five NAD cases. The approach has worked so far because challenged advertisers have voluntarily dropped or modified claims, and NAD can refer non-participants to the FTC, state attorneys general and the platforms carrying the ads.
- Research
Novo Nordisk opens the first zenagamtide Phase 3 trial
AMBITION 7, a 1,778-participant type 2 diabetes trial comparing zenagamtide against insulin glargine, began enrolling. AMAZE 7 (a head-to-head against semaglutide in obesity) and AMAZE 9 (zenagamtide tablets) were registered with planned starts in September 2026.
- Research
Amgen opens the MARITIME-2 long-term extension to enrollment
Amgen's MARITIME-2-EXTENSION, a Phase 3 long-term extension evaluating maintenance of weight loss with monthly and every-eight-week MariTide dosing in adults with obesity or overweight and type 2 diabetes, moved from not yet recruiting to recruiting. A parallel MARITIME-1 extension tests monthly, every-eight-week and quarterly maintenance in participants without diabetes. The extensions are where Amgen's four-to-six-doses-a-year claim will be tested.
- Compounding
Lilly and Novo add advertising-board challenges to their campaign against GLP-1 copycats
Bloomberg Law reported that both manufacturers are increasingly using BBB National Programs' National Advertising Division, a self-regulatory body that resolves advertising disputes faster than litigation, against compounders and telehealth sellers. Novo has filed 130 federal lawsuits and five NAD challenges; Lilly has filed dozens of federal suits and at least five NAD challenges. The shift comes as FDA enforcement has stayed narrowly focused on active-ingredient and product-performance claims.
- Compounding
Lilly and Novo Nordisk open a new Lanham Act front against compounders' 503B claims
Bloomberg Law reported that Eli Lilly and Novo Nordisk have begun suing compounding pharmacies over false statements about their own 503B outsourcing-facility compliance, a theory a court allowed to proceed in mid-August. The angle sidesteps the harder question of whether a given compounded product is lawful and attacks the marketing claim instead. It gives both manufacturers a broader tool than trademark or patent claims against sellers of copycat semaglutide and tirzepatide.
- Compounding
NAD record shows Noom and Willow Health dropped challenged compounded-GLP-1 claims
Coverage of the drugmakers' self-regulatory campaign detailed two outcomes. In May 2026 NAD recommended that Noom modify or discontinue its "A Smaller Dose. A Smarter Start. Microdose GLP-1Rx Starts at $119" claim, finding it conveyed an unsupported message that a smaller dose itself delivered a health benefit; Noom disagreed but agreed to comply and separately discontinued other dosing, efficacy and side-effect claims. Willow Health Services, which had ignored a December 2025 decision and been referred to the FTC and state attorneys general, returned to NAD and in July 2026 permanently discontinued all the challenged claims.
- FDA & regulation
NICE asks Lilly for more information on Foundayo after a first committee meeting
As Lilly launched Foundayo in the UK through private prescription, a NICE spokesperson said the agency had requested further information following its first appraisal committee meeting, with no date set for a second review. Lilly said it is working with NICE during the assessment; NHS access depends on the outcome. Lilly indicated the pill will be priced between roughly £100 and £120 a month against £330 for a month of Mounjaro through private providers.
- Research
Novo Nordisk will test zenagamtide head-to-head against its own semaglutide in Korea
Korean regulators cleared a Novo Nordisk trial pitting zenagamtide, the unimolecular GLP-1 and amylin receptor agonist formerly called amycretin, against semaglutide. Running the comparison against its own marketed molecule rather than placebo is the clearest signal yet that Novo Nordisk intends zenagamtide as a semaglutide successor rather than a companion. Phase 2 data presented at ADA 2026 showed up to 14.6% weight loss at week 36 on the 40 mg weekly dose in type 2 diabetes.
- Competition
Reuters documents how drugmakers work around China's ad rules for obesity drugs
A Reuters investigation described how Novo Nordisk, Eli Lilly and Chinese rivals promote weight-loss medicines in China through disease-awareness campaigns, subway advertising and social-media placements that sidestep restrictions on direct prescription-drug advertising. Innovent's mazdutide, sold as Xinermei, was among the products patients requested more often. China's National Health Commission has said the share of adults who are overweight or obese could exceed 65 percent by 2030.
- FDA & regulation
English High Court grants a dynamic website-blocking order against counterfeit medicine sellers
The English High Court issued a dynamic blocking order requiring internet service providers to block websites selling counterfeit medicines, with the order able to extend automatically to mirror sites as they appear. The remedy, borrowed from copyright and trademark enforcement, is newly relevant to GLP-1 drugs, where counterfeit Ozempic and Wegovy pens have repeatedly reached patients through online sellers. It gives brand owners a faster tool than suing each storefront in turn.
- Research
Post hoc analysis reports about 13% weight loss with orforglipron in adults 65 and older
A post hoc subgroup analysis of ATTAIN-1 and ATTAIN-2, published in Obesity Pillars, examined orforglipron in patients aged 65 and older with and without type 2 diabetes. The analysis reported weight reduction in the older subgroup broadly consistent with the overall trial populations. Subgroup analyses of this kind are hypothesis-generating and were not powered as independent efficacy tests.
- Research
Real-world analysis links tirzepatide to lower one-year MACE risk in type 2 diabetes
A real-world analysis reported that adults with type 2 diabetes on tirzepatide had a lower one-year rate of major adverse cardiovascular events than comparators, alongside a lower rate of serious infections. The findings are observational and subject to confounding by indication. They arrived days before the FDA approved Mounjaro's cardiovascular risk-reduction indication on the basis of the randomized SURPASS-CVOT trial.
- Culture
Reporting details how Lilly and Novo market weight-loss drugs in China
A Kyodo News feature carried by the Japan Times documented subway advertising, social-platform placements and indirect promotion used by Lilly and Novo Nordisk to build demand for weight-loss drugs in China, where direct-to-consumer prescription advertising is restricted. Mounjaro joined China's national reimbursement list in January 2026, a decision Lilly has cited as a driver of sharply lower realized prices outside the United States. The piece is a market-conduct story rather than a regulatory action.
- Culture
Clinicians weigh in on parents hiding GLP-1 use from their children
A local health segment examined what happens when parents conceal GLP-1 treatment from children, with clinicians arguing that secrecy models shame around both weight and medication. The piece reflects how quickly household disclosure has become a practical question for a large user base. It is expert opinion rather than research.
- Culture
Class action accuses a 'GLP-1 patch' seller of selling a product with no GLP-1 in it
A proposed class action against Ledisa alleges its marketed GLP-1 patches contain no glucagon-like peptide-1 and cannot deliver the advertised effect, framing the product as false advertising rather than an unapproved drug. It is one of a growing number of private consumer actions filling the space where federal supplement enforcement has been slow. No court has ruled on the allegations.
- Policy
Most states reject the White House Medicaid deal offering Wegovy at $245 a month
POLITICO reported that most state Medicaid programs, red and blue alike, are declining the Trump administration's offer of discounted GLP-1 pricing, saying the budget hit is too large even at the reduced rate. Novo Nordisk told the outlet states are offered Wegovy at $245 per monthly dose under the model, with the true state cost lower once federal match and manufacturer rebates are counted; Indiana said it would pay $85.16 of the $245. Novo Nordisk argued Wegovy's cardiovascular and liver benefits should reduce downstream program costs.
- Safety
BMJ fact-checks the UK headlines linking GLP-1 drugs to hundreds of deaths
The BMJ examined UK press reports, led by an August 5 story in The Times, that tied GLP-1 drugs to hundreds of deaths and thousands of adverse events, and explained that Yellow Card totals are suspected-reaction reports rather than confirmed harms. It noted semaglutide accounted for 3,454 serious reports in women and 1,216 in men, while fatal outcomes split almost evenly at 28 and 29, with deaths clustered in the 60 to 69 age band. The piece also confirmed that Genomics England and the MHRA have closed recruitment to a Yellow Card Biobank pilot testing whether genetics predicts GLP-1 side effects, with analysis under way.
- Research
Tirzepatide linked to lower stroke risk than other GLP-1 drugs in atrial fibrillation
A Nature Communications analysis of 14,118 matched pairs of adults with atrial fibrillation and type 2 diabetes found lower risks of any stroke, ischemic stroke, hemorrhagic stroke and death with tirzepatide than with established GLP-1 drugs, with an absolute stroke difference of 2.1 percentage points at one year. The authors said randomized trials are required before recommendations change.
- Prices
Analyses spell out Medicare's $274 negotiated 2027 price for semaglutide
Coverage of the second Medicare drug price negotiation cycle detailed what the $274 maximum fair price for Ozempic, Wegovy and Rybelsus means in practice when it takes effect on January 1, 2027, down from a list price near $959. Commentators stressed that the negotiated price sets what Medicare pays, not what a beneficiary pays: Part D plan design still determines the copay. CMS has put total enrollee savings across the 15 negotiated drugs at roughly $685 million.
- Business
Lilly breaks ground on its $6.5 billion Houston API campus
Eli Lilly began construction on a 236-acre, $6.5 billion manufacturing campus at Generation Park northeast of Houston, the site earmarked for small-molecule active pharmaceutical ingredient production including orforglipron. Lilly has said the site will bring 615 permanent jobs and about 4,000 construction jobs, with overall campus completion estimated around 2030. CRB and Jacobs are listed as design firms on Texas permitting filings.
- Competition
Regeneron's olatorepatide Phase 2 obesity studies appear on the US registry
Two Regeneron Phase 2 studies of olatorepatide, the GLP-1/GIP dual agonist licensed from Hansoh Pharma, were captured in registry monitoring: a 360-participant trial in adults with overweight or obesity without diabetes that is recruiting, and a 120-participant US study listed as active but not recruiting. Hansoh reported up to 19.3 percent weight loss at week 48 in a Chinese Phase 3 of the same molecule in March 2026. Regeneron is pairing the incretin with its muscle-preservation antibodies trevogrumab and garetosmab.
- FDA & regulation
Scholar Rock updates global regulatory progress for apitegromab
Scholar Rock issued an update on apitegromab's regulatory progress across the United States, Europe and Japan, setting up a US action date of September 30, 2026 after a 2025 complete response letter tied to a third-party fill-finish facility rather than the drug itself. The myostatin inhibitor's obesity relevance rests on the Phase 2 EMBRAZE trial, which combined apitegromab with tirzepatide in 102 participants over 24 weeks and reported 54.9 percent greater relative lean-mass retention than tirzepatide plus placebo.
- Research
Scholar Rock's EMBRAZE data put a number on drug-assisted lean mass preservation
Scholar Rock issued a global regulatory update as its phase 2 EMBRAZE trial, published in Nature Medicine, reported that adding the myostatin inhibitor apitegromab to tirzepatide preserved 54.9% more relative lean mass over 24 weeks than tirzepatide plus placebo, with similar total weight loss. It is the most concrete randomized evidence to date that the lean mass component of GLP-1 weight loss can be pharmacologically blunted. The combination remains investigational and is not approved for weight management.
- Research
Structure's two Phase 3 aleniglipron trials show as recruiting on the registry
Registry records confirm ACCOMPLISH-1, enrolling up to 3,600 adults with obesity or overweight and a weight-related comorbidity, and ACCOMPLISH-2, enrolling up to 1,100 adults with obesity or overweight and type 2 diabetes, both recruiting for Structure Therapeutics' oral small-molecule GLP-1 aleniglipron. The company says the program initiated in August 2026 with topline data expected in the second half of 2028. Structure is the smallest of the credible oral GLP-1 challengers, with about $1.34 billion in cash.
- Prices
UnitedHealthcare publishes updated GLP-1 quantity limits for September 1, 2026
UnitedHealthcare's supply-limit list set monthly caps of 4 Wegovy pens, 30 Wegovy tablets (60 per 365 days for 1.5, 4 and 9 mg), 4 Zepbound autoinjectors or vials, 1 Zepbound KwikPen, 1 Ozempic pen, 4 Mounjaro pens and 5 Saxenda pens, and applied a rule that two one-month fills are required before a three-month fill becomes available.
- Culture
Affordability and prescriber preference, not efficacy, may decide the GLP-1 race
BioPharma Dive surveyed the evidence on what actually drives GLP-1 uptake and concluded that cost and perception are becoming the deciding variables as Eli Lilly and Novo Nordisk fight for share. It cited KFF polling in which 55% of insured current or former users said affording their prescription was difficult. The analysis frames the next phase of competition around out-of-pocket price and physician habit rather than incremental weight loss.
- FDA & regulation
Delhi High Court orders Sun Pharma to seek approval before launching semaglutide tablets
In Novo Nordisk's patent suit against Sun Pharmaceutical, the Delhi High Court directed the Indian generics maker to obtain prior court approval before launching oral semaglutide tablets. The order is one of several skirmishes in India since Novo Nordisk's species patent on semaglutide expired on March 20, 2026, opening the market to Dr. Reddy's, Sun Pharma, Zydus, Glenmark and others. Novo Nordisk's remaining Indian leverage rests largely on formulation patents such as the SNAC absorption-enhancer patent, valid to 2031.
- Business
Rexall and Novo Nordisk Canada launch nationwide home delivery for Ozempic, Wegovy and Rybelsus
Rexall and Novo Nordisk Canada began a Novo Nordisk Care Rx home delivery service covering Ozempic, Wegovy and Rybelsus across every province and territory except Quebec. It is a direct-to-patient channel of the kind Novo Nordisk has built in the United States through NovoCare Pharmacy, launched here to defend brand volumes as Canadian generics arrive. Quebec's separate drug-distribution rules keep it outside the program.
- Prices
Aon projects US employer healthcare costs will rise 9.5 percent in 2027, citing GLP-1 and specialty drug use
Aon told Reuters that employer healthcare costs are set to increase 9.5 percent in 2027, based on data from more than 1,100 US employers covering 7.9 million employees and $135 billion in 2026 health spending. The consultancy named greater use of specialty medicines and GLP-1 treatments for diabetes, obesity and other conditions as a driver of prescription drug costs. Average employer cost per employee is expected to reach $14,432 in 2026, with total plan costs of $17,562.
- Prices
PBM trade group and ten pharmacy benefit managers commit to showing TrumpRx cash prices inside benefit tools
The Pharmaceutical Care Management Association and ten pharmacy benefit managers announced a commitment, coordinated with CMS, to present TrumpRx cash prices alongside a patient's benefit price through real-time benefit tools, where consistent with plan coverage and permitted by law. CMS Administrator Mehmet Oz said displaying negotiated and cash prices side by side would help patients find the better deal. For GLP-1 patients the change makes the comparison between a plan copay and a LillyDirect or NovoCare cash price visible at the point of prescribing.
- Culture
A national survey finds GLP-1 drugs reshaping how Americans get care
USA Today reported that a large share of people now start weight-loss treatment through telehealth and direct-pay channels rather than a primary care visit, a structural change that Zepbound and Wegovy drove together.
- Competition
Gubra's half-year report tracks three partnered obesity programs into Phase 2
Gubra reported that Boehringer Ingelheim had initiated Phase 2 development of BI 3034701, a first-in-class GLP-1/GIP/NPY2 receptor triple agonist, triggering a EUR 10 million milestone payment, and that AbbVie reported 12- and 13-week Phase 1 results for the long-acting amylin analog ABBV-295 ahead of a Phase 2 start in the third quarter. Its own GUB-UCN2 entered a Phase 1/2a trial in July. The Danish peptide house now has three obesity assets in or entering mid-stage testing across two large partners.
- Research
Meta-analysis of 13,243 patients links GLP-1 drugs to less papilledema in intracranial hypertension
A systematic review and meta-analysis in Headache pooled eight studies of GLP-1 receptor agonists in idiopathic intracranial hypertension. It found lower risk of papilledema at 3 months (RR 0.430) and 24 months (RR 0.469), lower headache frequency (RR 0.690 and 0.796), fewer visual disturbances and less refractory disease. The authors stressed that the evidence is dominated by observational studies at moderate to serious risk of confounding, making the findings low-certainty and useful mainly for designing randomized trials.
- Research
Novo Nordisk starts a Phase 3 trial hunting the lowest effective Wegovy pill dose
A new late-stage study registered on the US clinical trials database tests smaller doses of oral semaglutide to find the lowest dose that still produces meaningful weight loss. The design responds to what Novo Nordisk has already seen commercially: at launch, 88% of Wegovy pill volume was the lowest 1.5 mg strength, which chief executive Mike Doustdar read as evidence that most buyers were new to GLP-1 therapy. A lower approved maintenance dose would also change the arithmetic of supply and self-pay pricing.
- Culture
Brazilian survey documents how widely GLP-1 drugs are self-prescribed
A web-based survey of Brazilian adults published in the International Journal of Obesity quantified self-medication with GLP-1 receptor agonists, including use obtained without a prescription or clinical supervision. The authors describe self-medication as common enough to constitute a public health concern in a market where the drugs are widely advertised. Survey samples of this kind are self-selected and cannot be read as national prevalence.
- Business
Lilly marks the grand opening of its Kenosha site expansion
Lilly celebrated the opening of an expansion at its Kenosha County, Wisconsin site, which handles injectable finishing for the company's incretin portfolio. The Kenosha facility was acquired and expanded during the tirzepatide shortage years and is one of the capacity additions the FDA cited when it concluded that supply would meet or exceed projected demand. Lilly did not publish incremental output figures for the expansion.
- Business
Upper Macungie planners endorse Lilly's Lehigh Valley manufacturing campus
Planning officials in Upper Macungie Township, Pennsylvania endorsed Eli Lilly's plan for its Fogelsville manufacturing campus, the $3.5 billion injectable medicine and device site the company selected in early 2026. The seven-building campus is tied to Lilly's injectable incretin portfolio and to retatrutide. Township review continued into September over construction traffic and worker transportation.
- Research
AstraZeneca starts three SELENE Phase 3 trials for the amylin analog AZD6234
SELENE 1 (2,500 participants), SELENE 2 (1,500) and SELENE 3 (500) opened within days. SELENE 3 is the notable one: it tests AZD6234 as an add-on for people already taking an incretin drug, one of three Phase 3 programs in 2026 aimed at existing GLP-1 patients rather than new starts.
- Compounding
Mississippi boards jointly bar providers from research-grade peptides
The state's medical licensure, nursing and pharmacy boards issued a joint statement prohibiting licensees from compounding, administering, dispensing, recommending or prescribing non-FDA-approved or research-grade peptides, and from delegating those acts.
- FDA & regulation
Novo Nordisk presses FDA to place semaglutide on the demonstrable-difficulties list
Novo Nordisk pushed the FDA again to add semaglutide to the Demonstrable Difficulties for Compounding lists, the register of drug products considered too complex to compound safely. The nomination, first filed in October 2024 under docket FDA-2017-N-2562, argues that recombinant yeast-produced semaglutide cannot be reliably reproduced by synthetic peptide chemistry and that compounded versions carry different impurity profiles and immunogenicity risk. Placement on the list would bar compounding of semaglutide even if a future shortage were declared, making it a backstop to the pending 503B bulks list exclusion.
- Research
PCOS does not blunt tirzepatide weight loss in a 54,114-woman cohort
A retrospective open-cohort study in the Journal of the Endocrine Society followed all 54,114 women prescribed tirzepatide through a UK digital weight-management service between February 2024 and January 2025, of whom 4,241 reported PCOS. At 10 months, mean weight change was -19.40 percent in women with PCOS versus -18.74 percent in women without, not a significant difference, and 57.66 percent of the PCOS group had lost at least 20 percent of body weight. Only 40 women with PCOS actually reached the 10-month timepoint, and PCOS status was self-reported.
- Business
Pharmacy acquisition cost for generic liraglutide falls about a third in six months
CMS NADAC data effective 2026-08-19 priced the generic two-pen carton at $33.8176 per mL, down from $48.7442 in the file effective 2026-02-18, and the five-pen weight-management carton at $47.6947 per mL, down from $73.7391 in January. Brand Victoza and Saxenda stayed near $87 per mL.
- Research
VA opens a 622-veteran semaglutide trial for alcohol use disorder across 18 sites
The Department of Veterans Affairs began recruiting for the Cessation or Reduction of Alcohol Consumption in Veterans trial, a 24-week randomized comparison of weekly semaglutide against placebo in veterans aged 18 to 80 with moderate or severe alcohol use disorder. Investigators said the trial was designed to FDA requirements for an alcohol use disorder indication, including a minimum six-month duration and a sample size large enough to test efficacy and safety. Enrollment is expected to take about two years; semaglutide is not approved for alcohol use disorder.
- Research
ACHIEVE-5 reports orforglipron improves A1C and weight on top of basal insulin
Coverage of the ACHIEVE-5 Phase 3 trial described once-daily oral orforglipron improving blood sugar control and body weight in adults with type 2 diabetes already taking basal insulin. ACHIEVE-5 is one of four Phase 3 diabetes studies Lilly cites in its regulatory filings for the type 2 diabetes indication, alongside ACHIEVE-1, ACHIEVE-2 and ACHIEVE-3. The insulin add-on setting matters commercially because it is where injectable GLP-1 use is already most entrenched.
- Competition
Amylin design debate sharpens ahead of Lilly's eloralintide mid-stage data
Endpoints News reported that molecular design has become the dividing line in the amylin class as Lilly approaches a mid-stage weight-loss readout for eloralintide and Novo Nordisk's CagriSema moves toward becoming the first approved amylin-GLP-1 combination. Eloralintide's Phase 2 results reached up to 20% weight loss at 9 mg over 48 weeks, above the roughly 10% to 12% band amylin monotherapies have historically produced, but with nausea rates up to 64% in one arm. Lilly is running eloralintide in Phase 3 both alone and in combination with tirzepatide.
- FDA & regulation
Lawyers flag the Hims suit as the FTC's first tracking-pixel health case
Privacy counsel noted that the July 29 action against Hims & Hers is the current FTC's first enforcement action targeting tracking pixels and unauthorized health-data sharing with third-party advertising platforms. Unlike the GoodRx and BetterHelp cases, the complaint does not rely on the Health Breach Notification Rule, resting instead on Section 5 of the FTC Act, the Restore Online Shoppers' Confidence Act, and California and Utah consumer-protection statutes. That theory does not require proving a breach, which lowers the bar for other digital health defendants.
- Science
Nature Reviews Endocrinology calls the GIP direction question a 'seeming paradox'
A research highlight summarizing the 2026 brain-region findings frames the field's position plainly: both GIP receptor agonism and antagonism increase weight loss alongside GLP-1 receptor agonism, and the two appear to work through different neuron populations.
- Policy
Overton nominated to lead FDA with the compounding dockets on the desk
President Trump nominated Dr. Heidi Overton, deputy director of the White House Domestic Policy Council, to lead the FDA, his third choice for the post after acting commissioner Kyle Diamantas and former Representative Brad Wenstrup declined. Overton has made no public statements on peptide compounding, the 503A or 503B bulks lists, or GLP-1 policy. No hearing date has been set, and both the 503A bulks rulemaking and the undecided 503B GLP-1 exclusion will land on whoever holds the job.
- Culture
Researchers ask whether the GLP-1 era is reviving diet culture and eating disorders
Northeastern University clinicians argued that the normalization of GLP-1 weight loss has pulled explicit diet culture back into mainstream conversation and raised the risk of disordered eating, particularly among younger users and people with prior restriction histories. The piece is expert commentary rather than new data. It sits alongside a wave of August 2026 analyses arguing that obesity medicine and eating disorder care can no longer be treated as separate fields.
- Culture
Medscape frames retatrutide demand as pitting physicians against patients
A Medscape commentary described clinicians fielding requests for retatrutide from patients who have read the TRIUMPH headlines and found the compound for sale online. Retatrutide is not approved anywhere and is available only through Lilly-sponsored trials or narrow expanded access. The piece documents the clinical counseling problem created by an investigational drug with a large public profile and an active gray market.
- Research
REMODEL findings suggest kidney protection is not diabetes-specific
At the World Congress of Nephrology 2026, investigators presented mechanistic data suggesting semaglutide's kidney effects work through inflammation and endothelial pathways that may extend to non-diabetic kidney disease.
- Business
Resilience and Lilly commit $750 million to expand US-manufactured medicine supply
Contract manufacturer Resilience and Eli Lilly announced a multi-year strategic biomanufacturing partnership backed by $750 million of combined investment to increase the volume of medicines made in the United States. The arrangement adds third-party capacity alongside Lilly's own multi-site domestic build-out. Neither party detailed how much of the capacity is earmarked for incretin products.
- FDA & regulation
South Korea's regulator says no causal link is confirmed in reported Mounjaro pancreatitis cases
South Korean authorities responded to domestic reports of acute pancreatitis in tirzepatide users by saying no causal relationship had been established and that monitoring would continue. The statement follows the UK MHRA's January 2026 warning about acute pancreatitis, including necrotizing and fatal cases, across the GLP-1 and dual agonist classes. Pancreatitis already appears in US labeling for the class.
- Competition
Trade analysis: Novo Nordisk wins the first round of the oral obesity duel
BioSpace assessed the head-to-head launch of the Wegovy pill against Eli Lilly's Foundayo and concluded Novo Nordisk had taken the opening round, with oral semaglutide holding roughly a four-to-one lead in weekly prescriptions. The advantage rests on a three-month head start and on full commercial insurance coverage from launch week, which Foundayo did not have until CVS Caremark added it on June 1, 2026. The open question is whether Novo Nordisk can hold the gap as Foundayo's formulary position improves.
- Science
Circulation analysis of SELECT reports a 37.8% drop in inflammation with semaglutide
A prespecified secondary analysis found hsCRP fell 37.8% by 104 weeks, with reductions visible by weeks 4 and 8 and even among participants who lost little weight, though the authors stopped short of claiming a weight-independent mechanism.
- Competition
Canada warns on illegal retatrutide sales as US seizures jump
A warning was issued in Canada on August 18 about unapproved and illegal sales of retatrutide, extending the gray market for Eli Lilly's unapproved triple agonist beyond the United States. An Axios report on August 24 said US Customs and Border Protection intercepted more than 690 shipments of illicit GLP-1 drugs in all of fiscal 2025 but more than 1,400 in July 2026 alone. Retatrutide has not been submitted for approval anywhere and its Phase 3 trials are still running.
- Competition
Enveda completes Phase 1 of ENV-308, an exercise-mimetic aimed at weight maintenance
Enveda Biosciences completed a Phase 1 study of ENV-308 in 88 healthy adults with no serious adverse events and no discontinuations or dose interruptions, and said it is moving to Phase 2. The molecule, found using the company's machine-learning discovery platform, mimics Lac-Phe, a hormone released during intense exercise and after meals, and is positioned as maintenance therapy against weight regain after stopping a GLP-1. Phase 1 measured safety and tolerability, not weight loss, and the lean-mass claims attached to the drug come from preclinical work.
- Prices
Fact-checkers and KFF say the drug price drop has more causes than the administration's policies
Reviewing the administration's claims, FactCheck.org quoted KFF senior vice president Cynthia Cox saying that both Republican and Biden-era policies may be at play but that market forces around GLP-1 drugs are hard to ignore. A Johns Hopkins pharmaceutical economist added that most-favored-nation prices currently reach the Consumer Price Index only through TrumpRx, which serves a comparatively small set of cash-paying patients.
- Compounding
Law firm analysis finds no lawful compounding pathway for retatrutide
A Frier Levitt analysis of Lilly's August 12 lawsuits concluded that retatrutide cannot lawfully be compounded under Section 503A because it is not a component of an FDA-approved drug, does not appear on the FDA's bulk drug substances list and lacks a USP or NF monograph. The six cases were filed across four federal district courts in Texas and name four research-use-only sellers, a medical spa and a compounding pharmacy. The firm framed the actions as a warning to businesses marketing investigational peptides for human use.
- Compounding
Lilly's retatrutide suits described as a new enforcement playbook
A legal analysis of the six federal lawsuits Eli Lilly filed on August 12 details the mix of defendants: four research-use-only peptide sellers, one med spa and one compounding pharmacy. The analysis emphasizes that retatrutide has never been approved anywhere and was never in shortage, so no compounding exception has ever applied to it, and cites the FDA's statement that retatrutide cannot be used in compounding under federal law. The suits are framed as a template for pursuing gray-market sellers of unapproved molecules rather than copies of approved drugs.
- Research
Switching from injectable incretins to oral orforglipron maintained weight loss in a Phase 3 trial
Coverage of Lilly's first-of-its-kind maintenance trial described patients transitioning from injectable incretin therapy to once-daily oral orforglipron and holding their weight loss over the study period. The design addresses one of the central commercial questions for Foundayo: whether an oral product can serve as maintenance therapy after injectable induction. Results were reported by Lilly rather than published as an independent peer-reviewed analysis at the time of coverage.
- Science
GLP-1 receptor activation suppresses pathological defensive aggression in mice
A preclinical study found that GLP-1 receptor activation in the dorsomedial periaqueductal gray reduced pathological defensive aggression in mice. It adds to a growing body of animal work placing GLP-1 receptors in circuits that have nothing to do with feeding. No GLP-1 drug is approved or being tested for aggression or any behavioral indication of this kind in people.
- Business
Hims CEO tells CNBC the FTC wanted a headline, and the stock recovers its losses
Chief executive Andrew Dudum told CNBC on August 18 that the Federal Trade Commission "wanted more of a headline than a real agreement here," after nearly three years of investigation and settlement talks that failed. Hims & Hers shares, which fell about 15 percent to $25.00 on the day the FTC suit was filed, closed at $31.10 on August 19, above where they traded before the complaint existed. The company continues to call the allegations baseless.
- Prices
White House claims credit for the largest prescription drug price drop in sixty years and puts TrumpRx savings at $700 million
A White House release tied the July Consumer Price Index reading to its most-favored-nation framework and the TrumpRx platform, saying the site has generated $700 million in patient savings since its February launch and that GLP-1 medications that once cost more than $1,000 a month now start as low as $149. The release also said prescription drug prices are down 3.9 percent since the start of the administration and that the Department of Veterans Affairs locked in more than $10 billion in pharmaceutical savings this fiscal year.
- Prices
Axios analysis attributes the drug price decline partly to GLP-1 competition rather than policy alone
An Axios analysis of the July price data concluded that TrumpRx likely accounts for only part of the decline, and pointed to Inflation Reduction Act negotiated prices that took effect in January for ten Part D drugs, continued patent expirations and generic entry, and competitive price cutting in the GLP-1 class. A USC health economist quoted in the piece said TrumpRx mostly makes existing discounts easier to find rather than creating new ones.
- Compounding
Danish reporting puts Novo Nordisk's knockoff litigation at 132 companies sued
Børsen reported that Novo Nordisk has sued 132 companies over products marketed as semaglutide, seeking damages the paper characterized as running into the billions. Novo Nordisk's own tallies have described federal complaints filed across roughly 40 US states against compounding pharmacies, telehealth providers and medical spas, with dozens of permanent injunctions already entered. The scale makes it one of the largest coordinated anti-counterfeiting campaigns in pharmaceutical history.
- Culture
International Journal of Obesity names GLP-1 'treatment-related stigma' as a distinct construct
A review argued that narratives framing GLP-1-assisted weight loss as a shortcut constitute an emerging treatment-related stigma separate from ordinary weight stigma, and called for conceptual clarity so it can be measured and addressed.
- Culture
Nestle plans a product line aimed at 'Ozempic face' and other GLP-1 side effects
Nestle said it is developing food, supplement and skincare-adjacent products targeted at people on GLP-1 drugs, explicitly naming facial volume loss, muscle loss and nutrient gaps as the problems it wants to sell against. The company also outlined an AI-driven approach to formulating for GLP-1 users' smaller portions and higher protein needs. It is the clearest sign yet that the side-effect profile of the drug class has itself become a consumer category.
- Safety
New NAION suits put a face on the US label divergence over vision loss
Local television coverage in Boston and Atlanta featured plaintiffs who lost vision after starting semaglutide, including a Georgia nurse who is campaigning for a NAION warning on every US GLP-1 label. European and UK regulators added NAION to product information in June 2025 as a very rare side effect; the FDA has not required an equivalent change. The stories track the growth of MDL 3163, which had 216 pending cases as of the September 1 JPML report.
- Prices
Novo Nordisk Canada launches an Ozempic savings card to match generic pricing
Novo Nordisk Canada introduced a savings card intended to bring brand-name Ozempic to roughly generic price levels for uninsured Canadians, distributed through Rexall pharmacies and excluding Quebec. It is a defensive move against Dr. Reddy's generic semaglutide, which reached Canadian pharmacies on May 15, 2026. University of Toronto drug policy researcher Mina Tadrous has said he expects Novo Nordisk to hold more share after generic entry than is typical.
- FDA & regulation
Mexico approves the Wegovy oral tablet, the first Latin American market to clear it
Mexican regulators authorized oral semaglutide 25 mg for weight management, making Mexico the first Latin American country to approve the Wegovy tablet. The clearance extends a rolling sequence of ex-US approvals that began with the United States in December 2025 and continued through the United Arab Emirates, the United Kingdom and the European Union. No Mexican launch date or price was announced with the approval.
- Science
Prolonged GLP-1 exposure flips a molecular switch in pancreatic beta cells
Researchers reported that sustained GLP-1 receptor signaling remodels gene expression across roughly a thousand genes in pancreatic beta cells, a change the authors describe as flipping a molecular switch. The work suggests long-term treatment may leave beta cells in a different, potentially more resilient state rather than simply stimulating insulin release episodically. The findings are preclinical and have not been confirmed in humans.
- Culture
Experiment documents that weight-loss-drug users are judged more harshly
A randomized vignette study of 297 participants in Social Science & Medicine found that a person described as losing weight via a weight-loss medication was viewed more negatively and assumed to be less healthy than one who used diet and exercise — the first clean experimental evidence that weight stigma differs by method.
- Compounding
One year after the semaglutide shortage ended, compliance analysts take stock
A widely circulated commentary marked roughly twelve months since the FDA determined the national semaglutide shortage had been resolved, the event that started the enforcement clock for compounders operating under the shortage exception. The analysis describes a sector that has shrunk to patient-specific 503A work, with the 503B bulk pathway closed and the legal basis for large-scale copying gone. It frames 2026 enforcement as the consequence of deadlines set in 2025 rather than any new rule.
- Policy
State legislatures and pharmacy boards build restrictions above the federal floor
An industry analysis catalogs the growing patchwork of state-level rules on compounded GLP-1s and peptides, layered on top of federal requirements. States are adding prescribing limits, telehealth examination standards, sourcing rules and advertising restrictions that vary by jurisdiction. For multi-state telehealth platforms the practical effect is that federal compliance no longer settles the question of whether a given program is lawful in a given state.
- Business
Lilly says more than 80% of Foundayo prescriptions went to patients new to GLP-1 therapy
In commentary on Lilly's expanding obesity portfolio, the company's own launch data showed that more than 80% of Foundayo (orforglipron) prescriptions were written for patients with no prior history of GLP-1 use. Lilly has argued that the oral product expands the treated population rather than cannibalizing Zepbound. The figure is a company disclosure and has not been independently verified against IQVIA or telehealth-channel data.
- Competition
Novo Nordisk moves for a preliminary injunction against Lilly's GLP-1 advertising
Novo Nordisk filed a motion for a preliminary injunction on August 14 in the U.S. District Court for the District of New Jersey, asking the court to halt Eli Lilly's current obesity and diabetes advertising campaigns while the underlying case proceeds. The court set the motion for consideration three days later, on August 17. The motion escalates the false-advertising and unfair-competition suit Novo filed on July 21 over Lilly ads that compare maximum tirzepatide doses against lower, older semaglutide doses.
- Business
Anti-obesity drugs become the fourth-largest therapy class
At the AMCP 2026 annual meeting, IQVIA said the anti-obesity market had become the fourth largest therapy class and was still growing, with distribution overwhelmingly retail. The pipeline held about 190 obesity-related products.
- Culture
Lilly sues makers of generic-style Mounjaro and Zepbound copies
The company extended its litigation from compounders to firms selling copies as generics, as GLP-1 legal disputes multiplied on several fronts at once.
- Culture
Survey of 1,226 patients puts numbers on skin laxity, facial volume loss and hair shedding
More than 60% of patients undergoing medical weight management reported aesthetic concerns including skin laxity, facial volume loss and hair shedding, with concerns more common among GLP-1 users, who lost more weight. The authors argued these effects can undermine treatment adherence and called for nutrition and strength preservation as the first response.
- Science
Researchers map a brain switch that can drive weight loss in two opposite ways
A mechanistic study described a single neural switch capable of producing weight loss through opposite routes, adding to a run of 2026 work separating appetite suppression from energy expenditure in GLP-1 biology. The finding is preclinical and has not been tested in people. It feeds a broader research push to identify which brain circuits could be targeted without the nausea that limits current drugs.
- FDA & regulation
Foundayo's label establishes the first no-timing-rules oral GLP-1 for weight
The US prescribing information for Foundayo (orforglipron) was published, indicating it for adults with obesity or overweight plus a weight-related comorbid condition, with a 0.8 mg starting dose escalating at 30-day intervals to a 17.2 mg maximum. Unlike oral semaglutide, it is taken with or without food and carries no water limit or 30-minute waiting rule, removing the practical barrier that made oral semaglutide hard for some people to take consistently.
- Prices
KFF prior authorization metrics show 12 to 18 percent denial rates and high overturn rates on appeal
KFF's analysis of new insurer transparency data found average denial rates of 12 percent of standard prior authorization requests in Medicare Advantage, 14 percent in Medicaid managed care and 18 percent in ACA federally facilitated Marketplace plans, while 67 percent, 47 percent and 43 percent of appealed denials respectively were overturned. Denials are rarely appealed. KFF published the brief on August 13, 2026; the underlying CMS transparency metrics cover calendar year 2025 and exclude prescription drugs.
- Compounding
Lilly asks platforms and payment processors to shut down retatrutide sellers
Alongside six lawsuits, the company publicly called on online marketplaces, social networks and payment companies to stop handling sales of an unapproved drug. Pharmacy boards were urged to act in September.
- Research
Zealand Pharma sets second-half deadlines for petrelintide Phase 3 and ZUPREME-2
In its half-year report, Zealand Pharma confirmed that topline results from the Phase 2 ZUPREME-2 trial of petrelintide in overweight or obesity with type 2 diabetes are due in the second half of 2026, and that it and Roche expect to start registrational Phase 3 trials of petrelintide monotherapy in the same window. The companies also plan to begin the Phase 2 ZYNERGY trial of petrelintide combined with a GLP-1/GIP dual agonist. Petrelintide's argument is tolerability close to placebo rather than peak weight loss.
- Competition
Eli Lilly files six lawsuits against sellers of black-market retatrutide
Lilly sues Aesthetic Envy Cosmetic Centers, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide, and says it has referred more than 200 individuals and entities to the FDA, DOJ, state attorneys general, law enforcement and licensing boards. The defendants include compounding pharmacies, medical spas and clinics, not only anonymous online vendors. Retatrutide had not yet been submitted for FDA approval.
- Research
Anesthesiology analysis finds no increased aspiration risk with preoperative GLP-1 use
A propensity-matched TriNetX analysis of surgeries from June 2013 to June 2023, before the 2023 ASA guidance to hold these drugs, found preoperative GLP-1 use associated with lower 14-day mortality than metformin (risk ratio 0.44) and DPP-4 inhibitors (0.63), with no increased aspiration risk versus any comparator class.
- Prices
Federal price data show prescription drug prices down 3.1 percent year over year, the steepest annual decline since 1963
The Bureau of Labor Statistics reported that the prescription drug component of the Consumer Price Index fell 0.8 percent from June to July 2026 on a seasonally adjusted basis and was down 3.1 percent over the twelve months ending in July. It is the largest year-over-year decline since March 1963. Drug prices had not risen in a single month of 2026 through July and fell in five of the previous six months.
- Search trends
U.S. News launches 2026-2027 GLP-1 telehealth platform ratings, raising the bar in the highest-value affiliate cluster
A formal ratings methodology from a major ranking brand entered a SERP previously held by affiliate roundups with no stated methodology. Competing roundups now need published criteria and demonstrable hands-on testing to be credible.
- Research
Kailera says oral ribupatide IND is active and global Phase 3 will start in 2027
In second-quarter results, Kailera Therapeutics said the US IND for oral ribupatide is active with the FDA and global Phase 3 obesity trials are planned for the first half of 2027. The US Phase 2b high-dose injectable trial is fully enrolled with data expected mid-2027, and the global Phase 3 KaiNETIC program is on track for more than 4,700 participants with data in 2028. Kailera posted a second-quarter net loss of $111.3 million against about $1.17 billion in cash.
- Culture
Novo's CEO defends the lawsuit and concedes Lilly's lead
Mike Doustdar told CNBC that "competition has to be fair" and acknowledged Lilly's greater volume and share uptake in injectables, while pointing to more than 5 million US prescriptions for Novo's Wegovy pill.
- Business
Altimmune closes the quarter with $519 million, funding pemvidutide to 2029
Altimmune reported $519 million in cash, equivalents and investments at the end of the second quarter and said the balance funds the company through the 52-week PERFORMA MASH readout expected in 2029. The company also completed enrollment in the RESTORE Phase 2 trial in alcohol-associated liver disease, adding a third parallel indication alongside MASH and alcohol use disorder. Pemvidutide holds FDA breakthrough therapy designation in MASH.
- FDA & regulation
Foundayo wins its first European approval
The pill cleared its first European regulator, starting a staged international rollout that reached UK pharmacies later in the month.
- Science
Researchers trace GLP-1 craving effects to the brain's lateral septum
Reported research pointed to the lateral septum, a brain region linking memory and motivation, as a hub for the reduced cravings people describe on GLP-1 drugs. The work may help explain observed effects on alcohol and other substances.
- Business
Hims & Hers 10-Q puts a $60 million number on the FTC case
In its second-quarter Form 10-Q, filed August 10, Hims & Hers disclosed a legal contingency accrual of approximately $60 million as of June 30, 2026 for the Federal Trade Commission matter, with total accrued legal contingencies of $62.5 million against $0 at the end of 2025. The filing confirms the company received an October 2023 civil investigative demand, says settlement negotiations with the FTC were unsuccessful, and discloses a follow-on consumer class action, Doe v. Hims & Hers Health, Inc., brought under the federal wiretap statute and two California privacy laws. Hims warns the accrual may increase or decrease materially.
- Competition
MHRA authorizes Lilly's orforglipron, a European first
The UK regulator authorized orforglipron, branded Foundayo, for weight management and type 2 diabetes, making Britain the first country in Europe to license the tablet. It covers adults with a BMI of 30 or above, or 27 to 30 with a weight-related condition.
- Business
UK becomes the first country in Europe to authorize orforglipron
The MHRA authorized Foundayo for both weight management and type 2 diabetes in adults, a broader label than the US approval. The agency confirmed the same 0.8 to 17.2 mg dose ladder, said the tablet can be taken at any time of day with no food or water restrictions, and noted the product is not available on the NHS pending a NICE evaluation.
- Culture
Case series reports muscle and grip-strength gains on tirzepatide — with testosterone in the mix
A retrospective series of 93 men combining tirzepatide, testosterone therapy and resistance-focused coaching reported 20.9-22.6 kg weight loss, 16.6-17.1 kg fat loss, 1.6-3.7 kg gain in skeletal muscle mass and 5.7-7.1 kg gain in grip strength over 12 months. The testosterone makes the muscle result impossible to attribute to training, a caveat routinely dropped when the study circulates online.
- Compounding
Hims & Hers reports Q2 2026 revenue of about $753 million with a GAAP loss
Subscribers grew 19 percent to 2.89 million and revenue rose 38 percent, but gross margin fell from 76 percent to 64 percent as branded GLP-1s replaced compounded product, producing an $86 million net loss.
- Culture
Systematic review finds no evidence for a best injection day
A review in Medicina screened 1,471 records and found only three relevant studies, concluding that current evidence does not support a specific optimal day of the week for semaglutide or tirzepatide administration, and recommending flexible schedules tailored to patient lifestyle to maximize adherence.
- Business
Novo Nordisk and AWS partner on AI drug discovery
Novo Nordisk announced a strategic partnership with Amazon Web Services to accelerate drug discovery using artificial intelligence. The deal signaled where the company plans to spend as its semaglutide franchise faces pricing pressure.
- Research
Second Obesity commentary sets out the safety and evidence gaps in tirzepatide dose splitting
A follow-up piece in Obesity, 'Microdosing Tirzepatide in Multi-Dose Pens: Clinical Individualization, Safety, and Evidence Gaps,' extended the June commentary. Together the two pieces frame the central problem: multi-dose devices make off-label dose manipulation physically easier, some patients will do it regardless, and there is no trial evidence on whether below-label dosing preserves any of the drug's demonstrated benefits.
- Policy
United Kingdom secures lower Section 232 pharmaceutical tariff rates in a bilateral arrangement
Trade advisories reported that the United Kingdom obtained reduced Section 232 tariff treatment for pharmaceutical exports to the United States, joining Japan, the European Union, Korea, Switzerland and Liechtenstein among jurisdictions carrying a 15 percent rate rather than the headline 100 percent duty on patented products. The Section 232 pharmaceutical framework took effect July 31, 2026 for most companies, with a September 29, 2026 start date for firms named in Annex III. GLP-1 manufacturers with most-favored-nation agreements are separately exempt.
- Business
Doustdar frames the Wegovy pill as a must-win as Canadian generics land
Novo Nordisk chief executive Mike Doustdar described the oral Wegovy launch as the must-win battle of 2026, speaking as Dr. Reddy's and Apotex generic semaglutide reached Canadian pharmacies. The framing sets the pill against two simultaneous pressures: Eli Lilly's Foundayo in the United States and generic injectable semaglutide in markets where patents have already lapsed. Novo Nordisk has said the pill accounts for the bulk of its 2026 growth.
- Business
A federal judge dismisses the Strive antitrust suit against Lilly and Novo Nordisk
U.S. District Judge Micaela Alvarez in San Antonio granted the manufacturers motions to dismiss, holding that Strive failed to plausibly allege a relevant product market because compounded GLP-1s are available only when a prescriber determines a branded drug cannot meet a patient specific need, making the products not reasonably interchangeable. The court added that antitrust law protects competition, not individual competitors. The dismissal was reported as with prejudice.
- Prices
CMS extends the Medicare GLP-1 Bridge through December 31, 2027 after BALANCE is delayed in Part D
With the BALANCE model not launching in Part D in 2027, CMS extended the Bridge demonstration through the end of 2027 to keep eligible beneficiaries covered and to collect additional GLP-1 utilization data to share with Part D plan sponsors ahead of any later BALANCE implementation.
- Research
Network meta-analysis ranks liraglutide last of the three obesity GLP-1 drugs
A systematic review and network meta-analysis of 24 randomized trials in the Journal of Endocrinological Investigation ranked tirzepatide 15 mg highest for weight and waist reduction and found liraglutide 3.0 mg produced the smallest weight loss, with higher risks of any adverse event and of discontinuation due to adverse events.
- Compounding
Reuters reports the GLP-1 antitrust dismissal
Wire coverage confirms Lilly and Novo defeated the compounders' antitrust theory.
- FDA & regulation
Canada's generic backlog tops 500 files with seven semaglutide submissions still waiting
The Canadian Generic Pharmaceutical Association said more than 500 generic submissions were sitting at Health Canada with over 100 formally backlogged, and that seven generic semaglutide files still awaited decisions. The queue matters for pricing: under Canada's pan-Canadian framework, the list price of a molecule falls step by step as more generics reach the market. Dr. Reddy's and Apotex were already authorized at that point.
- Policy
CMS issues Bridge operating guidance for Part D plans
CMS published implementation guidance for Part D plans participating in the Medicare GLP-1 Bridge, confirming that the demonstration sits outside the Part D benefit's coverage rules. The program runs from July 1, 2026 through December 31, 2027.
- Business
Eli Lilly reports 48% revenue growth and raises 2026 guidance to $85-87 billion
Lilly reported Q2 2026 revenue of $23.0 billion with Mounjaro at $9.9 billion and Zepbound at $4.9 billion, driven by a 60% volume increase and a 13% decline in realized prices. Foundayo contributed $98 million in its first quarter. Lilly also committed an additional $4.5 billion to Indiana manufacturing.
- Competition
Lilly Q2 revenue jumps 48% to $23 billion while its obesity pill disappoints
Mounjaro reached $9.94 billion, up 91%, and Zepbound $4.93 billion, up 46%. Foundayo brought in $98 million in its first quarter, below the roughly $130 million consensus. Lilly put its US incretin share at 60.9% against Novo Nordisk's 38.8%. Non-GAAP earnings per share of $8.38 beat consensus of $6.40.
- Prices
Lilly reports that self-pay is now most new Zepbound prescriptions
The majority of new Zepbound starts are now cash. That single statistic reframes the entire cost cluster: the primary question is no longer 'will insurance cover it' but 'what is the cheapest legitimate cash route', which is a different page with much higher commercial value.
- Culture
Mounjaro and Zepbound top $14.8 billion in a single quarter
Q2 2026 brought Mounjaro to $9.943 billion worldwide and Zepbound to $4.928 billion, close to 65% of Lilly's $23.0 billion in revenue, and Lilly raised full-year guidance to $85-$87 billion.
- Business
Foundayo posts $98 million in its first partial quarter, below expectations
Lilly reported Foundayo revenue of $98 million worldwide, including $67 million in the US, in the second quarter of 2026, against a Wall Street consensus near $130 million. Lilly added Foundayo to its Key Products list and confirmed the US type 2 diabetes submission had been filed. Executives pointed to June PBM coverage and the July Medicare Bridge as the start of an inflection.
- Competition
Lilly climbs and Novo slips as the obesity battle intensifies
Eli Lilly reported Mounjaro and Zepbound combining for $14.9 billion in second-quarter sales, while Novo Nordisk's shares fell about 5% as lower prices weighed on revenue. Foundayo contributed $98 million in its first partial quarter.
- Competition
Lilly completes the retatrutide data package and plans a 2027 filing
Eli Lilly said the retatrutide clinical package was complete and that it planned to submit to the FDA in the first quarter of 2027 for obesity, obstructive sleep apnea and knee osteoarthritis pain. Lilly is fighting the FDA over whether retatrutide can be filed as a biologic, a distinction worth 12 years of exclusivity instead of five.
- Prices
Lilly reports tirzepatide revenue of $14.9 billion in one quarter and a 13% fall in realized prices
Q2 2026 Mounjaro revenue was $9.943 billion worldwide and US Zepbound revenue $4.928 billion, together 64.7% of company revenue. Worldwide revenue rose 48% on 60% volume growth while realized prices fell 13%, which Lilly attributed largely to Zepbound and Mounjaro including the cash-pay price cuts.
- Research
Amgen's second quarter puts nine MariTide Phase 3 trials in the field
Amgen's second-quarter report described nine global Phase 3 MariTide studies running across obesity, type 2 diabetes, cardiovascular disease, heart failure and obstructive sleep apnea, with three further Phase 3 diabetes trials to start in 2026 and a Phase 2b liver-fat study enrolling. The company also confirmed the discontinuation of AMG 513, leaving MariTide as its only obesity asset. MARITIME-1 and MARITIME-2 carry primary completion dates in January 2027.
- FDA & regulation
Lilly and the FDA head for a decision on whether retatrutide counts as a biologic
The classification determines exclusivity and the pathway generics would use. Trade press reported the dispute coming to a head as Lilly prepared a first-quarter 2027 filing, and an appeals court set a September hearing.
- Research
Network meta-analysis compares GLP-1 therapy with testosterone therapy in men with obesity
The Journal of Sexual Medicine published a network meta-analysis of 23 randomized trials and 1,899 men with obesity-related functional hypogonadism. Testosterone replacement plus structured lifestyle therapy produced the largest testosterone increase and was the only intervention that significantly improved erectile function scores; GLP-1-based therapy did not lead the network.
- Science
Lilly's public pipeline table lists brenipatide, macupatide and a long-acting GIPR agonist
The company's clinical development pipeline, current as of this date, shows eloralintide across multiple indications plus an incretin add-on program, along with brenipatide and macupatide in Phase 2 and a separate long-acting GIP receptor agonist.
- Compounding
Novo Nordisk wins a preliminary injunction against a Dutch compounded semaglutide nasal spray
Novo Nordisk obtained a preliminary court injunction in the Netherlands against a compounded semaglutide nasal spray, extending its enforcement campaign against unapproved semaglutide formulations into a new route of administration and a new jurisdiction. Nasal and sublingual semaglutide products have no approved dosing or bioavailability data anywhere in the world. The action is part of a broader global push that Novo Nordisk has described as patient-safety litigation.
- Business
Novo Nordisk raises its 2026 outlook on Wegovy pill momentum
Novo Nordisk reported adjusted second-quarter operating profit of DKK 33.4 billion and lifted its full-year guidance, now expecting adjusted sales growth of -4% to -12% at constant exchange rates instead of -5% to -13%. CEO Mike Doustdar credited the Wegovy pill, used by more than a million patients since January, and the Wegovy HD launch.
- Business
Novo Nordisk's Q2 brand detail: Ozempic DKK 31.4 billion, Wegovy injection flat, Wegovy pill DKK 3.2 billion
Inside the second-quarter report, Ozempic sales rose 3% to DKK 31.375 billion while Wegovy injection grew just 1% to DKK 19.484 billion and the Wegovy pill contributed DKK 3.218 billion in its second full quarter. Adjusted sales were DKK 78,488 million, up 7% at constant exchange rates, and adjusted operating profit was DKK 33,389 million, up 11%. The split shows the pill, not the injection, carrying the franchise's US growth.
- Research
REIMAGINE 4 misses its dual primary endpoint against tirzepatide
Novo Nordisk disclosed 68-week REIMAGINE 4 results in its second-quarter report: CagriSema produced 15.2% weight loss and a 1.9 point HbA1c reduction versus 15.8% and 2.2 points for tirzepatide 15 mg in type 2 diabetes. The combination met non-inferiority on weight but missed it on blood sugar, so the trial did not succeed on its stated terms.
- Business
Novo Nordisk books DKK 6.3 billion in non-cash pipeline impairments, including monlunabant
Novo Nordisk's reported second-quarter operating profit fell 16% at constant exchange rates, hit by DKK 6.3 billion of non-cash impairment charges on intangible pipeline assets, with roughly DKK 4.0 billion tied to the discontinued oral obesity candidate monlunabant. Reported results were also depressed by the prior-year reversal of a DKK 2.6 billion US 340B rebate provision. The company returned DKK 41.2 billion to shareholders through dividends and buybacks in the first half.
- Competition
Pfizer cuts two more ex-Metsera obesity programs in a quarterly pipeline clearout
Pfizer removed MET-224o, an oral ultra-long-acting GLP-1 acquired in the Metsera deal, and PF-07976016, a Phase 2 GIPR antagonist, from its pipeline. MET-224o was one of Metsera's two lead oral candidates; the other, MET-097o, had already disappeared from Pfizer's first post-close pipeline update. The cuts concentrate Pfizer's obesity thesis on the injectable berobenatide franchise and its licensed Chinese oral, YP05002.
- Science
PNAS study finds semaglutide needs the brain's hunger neurons to keep fat off
A Yale-led team reported in the Proceedings of the National Academy of Sciences that AgRP neurons, long described as hunger cells, are recruited rather than silenced during prolonged semaglutide treatment in female mice. Disrupting those neurons or blocking a fat-mobilization signaling pathway weakened sustained fat loss even though the animals kept eating less. The result complicates the standard account that GLP-1 drugs work purely by suppressing appetite, and the authors stress the effect depended on sex, diet and the method of disruption.
- Research
Altimmune starts PERFORMA, a registrational Phase 3 of pemvidutide in MASH
Altimmune initiated PERFORMA, a global randomized, double-blind, placebo-controlled Phase 3 trial of the GLP-1/glucagon dual agonist pemvidutide in metabolic dysfunction-associated steatohepatitis, testing fibrosis improvement, MASH resolution and clinical outcomes. The trial follows 48-week IMPACT Phase 2b data presented at EASL earlier in 2026. MASH is the nearer regulatory path for a company whose obesity pitch rests on glucagon-driven fat loss with muscle preservation.
- Research
Danish national cohort on semaglutide persistence published in JAMA Network Open
The peer-reviewed version of the EASD 2025 analysis of all 77,310 Danish adults without diabetes who started semaglutide for weight loss: 18% had stopped by three months and 52% by one year, with the highest dropout among adults aged 18-30.
- Policy
Lilly opens a broader expanded-access program for retatrutide
After criticism of the single compassionate-use case, the company said more patients could apply for access to the unapproved triple agonist while phase 3 trials finished. Some physicians objected that expanded access for an obesity drug sets a difficult precedent.
- Prices
Canadian plan sponsors brace for a 65% semaglutide list-price cut once a third generic lands
Benefits analysts warned Canadian plan sponsors that semaglutide list prices drop to 35% of brand, a 65% cut, as soon as a third generic reaches the market, with Sandoz targeting the third quarter of 2026 and Aspen Pharmacare going Canada-first. That single threshold, not the first generic approval, is what resets drug-plan budgets. It is the mechanism US employers do not have, and it explains why Canadian GLP-1 spending is expected to fall much faster than American spending.
- Research
Tirzepatide reported to help in partial lipodystrophy, a rare fat-storage disorder
A single-center retrospective study in the Journal of Clinical Endocrinology and Metabolism reported on all 40 patients with partial lipodystrophy treated with tirzepatide at one center between January 2022 and September 2025. Over a median 9.5 months, median body weight fell from 91.0 kg to 82.8 kg, with significant reductions also in glycemic control measures, serum triglycerides and daily insulin requirement. Metreleptin remains the only licensed lipodystrophy-specific treatment. The study has no control group and covers several genetic subtypes.
- Business
Eli Lilly holds about 60% of the US branded obesity market
IQVIA prescription data showed Zepbound ahead of the Wegovy franchise on weekly scripts through the summer, leaving the split at roughly 60% Lilly and 40% Novo Nordisk, with about a third of Wegovy volume coming from the pill.
- Competition
Structure Therapeutics doses the first patients in the Phase 3 ACCOMPLISH program
Aleniglipron became the third oral small-molecule GLP-1 in Phase 3, alongside Lilly's approved Foundayo and AstraZeneca's elecoglipron.
- Prices
CVS formulary decisions again shape the oral GLP-1 race
Analysts pointed to a CVS decision excluding an oral competitor as a factor in the 2026 market, echoing the Wegovy-versus-Zepbound formulary fight of 2025. Pharmacy benefit manager choices now move market share as much as trial data.
- Science
Lean mass questions move to the center of GLP-1 practice
Analyses of ATTAIN-1, SURMOUNT-1 and STEP 1 body-composition substudies showed lean mass accounting for roughly a quarter to 40% of total weight lost, broadly similar to lifestyle interventions but larger in absolute terms because total loss is greater. No head-to-head comparisons of lean mass across GLP-1s exist.
- Business
Multi-dose Wegovy FlexTouch pen reported to be rolling out in the US
Trade reporting said Novo Nordisk was preparing a US launch of the four-dose FlexTouch pen, with the device already cleared in FDA records. Novo Nordisk had not issued a launch press release as of September 2026.
- Competition
Obesity pipeline broadens beyond GLP-1 with new phase 3 starts
By late 2026 AstraZeneca had moved elecoglipron into phase 3, Structure Therapeutics had begun dosing in its aleniglipron program, and Zealand Pharma and Roche were advancing the amylin analog petrelintide. The field increasingly targets amylin, glucagon and non-incretin mechanisms alongside GLP-1.
- FDA & regulation
Ozempic 25 mg tablet awaits an FDA decision for type 2 diabetes
Novo Nordisk filed a supplemental application for a 25 mg Ozempic tablet strength for adults with type 2 diabetes, with a decision expected in 2026. Current Ozempic tablets top out at 9 mg.
- Competition
Pfizer readies a monthly obesity injection from the Metsera platform
Pfizer advanced PF-08653944, a monthly GLP-1 injection, through phase 2b testing and outlined more than 20 anti-obesity trials for 2026, including ten in phase 3. Less frequent dosing is the pitch against weekly semaglutide and tirzepatide.
- FDA & regulation
Zepbound label revision updates the diabetic retinopathy section
The Zepbound prescribing information revised 8/2026 lists Diabetic Retinopathy Complications in Patients with Type 2 Diabetes as changed in 08/2026, confirms Suicidal Behavior and Ideation was removed in 02/2026, and retains the instruction for patients on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose escalation.
- Business
Ziltivekimab fails the ZEUS heart trial, erasing about $30 billion of market value
The anti-interleukin-6 antibody lowered inflammatory markers but did not reduce major adverse cardiovascular events in more than 6,300 patients (hazard ratio 0.99). Two other outcomes trials continue, with readouts due in the first half of 2027.
- Research
Novo's ZEUS trial fails and shares drop 9%
Novo Nordisk said the phase 3 ZEUS trial of ziltivekimab in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation did not meet its primary endpoint. The stock fell about 9% on the day, extending a run of pipeline disappointments.
- Business
Section 232 pharmaceutical tariffs take effect for 17 named companies
The 100% tariff on imported patented pharmaceuticals became effective for the companies listed in Annex III of the April proclamation. Most of those companies, including Eli Lilly and Novo Nordisk, held agreements providing reduced or zero rates.
- Research
Cleveland Clinic publishes guidance advising against microdosing GLP-1s
Cleveland Clinic published consumer guidance advising against microdosing GLP-1 medications, citing dosing-error risk and the absence of evidence for meaningful or sustained benefit. It joined Cedars-Sinai in putting a major health system on record against the practice, at a point when telehealth companies were actively marketing microdose programs and FDA had already flagged 10-fold dosing errors with compounded semaglutide vials.
- Research
Comment period closes on the FDA proposal to end GLP-1 compounding at outsourcing facilities
The extended comment deadline on the FDA's proposal not to include semaglutide, tirzepatide and liraglutide on the 503B Bulks List passed. A final determination had not been announced as of September 14, 2026. A narrative review published the same month in Cureus framed microdosing as a response to cost and supply pressure rather than a strategy validated by trials.
- Prices
Sun Pharma wins Brazilian approval for semaglutide injections
The Indian manufacturer cleared Anvisa to make and market semaglutide for type 2 diabetes in Brazil, extending the generic wave across the southern hemisphere.
- Research
TREASURE-CKD completes without reporting results
The 134-participant phase 2 mechanistic MRI study of tirzepatide in overweight or obesity with chronic kidney disease reached its completion date. It measured renal sinus fat and kidney oxygenation, not kidney failure outcomes, and no results had been posted as of 2026-09-14.
- FDA & regulation
Two more generic semaglutide products sit approved but unmarketed in Canada's drug database
Health Canada's Drug Product Database listed Aspen-Semaglutide and Apotex's Sevmia as approved with no market date as of July 28, 2026, meaning neither could yet be bought at a pharmacy counter. Approval and marketing are separate steps in Canada, and launch timing turns on supply, provincial listing and pricing negotiations. Dr. Reddy's generic, by contrast, reached Canadian pharmacies on May 15, 2026.
- Compounding
FTC, Utah and Los Angeles County sue Hims & Hers over subscription billing and health data sharing
The FTC filed suit in the Northern District of California alleging violations of Section 5 of the FTC Act, the Restore Online Shoppers Confidence Act and state consumer protection law: auto-renewing prescription subscriptions without adequate disclosure, obstructed cancellation, and sharing sensitive health data with advertising platforms including Meta and Snap. The investigation dated to October 2023. Hims denied the allegations. The claims concern billing and privacy, not compounding.
- Research
Oral semaglutide reduces heavy drinking in a treatment-seeking trial
A phase 2 trial of 50 adults with moderate to severe alcohol use disorder missed its primary craving endpoint but significantly reduced heavy drinking days, drinks per drinking day, day-to-day craving, alcohol-related problems and cannabis use days.
- FDA & regulation
Patent expert says Novo Nordisk could have extended its Canadian Ozempic patent to 2028
Tahir Amin, chief executive of the Initiative for Medicines, Access & Knowledge, told the BBC that Novo Nordisk's Canadian semaglutide patent could have been extended to 2028 but was not renewed, saying somebody dropped the ball. Canada's certificate of supplementary protection register shows a March 20, 2026 expiry against a term that could have run to March 20, 2028. The lapse, combined with data protection ending on January 5, 2026, made Canada the first G7 country with generic semaglutide.
- Research
Viking guides oral VK2735 Phase 3 to the fourth quarter of 2026
In its second-quarter update, Viking Therapeutics said the oral VK2735 Phase 3 program would start in Q4 2026, said maintenance and reduced-frequency dosing results were expected in Q3 2026, and reported $502 million in cash. The VANQUISH-1 and VANQUISH-2 injection trials remain on track for primary completion July 1, 2027.
- Research
Japanese cohort finds 2.5 mg and 5 mg tirzepatide produce similar six-month weight loss
The closest published evidence to deliberate low-dose tirzepatide use. A multicenter prospective cohort of 112 non-diabetic Japanese adults, all starting at 2.5 mg and then either staying there or moving to 5 mg by shared decision-making, reported mean weight loss of 15.3 percent versus 16.1 percent at six months, a non-significant difference, with fewer adverse events at the lower dose (35 versus 50 percent). The study was not randomized, ran six months, and enrolled a population with a mean BMI of 30.8 and 96.4 percent dietary adherence, all of which limit how far it generalizes.
- Competition
Altimmune reports positive Phase 2 results for pemvidutide in alcohol use disorder
The RECLAIM trial met its primary endpoint with a highly statistically significant reduction in heavy drinking, extending GLP-1-class research into addiction.
- Competition
Gubra opens Phase 1/2a of GUB-UCN2, its own non-incretin obesity peptide
Gubra started a combined Phase 1/2a trial of GUB-UCN2, a urocortin-2 analog aimed at fat loss with lean-mass preservation, moving its lead internal asset into the clinic. The company frames UCN2 as its next potential mega program alongside partnered assets ABBV-295 and BI 3034701. The start predates Genentech's August licensing deal for Hanmi's competing UCN2 analog, HM17321.
- Business
Judge lets CagriSema securities fraud claims against Novo Nordisk proceed
US District Judge Robert Kirsch in New Jersey dismissed most of a shareholder class action over Novo Nordisk's December 2024 REDEFINE 1 readout but allowed a narrower set of claims to move into discovery. Investors alleged the company and development chief Martin Holst Lange misled them about CagriSema's tolerability and about a flexible dosing design under which only 57.3% of participants reached the highest dose. Novo Nordisk's American depositary receipts fell 17.8% on December 20, 2024, when CagriSema produced 22.7% weight loss against a 25% target.
- Research
REST trial protocol published, formalizing the taper question
PLoS One published the REST trial protocol, stating the hypothesis that gradual dose reduction before complete discontinuation of semaglutide may reduce weight regain and cardiometabolic deterioration compared with stopping outright. Publishing the protocol put the tapering question on the record as an open, testable one rather than a matter of clinician preference, and set the terms by which the 2029 result will be judged.
- Science
Two brain regions found to explain the GIP paradox
A Nature Metabolism study using region-specific GIP receptor knockouts finds the area postrema drives the appetite-suppressing effect of GIP receptor agonists, while hypothalamic GIP receptors drive the extra weight loss from adding a GIP receptor blocker to GLP-1 or amylin agonism.
- Competition
Retatrutide wins two more Phase 3 trials and Lilly sets a Q1 2027 FDA filing
TRIUMPH-2 (obesity with type 2 diabetes) reached 20.8% at 12 mg and TRIUMPH-3 (BMI 35 or higher with cardiovascular disease) reached 22.6%. Lilly said it plans to submit a Biologics License Application in the first quarter of 2027, a slip from an earlier expectation of a 2026 submission tied to manufacturing and quality-control data rather than trial results.
- Compounding
FDA advisory committee recommends six peptides for the 503A bulks list
At its July 23-24, 2026 meeting the Pharmacy Compounding Advisory Committee voted, narrowly and over the objections of FDA scientific staff, to recommend BPC-157, KPV, TB-500, MOTS-c, epitalon and semax for the 503A bulks list, and voted down emideltide 7-6 with one abstention. The votes are recommendations only and do not amend the list. No GLP-1 was on the agenda.
- Research
Lilly says retatrutide is ready to file, targeting obesity, sleep apnea and knee osteoarthritis
With TRIUMPH-2 and TRIUMPH-3 reported, Lilly said five positive phase 3 trials give it the clinical package to seek registration in obesity, obstructive sleep apnea and knee osteoarthritis pain, with a US filing planned for the first quarter of 2027. TRIUMPH-3, in people with severe obesity and established cardiovascular disease, showed 22.6 percent weight loss.
- Research
Systematic review finds GLP-1 drugs raise testosterone only in metabolically unwell men
A PRISMA systematic review in Cells identified eight studies of GLP-1 receptor agonists and male reproductive endocrinology, including one randomized placebo-controlled crossover trial. In men with obesity, type 2 diabetes or functional hypogonadism, the drugs were associated with modest testosterone increases and improvements in erectile function or selected semen parameters. In healthy men with normal testosterone, the placebo-controlled trial found no significant endocrine or reproductive effect. The authors conclude the response depends on baseline metabolic status.
- Safety
BMJ study finds a hair loss signal across the GLP-1 class
A target trial emulation in adults with type 2 diabetes found GLP-1 receptor agonist initiators, tirzepatide included in the exposure definition, had a higher risk of alopecia than SGLT2 inhibitor initiators (hazard ratio 1.37) or DPP-4 inhibitor initiators (1.68). The association was specific to non-scarring alopecia. The authors note the FDA has indicated it is evaluating the signal.
- Competition
Novo Nordisk moves to stop Eli Lilly GLP-1 advertising campaigns
Filed in New Jersey federal court under the Lanham Act, the complaint says Lilly's national campaigns compare the highest doses of Zepbound and Mounjaro against lower doses of Wegovy and Ozempic while omitting the 7.2 mg Wegovy dose approved in March 2026. Novo says the ads ran more than 700 million times after an April cease-and-desist letter. Lilly says its advertising rests on SURMOUNT-5, the only head-to-head randomized trial, and will defend the case.
- Business
President announces phased tariffs on imported generic drugs
Generic drugs would stay at 0% tariffs for two years from August 1, 2026, then face 100% from August 2028 and 200% from August 2029, a schedule announced to force reshoring of generic manufacturing and one that will shape what US generic semaglutide costs after 2031.
- Research
Review maps the off-label evidence across five domains and finds it thin everywhere
A review in Biomedicines surveyed unconventional uses of semaglutide and tirzepatide across oncology, psychiatry and addiction medicine, orthopedics, aesthetic medicine and human reproduction. It reports signals in each domain — antitumor activity through immune and metabolic reprogramming, reward-pathway effects on alcohol and binge eating, knee osteoarthritis pain and function, inflammatory skin disease, and PCOS and male fertility — and concludes that across all five the evidence derives predominantly from preclinical models, observational cohorts and pharmacoepidemiologic studies, with randomized trials remaining limited.
- Competition
Hengrui reports a positive Phase 3 diabetes readout for ribupatide in China
The HRS9531-302 trial demonstrated superiority on its primary endpoint in treatment-naive Chinese patients with type 2 diabetes, broadening the asset beyond obesity.
- Culture
Rebel Wilson becomes Noom's chief wellness officer
Noom named Wilson to lead a campaign arguing GLP-1 medication and habit change work better together, the clearest sign that legacy weight-loss brands had stopped fighting the drugs and started selling alongside them.
- Competition
Boehringer Ingelheim starts a Phase 2 trial of a Gubra-originated triple agonist
The partnered first-in-class triple receptor agonist entered Phase 2 in people with overweight and obesity following strong late-2025 clinical results.
- Business
EMA approves Wegovy pill and Wegovy 7.2 mg single-dose pen in the EU
The European Commission cleared once-daily oral semaglutide 25 mg for adults with a BMI of at least 30, or at least 27 with a weight-related condition, making it the first oral GLP-1 weight-management treatment available EU-wide. The Commission also approved the Wegovy 7.2 mg single-dose pen.
- Culture
Expert consensus sets meal-pattern targets for GLP-based therapy
An Obesity Pillars consensus recommended protein at 20-30% of energy progressing to 1.2-1.5 g/kg/day or higher, fluid above 2 L/day, fiber 20-30 g/day escalated gradually with mixed soluble and insoluble sources, and 4 to 5 small eating occasions a day rather than large portions, with slow eating and no large evening meals.
- FDA & regulation
Wegovy pill reaches its fifth regulatory approval
With the EU decision, the Wegovy pill had been cleared in the United States, the United Kingdom, the United Arab Emirates, Bahrain and the European Union. Novo said it would introduce the tablet in more countries in the second half of 2026.
- Culture
Sam's Club bundles a WeightWatchers benefit against Costco's GLP-1 program
Warehouse clubs turned weight management into a membership war, with Sam's Club offering members free months of a weight-loss and wellness program as Costco expanded discounted telehealth GLP-1 access.
- Research
Three-case series describes flat mood and lost motivation at tirzepatide 15 mg
Obesity Pillars published a series of three women with obesity on tirzepatide 15 mg weekly who reported reduced motivation, emotional flatness or loss of interest in previously enjoyable activities despite successful weight loss. Two had no prior mood disorder, and the patients described the symptoms as distinct from depression. All three had the dose reduced to 10 mg or lower; two improved markedly on dose reduction alone and one needed added bupropion, with symptoms recurring on re-escalation in one case. The authors link it to the same reward-pathway effects that reduce food craving.
- Prices
GoodRx reports 114 million Americans with no commercial coverage for Zepbound
As of July 2026 the share of commercially insured people with no Zepbound coverage had risen from 51% to 60%, an increase of about 17 million people. Unrestricted coverage fell from 5% to 4% and restricted coverage from 45% to 37%, so roughly nine in ten of those with any Zepbound coverage faced prior authorization, step therapy or both.
- Safety
Largest tirzepatide FAERS study finds medication errors top the signal list
An analysis of 123,145 reports and 251,435 adverse events from Q2 2022 to Q4 2025 found medication errors and injection-site reactions were the strongest signals, ahead of gastrointestinal disorders. Median time to onset was 13 days, with 67.1% of events within 30 days. Compared with semaglutide, tirzepatide showed lower reporting odds of vomiting, constipation and decreased appetite. Novel unlabelled signals included eructation, hunger, food craving and starvation ketoacidosis.
- Research
Structure Therapeutics starts the ACCOMPLISH Phase 3 program for aleniglipron
ACCOMPLISH-1 (3,600 participants) and ACCOMPLISH-2 (1,100) began enrolling within days of each other. Aleniglipron is the leading biotech-developed oral small-molecule GLP-1 and the closest challenger to orforglipron. Topline is expected in the second half of 2028.
- Policy
CMS publishes patient guidance for the Medicare GLP-1 Bridge
CMS posted beneficiary-facing guidance explaining eligibility, the $50 flat copay and the drugs covered under the GLP-1 Bridge. Humana serves as the central claims processor, and the program runs outside normal Part D rules.
- Research
Meta-analysis finds no clear rise in birth defects after GLP-1 exposure
A Scientific Reports meta-analysis searching databases through January 2026 found maternal periconceptional or pregnancy GLP-1 exposure was not clearly associated with major congenital malformations, with one companion analysis reporting a relative risk of 1.02.
- Research
Military Health System cohort reports 82% one-year persistence on tirzepatide
Among 10,649 active-duty service members in a weight-management cohort, one-year persistence was 81.9% for tirzepatide, 70.7% for semaglutide and 34.2% for liraglutide. The adjusted hazard of discontinuation was 33% lower for tirzepatide than semaglutide. The population has guaranteed coverage, so the numbers do not generalize.
- Culture
PERCEPTIONS survey quantifies the workplace side of obesity treatment
Among 518 employed US adults initiating tirzepatide, Work Productivity and Activity Impairment scores showed 32.4% overall work impairment driven primarily by presenteeism. 96.5% believed employer-provided insurance should cover obesity medication and 52.3% said they would change jobs to get that coverage.
- Research
BMJ network meta-analysis: biggest fat loss and biggest lean loss come together, and quality of life barely moves
A network meta-analysis of 262 trials and 99,791 participants across 19 obesity drugs found tirzepatide reduced fat mass most (25.7%) and lean mass most (8.3%), and that subcutaneous semaglutide was the only drug associated with reduced all-cause mortality. Across 43 trials and 45,663 participants, no drug convincingly improved quality of life beyond established minimal important differences.
- Prices
IFEBP finds employer weight-loss GLP-1 coverage flat and claims share rising
A June 2026 survey of almost 300 employer health plans found 36% cover GLP-1s for both diabetes and weight loss, unchanged from 2025, 60% for diabetes only, and 45% for other approved conditions such as sleep apnea. GLP-1s rose from 6.9% of annual claims in 2023 to 11.4% in 2026.
- Prices
FDA accepts a second generic tirzepatide application, from Amneal and Adalvo
A second abbreviated new drug application covering generic tirzepatide was accepted for FDA review, giving the molecule a real generic pipeline for the first time while leaving the patent barrier untouched.
- FDA & regulation
Novo Nordisk publishes full STEP UP body composition detail with a Singapore label update
Company data showed mean weight loss of 20.7% on the efficacy estimand with semaglutide 7.2 mg, 31.2% of patients reaching at least 25% weight loss, and up to 84% of weight lost coming from fat mass.
- FDA & regulation
Wegovy pill reaches UK patients and raises questions for doctors
Weeks after the MHRA authorization, the semaglutide tablet became available to UK patients, prompting professional debate about prescribing, monitoring and demand. The BMJ noted the tablet is licensed for adults with a BMI of 30 or above, or 27 to 30 with a weight-related condition.
- Culture
SURMOUNT-OSA post hoc: biggest daytime-function gains in people who felt worst at baseline
Post hoc analyses in Sleep grouped SURMOUNT-OSA participants by self-reported baseline fatigue, sleepiness, snoring and sleep quality. Tirzepatide was consistently associated with greater improvement than placebo across subgroups, with numerically larger vitality gains in participants who reported baseline fatigue.
- Research
Case series reports fewer migraine attacks on tirzepatide, with a large caveat
A report in Headache described two patients whose migraine frequency fell after starting tirzepatide. The authors flagged that both also lost weight, identified this as a significant confounder that prevents any conclusion about a migraine-specific effect, and described the cases as preliminary observations requiring formal study. Obesity is an established comorbidity of migraine that raises attack frequency and drives chronification, so weight loss alone is a sufficient explanation.
- Prices
MassHealth stops covering drugs used only for obesity or overweight
Under Pharmacy Facts #271 (March 12, 2026, corrected), MassHealth ended coverage of anti-obesity medications — including Wegovy, Zepbound, Saxenda, Xenical, phentermine and the older appetite suppressants — when used for weight loss, effective July 3, 2026, in line with anticipated changes to 130 CMR 406.413(B). Coverage continues for members with another medically accepted indication, but a new prior authorization is required. Reporting put the number of members affected at about 22,000 and expected savings at roughly $15 million. The change removes Massachusetts from KFF’s January 2026 list of 13 states covering GLP-1s for obesity, leaving 12.
- FDA & regulation
MHRA approves Wegovy for liver disease
The UK added a MASH indication for semaglutide.
- Research
Audit finds the compounded GLP-1 market still operating after the shortage ended
JAMA Health Forum published an audit of the compounded GLP-1 market in two high-demand states after FDA declared the shortages resolved. Researchers found 75 weight-loss clinics and medical spas still offering compounded products, 56.0% of them combined with B vitamins. Among supplier facilities, 19.0% lacked sterile compounding licenses, 13.6% had faced state disciplinary action and one had received multiple FDA warning letters since 2023.
- Safety
MDL 3163 authorizes early motion practice on causation and preemption
Case Management Order 12 in the NAION MDL opened the first substantive motion practice on general causation and federal preemption, the same two questions the gastrointestinal MDL was already litigating.
- Compounding
Medicare GLP-1 Bridge begins, covering the Zepbound KwikPen only
Because federal law bars Medicare Part D from covering drugs used for weight loss, CMS launched a time-limited demonstration giving eligible Part D beneficiaries certain obesity GLP-1 drugs at a flat 50 dollar copay for a one-month supply, through December 31, 2027. Medicare's beneficiary fact sheet names exactly three covered products: Foundayo (orforglipron) tablets, Wegovy injection or tablets, and the Zepbound KwikPen only. The single-dose Zepbound pen and Zepbound vials are not covered, and neither are Ozempic, Mounjaro or Rybelsus. The drugs are furnished outside the Part D benefit payment flow, so the deductible does not apply, the copay does not count toward true out-of-pocket costs, and coupons may not be applied.
- Policy
Medicare GLP-1 Bridge begins, publishing explicit BMI eligibility numbers
CMS began a short-term demonstration giving eligible Medicare Part D beneficiaries access to Foundayo tablets, Wegovy injection or tablets, and the Zepbound KwikPen at a flat $50 monthly copay through December 31, 2027, outside the Part D benefit's coverage and payment flow. Medicare.gov publishes numeric eligibility criteria — BMI 35 or higher, BMI 30 or higher with diastolic heart failure, uncontrolled hypertension or CKD stage 3a or higher, or BMI 27 or higher with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease — at a time when the Wegovy, Zepbound and Foundayo indication sections no longer print BMI numbers. Beneficiaries already receiving a Part D-covered GLP-1, and those with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease, are excluded.
- Prices
Massachusetts GIC ends obesity-only GLP-1 coverage and shuts down the Vida prescribing requirement
For non-Medicare GIC members, coverage of GLP-1s prescribed solely for obesity ended June 30, 2026, and the Vida Health prescribing arrangement ended at the same time. From July 1, members work with their regular provider and request prior authorization through CVS Caremark, with coverage possible only when the prescription is tied to a qualifying FDA-approved medical condition. Medicare GIC members keep coverage through December 31, 2026.
- FDA & regulation
Lilly is picked for the FDA's PreCheck manufacturing pilot
The program is meant to speed review of new domestic plants. Lilly was building four at once, and the designation applied to sites that will make obesity drugs.
- Compounding
Apollo Care recalls roughly 162,000 vials of compounded semaglutide
The 503B outsourcing facility in Columbia, Missouri pulled about 156,611 vials of compounded semaglutide and 5,500 vials of semaglutide with glycine after nylon, polyamide and proteinaceous particulate was found in vials.
- Compounding
JAMA Health Forum secret-shopper study finds compounded GLP-1s still widely sold
Researchers surveying clinics in two high-demand states find compounded GLP-1 receptor agonists still on offer after the shortages ended, including a share of clinics selling oral or sublingual formulations.
- Safety
Summary judgment briefing completes in MDL 3094
With preemption, warnings adequacy and general causation fully briefed, the litigation moved toward the September Rule 702 hearing that will determine which expert opinions the jury can hear.
- Research
US nationwide cohort of 208,155 post-bariatric patients finds tirzepatide outperforms semaglutide
EClinicalMedicine published a retrospective cohort drawn from a de-identified electronic health record dataset spanning 43,104 US academic and private medical centers covering 2018 to 2025. Among people who stayed on therapy a year after bariatric surgery, tirzepatide produced 17.2 percent total weight loss versus 12.0 percent with semaglutide, and incretin therapy was not associated with major adverse cardiovascular events.
- Business
Amazon Pharmacy adds Lilly's obesity pill with same-day delivery
Amazon Pharmacy began offering Foundayo with same-day delivery, and the pill also became available through GoodRx. Distribution of oral GLP-1s moved rapidly into mainstream retail and e-commerce channels.
- Safety
Australia's TGA issues class-wide GLP-1 eye safety warnings
Australia's Therapeutic Goods Administration announced class-wide warning updates for marketed GLP-1 receptor agonists covering rare severe eye disorders, and advised prompt medical attention for sudden vision changes. The US Ozempic label still did not carry a NAION warning as of mid-2026.
- Research
SURPASS-CN-MONO published, completing tirzepatide's China registration package
In 206 Chinese adults with early type 2 diabetes, tirzepatide monotherapy lowered HbA1c by 1.93 to 2.04 points more than placebo at week 40, with weight loss of 6.0 to 9.7 kg and no clinically significant hypoglycemia.
- FDA & regulation
Foundayo Medication Guide reissued with the 7-day missed-dose restart instruction
Lilly reissued the Foundayo Medication Guide (OFG-0002-MG-20260729) with patient-facing wording for the missed-dose rules: take a missed dose as soon as possible, never take two doses in the same day, and call a healthcare provider about restarting if 7 or more days in a row are missed. It is the only currently marketed GLP-1 with a 7-consecutive-day reescalation trigger.
- FDA & regulation
Wegovy label consolidates injection and tablet into one prescribing information
The current Wegovy label covers both the injection and the 25 mg once-daily tablet, with separate escalation tables, separate indication sets (the tablet lacks the pediatric and MASH indications), and explicit instructions for switching between the two forms in either direction. For someone starting, it is the first time an oral and an injectable version of the same weight-management drug were governed by a single set of instructions.
- Compounding
FDA scientists publicly flag evidence gaps in compounded peptides
Ahead of the Pharmacy Compounding Advisory Committee's July 2026 meeting, agency scientists raised concerns about the substances the HHS Secretary had said would return to Category 1 compounding.
- Business
Sandoz files to revoke a Novo Nordisk semaglutide patent at the Unified Patent Court
Sandoz sued in the UPC's Milan Central Division seeking revocation of Novo Nordisk unitary patent 3 689 365, covering the 1 mg dose of semaglutide for diabetes in 18 EU countries.
- Prices
STAT reports a loophole in the White House pricing deal with Lilly and Novo
The analysis found that the most-favored-nation commitments left room for the companies to keep list prices high in channels the deal did not cover, complicating claims that American prices had come down across the board.
- Prices
Health Canada approves the first generic semaglutide for weight loss
Apotex's Sevmia, a generic of Wegovy indicated for chronic weight management in patients 12 and older, became the third generic semaglutide authorized in Canada. Health Canada said six other generic semaglutide submissions remained under review.
- Research
AstraZeneca opens the Embold Phase 3 master protocol for elecoglipron
A 4,500-participant obesity master protocol began enrolling, the anchor of one of the broadest Phase 3 programs in the class: five Eluminate diabetes trials plus Elevate-HF and Elevate-CKD outcomes trials totaling roughly 25,000 planned participants.
- Prices
FDA accepts the first generic tirzepatide application, from Sandoz
Sandoz's abbreviated new drug application covering generic tirzepatide for both the Mounjaro and Zepbound indications was accepted for review. Acceptance is not approval, and Lilly's patents run to 2036 and beyond, so no launch date follows from it.
- Policy
Britain partners with Lilly on a national obesity plan
The agreement pairs NHS rollout with Lilly investment, and arrived while the company was publicly pressing the UK to pay more for medicines.
- Research
FDA extends the comment period on the GLP-1 compounding proposal to July 30
In response to a request for more time, the FDA published a Federal Register notice extending the comment deadline on its proposal not to include semaglutide, tirzepatide or liraglutide on the 503B Bulks List. Comments were due by 11:59 p.m. Eastern on July 30, 2026. As of September 14, 2026 the agency had not announced a final determination, so the legal status of 503B compounding of these molecules remained unchanged.
- FDA & regulation
CHMP recommends adding SURPASS-CVOT results to the EU Mounjaro label
The EU folded the cardiovascular outcomes data into the product information two months before the FDA granted a US indication.
- Business
CMS data shows liraglutide brand spending collapsed in the first generic year
Medicare Part D and Medicaid spending files published by CMS showed Victoza spending in Part D falling from about $1.32 billion in 2023 to about $281 million in 2024, with generic liraglutide taking $48 million. Medicaid Saxenda spending fell from $129.5 million to $38.4 million.
- Business
LillyDirect launches in the United Kingdom
Lilly extended its direct-to-consumer platform to Britain, where Mounjaro is the weight-loss brand and private prescriptions already drove much of the market.
- Business
Lilly and Oura link wearable data to obesity treatment
The collaboration connects continuous sleep and activity data to incretin treatment, part of a wider push to wrap services around the prescription.
- Business
Lilly completes the Centessa acquisition
Closing the sleep-wake disorder deal and adding cleminorexton to the neuroscience portfolio under new unit head Carole Ho.
- Research
Hypothesis paper proposes tirzepatide for refractory endometriosis, with no human data
A paper in the International Journal of Molecular Sciences proposed a mechanistic framework in which tirzepatide might act on metabolic reprogramming, peritoneal immune dysfunction, inflammatory-fibrotic remodeling and nociceptive sensitization in treatment-refractory endometriosis, built on a concept of 'peritoneal incretin deficiency.' The authors state plainly that the concept rests on a single non-replicated case-control study, that the mechanistic chain relies on indirect evidence from other diseases, and that direct experimental or clinical validation is absent. It is logged here because it is likely to be cited online as if it were evidence.
- Policy
Lilly grants a single compassionate-use request for retatrutide, and Congress asks why
Reporting revealed that Lilly had given expanded access to one 79-year-old patient. Democratic lawmakers asked the White House who had received the special access, and Lilly opened a broader application process in August.
- Research
Los Angeles Times documents how far microdosing has spread
One obesity and neurology specialist estimated 30 to 40 percent of her roughly 5,000 patients were microdosing semaglutide or tirzepatide, defining a microdose as the lowest dose that quiets food noise without causing significant weight loss.
- Business
NHS England expands tirzepatide eligibility to a second cohort
From June 23, 2026 NHS England primary care eligibility expanded to include patients with BMI 35 to 39.9, or 32.5 to 37.4 with ethnic adjustment, plus four or more qualifying comorbidities.
- Culture
PwC finds one in five US households now includes a GLP-1 user
PwC reported 21% of US households had a current GLP-1 user as of May 2026, up from 9% in January 2025, with grocery spending down 5.5%, apparel up 9.9% and quick-service restaurant spending down 8.7% per household.
- Research
The Lancet issues an Expression of Concern on the exenatide Parkinson's trial
The journal's editors publish an Expression of Concern about the 2025 Exenatide-PD3 paper. As of September 2026 the paper has not been retracted, but any claim drawn from that trial should be treated as unsettled until the journal resolves the matter.
- FDA & regulation
Wegovy label consolidates four injection presentations plus tablets into one document
The June 2026 Wegovy label (US26SEMO01307) carries four distinct injection presentations — single-dose pen in five strengths, Wegovy HD 7.2 mg single-dose pen, single-dose prefilled syringe in five strengths, and the FlexTouch multi-dose pen — alongside the tablets, each with its own Instructions for Use, NDCs and storage window. Three different in-use rules now apply to the same molecule under the same brand name: 28 days for the single-dose devices, 56 days for FlexTouch after first use, and USP controlled room temperature for the tablets.
- Culture
PERCEPTIONS survey reports why 518 US adults started tirzepatide
A real-world survey found the top reasons for initiating tirzepatide were improving overall health and well-being (83.8%) and physical functioning (58.3%), while the top barriers were insurance coverage (90%) and treatment cost (57.7%). Participants reported substantial impairments in physical functioning and psychosocial well-being and high internalized weight bias before starting.
- Research
American College of Physicians issues a living guideline on obesity pharmacotherapy
The ACP published a living clinical guideline in Annals of Internal Medicine, conditionally recommending that clinicians initiate one of several pharmacologic treatments alongside lifestyle modification in nonpregnant adults with obesity, naming tirzepatide and semaglutide among first-line options. Being a living guideline, it is updated continuously as evidence accrues rather than on a fixed revision cycle, which matters while maintenance and withdrawal trials are still reporting.
- Business
FDA sends 25 letters to telehealth companies over compounded weight-loss drug claims
Provider-name-plus-legality searches spiked again. It is a reminder that telehealth review pages in this category carry regulatory risk as well as commercial upside and need dated, sourced statements about each provider's product.
- Research
Pooled analysis finds tirzepatide works about the same in adults 65 and older
Combining SURMOUNT-1 through -5, SURMOUNT-OSA and SUMMIT, researchers found weight reduction, cardiometabolic benefit and quality-of-life gains in adults 65 and older broadly comparable to younger adults, with no clinically meaningful differences in gastrointestinal tolerability, falls, fractures, depression, pancreatitis or organ-related adverse events.
- Safety
FDA issues 25 more warning letters to telehealth companies over compounded GLP-1 claims
A second 2026 wave of enforcement targeted allegedly false or misleading promotional claims about compounded GLP-1 products under the misbranding provisions of the Federal Food, Drug, and Cosmetic Act.
- Research
FDA publishes its list of unlawful compounded-drug marketing claims for telehealth companies
FDA updated its guidance page for telehealth companies, itemizing the claims it treats as false or misleading when applied to compounded drugs: implying the telehealth company manufactures the drug, describing it as a generic equivalent or identical to an approved version, claiming FDA approval or safety evaluation, marketing it as clinically proven to match an approved alternative, and describing the source as an FDA-approved or FDA-licensed facility. It gave consumers a concrete checklist for evaluating GLP-1 advertising.
- Compounding
FDA updates its guidance page for telehealth companies promoting compounded drugs
The refreshed page lists the specific marketing moves FDA considers false or misleading, including calling a compounded drug generic or equivalent and describing a pharmacy as FDA-approved or FDA-licensed.
- Research
Polish cohort shows how widely incretin drugs are already prescribed in PCOS
A retrospective study of 38,263 women with coded PCOS in a Polish private healthcare network found that 11.9 percent had a GLP-1 receptor agonist or tirzepatide prescription and 42.8 percent had metformin. Among incretin users, 75.5 percent also took metformin but only 11.5 percent had coded type 2 diabetes, meaning most were not being treated for diabetes. Median BMI was 31.2 among incretin users versus 26.3 for metformin-only and 22.1 for untreated women. Use rose sharply over the study period.
- Research
ENDO 2026: semaglutide linked to 15 percent fewer fractures despite more weight loss
A Stanford-led analysis of nearly 60,000 adults with type 2 diabetes found semaglutide was associated with a 15 percent lower fracture incidence than other GLP-1 drugs and weight-loss therapies, with 794 versus 1,045 fractures.
- Research
ENDO 2026 reports GLP-1 drugs do not harm and may help male fertility
Reviews presented at the Endocrine Society annual meeting found GLP-1 therapy improved testosterone in men with obesity and metabolic dysfunction, and a 24-week semaglutide study showed improved sperm shape with stable hormone levels.
- Competition
Retatrutide's ADA data lands as the Medicare tailwind arrives
Eli Lilly presented retatrutide's roughly 28% weight-loss data at ADA 2026 just weeks before Medicare's GLP-1 Bridge opened. Analysts flagged the combination of higher efficacy and broader coverage as the defining competitive dynamic of the second half of 2026.
- Prices
BCBS Federal Employee Program approves a Zepbound policy requiring two failed oral weight-loss drugs
The FEP Pharmacy and Medical Policy Committee approved policy 5.99.031, effective July 1, 2026, requiring inadequate response, intolerance or contraindication to at least two oral weight-management medications, documented participation in a comprehensive weight-management program, and a trial of the preferred product. The quantity limit is 12 single-dose pens per 84 days, with a 6-month initial approval and a 12-month renewal conditioned on 5 percent weight loss.
- Business
Surveys show employers pulling back on GLP-1 coverage for 2027
Business Group on Health found about 10% of covering employers planned to drop GLP-1 weight-loss coverage in 2027 and 72% said they would likely continue, while Mercer found 5% of employers with 500+ workers planned to drop coverage and 44% currently covered the drugs. BGH's later August 2026 survey put the share of surveyed employers covering GLP-1s for weight loss at 72% in 2025 falling to 60% in 2026, with 14% having dropped or planning to drop for 2027.
- FDA & regulation
UK becomes the first European country to license a GLP-1 weight-loss tablet
The Medicines and Healthcare products Regulatory Agency approved the semaglutide (Wegovy) tablet for adults with a BMI of 30 or above, or 27 to 30 with a weight-related condition, alongside diet and exercise. Novo said private providers would have it within weeks, and NHS availability would require a separate NICE evaluation.
- Business
Wegovy pill passes 3 million US prescriptions; Doustdar says he is 'a lot more optimistic'
At the American Diabetes Association meeting, Novo Nordisk said more than 80% of Wegovy pill prescriptions were going to people new to the GLP-1 class, and the CEO told Fierce Pharma the company's manufacturing ramp was now 'second to none.'
- Culture
Shaquille O'Neal fronts a national Zepbound sleep apnea campaign
Lilly's "Watch This" campaign used the most famous big man in American sports to talk about obstructive sleep apnea rather than weight, citing roughly 24 million US adults with moderate-to-severe OSA and 85% undiagnosed.
- Research
Pfizer starts the US Phase 3 trial of berobenatide
A 954-participant Phase 3 in adults with overweight or obesity began enrolling, with primary completion set for May 4, 2028. Pfizer separately registered once-monthly and once-weekly Phase 3 programs in Japan, making berobenatide the main rival to MariTide in less-frequent dosing.
- Business
Novo says 80% of Wegovy pill users are new to GLP-1s
Chief executive Mike Doustdar told CNBC that roughly 80% of Wegovy pill customers had never taken a GLP-1 before, and that the launch reached one million prescriptions in 12 weeks and three million by week 22. The pill appears to be expanding the market rather than cannibalizing injections.
- Competition
Goldman Sachs raises its 2030 obesity market forecast to $114 billion
Goldman lifted its estimate from $101 billion, citing faster adoption of oral obesity pills, stronger demand outside the US and improved affordability, partly reversing its February cut.
- Business
ACHIEVE-2, ACHIEVE-3 and ACHIEVE-5 presented at ADA 2026
Lilly presented the three remaining registrational diabetes trials, published in The Lancet, The Lancet and JAMA. It also restated all of the ACHIEVE results in Foundayo tablet doses for the first time, and confirmed it would file for type 2 diabetes with the FDA by the end of the quarter.
- Safety
CBS News finds clinicians promoting unapproved retatrutide online
An investigation documented providers selling and promoting a drug that has never been approved anywhere, sourced from research-chemical suppliers. Lilly sued six sellers in August and asked platforms and payment processors to cut them off.
- Safety
FAERS comparison puts tirzepatide's optic neuropathy signal far below semaglutide's
A comparative analysis of six incretin therapies found semaglutide with 355 optic ischemic neuropathy reports and a reporting odds ratio of 94.45, tirzepatide with 49 reports and a ratio of 2.94, and liraglutide with 13 reports and a ratio of 4.58. No signal was found for dulaglutide, exenatide or lixisenatide. The authors concluded the absence of a signal across the whole class argues against a uniform class effect.
- Science
ADA revises its Standards of Care for the multi-goal era
The American Diabetes Association issued a formal revision of its Standards of Care at the close of the 2026 Scientific Sessions, moving away from single-goal diabetes management. The change reflected trial evidence that GLP-1 drugs affect weight, heart, kidney and liver outcomes at once.
- Competition
Foundayo posts superior A1c control and weight loss in three diabetes trials
Eli Lilly reported that its oral GLP-1 Foundayo delivered superior A1c control and weight loss across three pivotal type 2 diabetes trials. The results positioned the pill for a diabetes indication on top of its obesity approval.
- Business
Wegovy pill passes 3 million prescriptions in five months
Novo Nordisk said the Wegovy pill had surpassed three million US prescriptions since its January launch, roughly one filled every five seconds, making it one of the strongest US pharmaceutical launches by volume on record. The company said about 80% of pill customers had never taken a GLP-1 before.
- Research
Annals of Oncology: GLP-1 use tied to 41 percent lower obesity-related cancer risk
A target trial emulation matched 80,899 GLP-1 users to 80,899 adults with obesity and no diabetes who received diet or exercise counseling. Over a median two years, obesity-associated cancer incidence was 41 percent lower for GLP-1 drugs as a class, with near 70 percent reductions in men and 58 percent for endometrial cancer. Semaglutide's own figure was a smaller 20 percent reduction (HR 0.80), with the largest effect seen among tirzepatide users.
- Research
Full REIMAGINE 1-3 CagriSema results presented at ADA 2026 and published
Novo Nordisk presented the complete phase 3 REIMAGINE program in type 2 diabetes, with simultaneous publication in The Lancet Diabetes & Endocrinology (REIMAGINE 1 and 2) and The Lancet (REIMAGINE 3). In REIMAGINE 2 (n=2,713) CagriSema cut HbA1c by 1.91 percentage points versus 1.75 for semaglutide 2.4 mg — statistically superior, but a margin of only 0.16 points.
- Research
Novo Nordisk presents CagriSema REIMAGINE and zenagamtide data at the ADA Scientific Sessions
Phase 3 CagriSema results in type 2 diabetes across background therapies were presented in New Orleans, alongside Phase 2b data for zenagamtide (formerly amycretin) in type 2 diabetes reported at about 14.6% weight loss. Neither dataset had appeared in a peer-reviewed journal as of September 2026.
- Business
Menopause analysis: weight loss at every stage
At ADA 2026, Lilly presented post-hoc analyses of more than 1,500 women in ATTAIN-1 and ATTAIN-2. Perimenopausal women on the highest dose lost up to 30.4 pounds (14.4%) and postmenopausal women up to 28.2 pounds (14.1%), with waist circumference down as much as 4.9 inches.
- Science
SYNCHRONIZE-1 published: survodutide is the first dual GLP-1/glucagon agonist with full Phase 3 obesity data
The New England Journal of Medicine published SYNCHRONIZE-1, in which once-weekly survodutide titrated to 3.6 mg or 6.0 mg produced up to 16.6% mean weight loss at 76 weeks versus 3.2% with placebo in adults with obesity and without diabetes.
- Safety
Ten-year FAERS review finds alopecia reporting signals for semaglutide and tirzepatide
A disproportionality analysis in the Journal of Cosmetic Dermatology detected reporting odds ratio signals for semaglutide in 2022 and 2024 and for tirzepatide in 2024 and 2025, with no signal for dulaglutide, liraglutide, lixisenatide, albiglutide or exenatide. The authors stressed FAERS cannot estimate incidence or adjust for confounders.
- Competition
Pfizer details monthly berobenatide data and plans 10 Phase 3 trials in 2026
At ADA 2026 Pfizer said berobenatide delivered continuous weight loss as patients moved from weekly to monthly dosing, and outlined more than 20 obesity trials for the year with first approvals targeted for 2028.
- Research
Retatrutide cuts sleep apnea severity by 60 percent in a TRIUMPH-1 basket trial
Nested basket trials within TRIUMPH-1 reported that retatrutide reduced the apnea-hypopnea index by up to 36.1 events per hour (60.6 percent) from a baseline of 58.6, and reduced knee osteoarthritis pain by up to 4.3 points (73.1 percent). Lilly said the package supports registrations in obesity, sleep apnea and knee osteoarthritis pain.
- Research
Retatrutide's ADA data add sleep apnea, knee pain and diabetes benefits
At the American Diabetes Association meeting Lilly presented a package showing improvements in weight, A1C, knee osteoarthritis pain and obstructive sleep apnea. Analysts described it as the widest single-drug benefit profile in the class.
- Science
Lilly lays out a five-molecule obesity strategy at ADA
At the ADA 86th Scientific Sessions, Lilly executives describe tirzepatide, orforglipron, retatrutide and eloralintide as four complementary molecules plus brenipatide for other indications, and say they expect to launch four or five obesity medicines by the end of the decade.
- Science
Novo presents semaglutide data across sleep apnea, asthma and liver disease
Novo Nordisk presented post hoc analyses from SELECT, STEP, ESSENCE and OASIS at ADA 2026, covering obstructive sleep apnea, asthma-related outcomes and other weight-related conditions. Post hoc analyses generate hypotheses rather than prove new indications.
- Research
SURMOUNT-MAINTAIN appears in print in The Lancet
The print publication set out the modified treatment-regimen estimand used for the primary analysis and the rescue-therapy rules from week 84, which matter for interpreting the placebo arm's -9.9% figure.
- Science
ADA 2026 opens in New Orleans with a wave of obesity data
The American Diabetes Association's 86th Scientific Sessions ran June 5 to 8, 2026, featuring phase 3 results for retatrutide, orforglipron and CagriSema plus revised ADA Standards of Care. Speakers described a field that had moved beyond GLP-1 alone toward glucagon and amylin mechanisms.
- Research
Consensus report issues practical guidelines for GLP-1 use in type 1 diabetes
Diabetes Technology and Therapeutics published a consensus report acknowledging that no GLP-1 or dual GIP/GLP-1 drug is approved for type 1 diabetes, naming hypoglycemia and ketosis as the main safety risks, and arguing that people with type 1 diabetes who already access these drugs through the obesity indication need structured safety education.
- Competition
Structure Therapeutics publishes aleniglipron Phase 2b data in Nature Medicine
The publication reported a 10.4% overall discontinuation rate and confirmed the Phase 3 design with a 2.5 mg starting dose.
- Research
Prospective cohort reports 18 percent weight loss with tirzepatide after bariatric surgery
Thirty-four patients who regained weight after bariatric surgery or endoscopic bariatric therapy lost 18.1 percent of body weight over 24 weeks on tirzepatide at doses of 2.5 to 10 mg weekly, with only mild gastrointestinal side effects and no discontinuations. The study was small, uncontrolled and excluded people with diabetes.
- Research
Telehealth survey reports real-world sleep improvements on tirzepatide
At the American Diabetes Association meeting, a telehealth platform reported that among 181 analyzable survey respondents with a history of sleep apnea taking tirzepatide, 86.7 percent reported improvement in at least one sleep-related outcome and 77.3 percent in more than one. The survey had a low response rate and was funded by the platform.
- Safety
Large cohort quantifies the motility risk for GLP-1 drugs including tirzepatide
In 313,342 matched pairs of GLP-1-based therapy versus SGLT2 inhibitor initiators, rates of a composite of severe constipation, gastroparesis and gastrointestinal obstruction were 1.02 versus 0.75 per 100 person-years, hazard ratio 1.37. The absolute risk was 1% or less, and the relative increase was consistent across agents including tirzepatide. This is the clearest quantification yet of how large the real motility risk is.
- Policy
Advocates flag the limits of the Medicare GLP-1 Bridge
The Medicare Rights Center noted that the flat $50 copay does not count toward the Part D deductible or out-of-pocket limit, that Extra Help does not apply and that the Prescription Payment Plan cannot be used. For lower-income beneficiaries the flat fee can be worse than normal Part D cost sharing.
- Research
Obesity journal asks whether multi-dose tirzepatide pens will drive microdosing
A commentary titled 'Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi-Dose Pens' argued that the arrival of multi-dose tirzepatide presentations makes off-label dose splitting physically easier and turns the evidence gap from academic into urgent. It follows the same argument made for semaglutide multidose pens in Diabetes Care in 2025. A companion piece appeared in the same journal in August 2026.
- Business
Rybelsus 3, 7 and 14 mg posted to the FDA discontinuation list
The FDA drug shortage database records all three original Rybelsus tablet strengths as to be discontinued, confirming the wind-down of the first oral GLP-1 brand in the US.
- Research
First randomized trial of tirzepatide in PCOS reports menstrual and pregnancy gains
Sixty overweight or obese Chinese women with PCOS were randomized to metformin alone or metformin plus low-dose tirzepatide for 16 weeks. The combination group lost 10.4 kg versus 1.7 kg and far more visceral fat, with higher rates of menstrual cycle recovery and pregnancy. The trial was open-label, small and short, and everyone enrolled had excess weight.
- Business
Wegovy pill becomes the most-chosen new weight-management start
Novo Nordisk said that over the course of 2026 more patients starting a new anti-obesity medicine chose Wegovy than any other option, helped by the pill and the high-dose injection. The company also reported strong early uptake of Wegovy HD.
- Business
Cigna drops GLP-1 coverage for its own employees
Cigna told staff it would stop covering GLP-1 weight-loss drugs including Wegovy and Zepbound in its own employee health plan effective July 1, 2026, one of several insurers and health systems to do so in 2026.
- Science
Phase 1b trial separates what GIP and GLP-1 each contribute in humans
Heise et al. report in Diabetes, Obesity and Metabolism that the selective GIP receptor agonist macupatide raised clamp insulin sensitivity 33.1% with a smaller effect on secretion, while dulaglutide did the reverse. The combination outperformed both, with the clamp disposition index up 321.5%.
- Business
CVS Caremark begins covering Foundayo
The new-to-market block on Foundayo was lifted for CVS Caremark commercial template plans. Jefferies analysts had identified the absence of CVS coverage as a key reason Foundayo's launch trailed the Wegovy pill, which had full coverage in its first week.
- FDA & regulation
Eli Lilly registers a pre-approval expanded access program for retatrutide
ClinicalTrials.gov record NCT07629401, status Available, opened single-patient expanded access for adults with a BMI of 35 or higher despite the highest tolerated approved therapy, two or more serious obesity-related complications, and no accessible trial. A physician must request it from Lilly and then from the FDA. It is the only legal non-trial route to retatrutide in the United States.
- Research
Survodutide's cardiovascular outcomes trial reaches primary completion
SYNCHRONIZE-CVOT, a 5,531-participant cardiovascular safety trial, finished its main measurement period. It is the first of the current wave of pipeline outcomes trials to complete. Results had not been published as of September 14, 2026.
- FDA & regulation
Ozempic injection label revised
The current Ozempic prescribing information carries indications for glycemic control, cardiovascular risk reduction and slowing chronic kidney disease progression in type 2 diabetes, with the familiar 0.25 mg to 2 mg weekly escalation.
- FDA & regulation
CagriSema's FDA decision date sets up a December catalyst
Novo Nordisk guided to an FDA decision on CagriSema by late 2026, with one pharmacy benefit manager naming December specifically. Approval would make it the first GLP-1 and amylin combination cleared for weight management.
- Research
SURPASS-EARLY two-year results favor starting tirzepatide early in type 2 diabetes
In 794 adults within four years of diagnosis, tirzepatide lowered HbA1c by 0.68 points more and weight by 8.0 kg more than intensified conventional care over two years. Normoglycemia was reached by 60.2% versus 24.0%.
- Science
Clinicians turn to muscle preservation and nutrition on GLP-1 therapy
Sessions at ADA 2026 focused on preserving lean body mass, optimal nutrition and osteoarthritis outcomes for people on GLP-1 drugs. Clinical guidance increasingly pairs the medicines with protein intake and resistance training.
- Research
Commentary raises bone, reproductive and eating disorder questions about adolescent GLP-1 use
The Journal of Pediatric and Adolescent Gynecology published a commentary arguing that adolescence is the critical window for peak bone mass acquisition, that pediatric trials showed weight reduction without short-term effects on growth or puberty but no long-term skeletal data exist, and that the appetite-suppressing effect raises misuse concerns in a population vulnerable to body image pressure.
- Science
EMBRAZE trial tests drugs to protect muscle during GLP-1 treatment
Phase 2 EMBRAZE results published in Nature Medicine showed apitegromab combined with tirzepatide as the clearest evidence yet that muscle loss during GLP-1 treatment might be limited with a drug. Across GLP-1 trials, lean mass has accounted for roughly 25% to 40% of total weight lost.
- Competition
Lilly files its obesity pill for type 2 diabetes under the priority voucher program
Eli Lilly submitted orforglipron for type 2 diabetes in the United States during the second quarter of 2026 under the Commissioner's National Priority Voucher pilot. A decision is possible in the fourth quarter of 2026.
- Science
Nature Metabolism paper maps how semaglutide signals in hindbrain neurons
Researchers showed semaglutide raises cyclic AMP in GLP-1 receptor-expressing area postrema neurons through both Gs-dependent and Gs-independent routes, refining the mechanism behind appetite suppression and nausea.
- FDA & regulation
Wegovy label revision consolidates pregnancy, lactation and pediatric guidance
The Wegovy prescribing information revised 06/2026 carries two contraindications, eleven Warnings and Precautions including Pulmonary Aspiration During General Anesthesia or Deep Sedation, an instruction to discontinue at least two months before a planned pregnancy, and a statement that breastfeeding is not recommended during treatment with Wegovy tablets.
- Competition
Viking completes enrollment in its phase 3 oral and injectable program
Viking Therapeutics completed enrollment in the phase 3 VANQUISH-2 trial of VK2735, one of several challengers aiming at both injectable and oral formats. The company remains years from a possible approval.
- FDA & regulation
FDA count reaches 990 adverse event reports for compounded semaglutide
The agency also logged more than 730 reports for compounded tirzepatide, and said the true numbers are likely higher because most compounding pharmacies are not required to report.
- Research
Nutrients publishes a nutrition-first framework for incretin therapy
A practical framework for dietary management, symptom tolerability and long-term weight maintenance during GLP-1 and dual incretin therapy, including proposed energy floors of roughly 1,200 kcal/day for most women and 1,500 kcal/day for most men, individualized to body size and activity.
- Research
STAT News revisits microdosing: still popular, still unsupported
A follow-up report found no legitimate long-term data supporting GLP-1 microdosing for weight loss or any other condition, and no accepted definition of what counts as a microdose.
- Research
STAT: microdosing GLP-1s is not a thing, and there is no agreed definition of it
An obesity physician writing in STAT laid out every FDA-approved Wegovy and Zepbound dose and pointed out that these are the only doses studied for safety and efficacy, that there are no legitimate long-term data supporting microdosing, and that there is not even a single definition of what microdosing means.
- Prices
CVS Caremark says Zepbound will return to its standard formulary
CVS Health announced on May 28, 2026 that Zepbound returns to its commercial formularies as an additional preferred option effective October 1, 2026, and that the new-to-market block on Foundayo was removed effective June 1, 2026. Wegovy keeps preferred status. The reversal restarts the switching cluster in the opposite direction, and because the effective date is later than the announcement date, a page that reports it without both dates will be wrong twice. Coverage pages that recorded the 2025 exclusion without a changelog are now stale.
- Business
All three major PBMs agree to cover Foundayo
Lilly announced that CVS Caremark, the last of the big three pharmacy benefit managers, would begin covering Foundayo on its commercial template on June 1, 2026, and would return Zepbound to those templates by October 1. Eligible commercially insured patients could pay as little as $25 a month.
- Prices
North Carolina treasurer says the state budget will not restore GLP-1 coverage for state employees
State Treasurer Brad Briner said he did not expect lawmakers to fund restoration of State Health Plan GLP-1 weight-loss coverage. A 2025 Senate budget proposal had included $25 million for it; the House proposal included none. The plan has been negotiating directly with manufacturers, and officials said coverage could resume without legislative action if those talks succeed.
- Competition
Novo Nordisk confirms amycretin has been renamed zenagamtide
Ahead of ADA 2026, Novo Nordisk described zenagamtide as a unimolecular long-acting GLP-1 and amylin receptor agonist in development in both oral and subcutaneous forms.
- Business
Patients report being unable to fill generic liraglutide 3 mg
Members of the r/liraglutide community describe a supply gap in five-pen weight-management cartons through late May and June 2026 while two-pen and three-pen diabetes cartons remained available. Several report eventually obtaining Cipla-labeled cartons after transferring prescriptions between pharmacy chains.
- Prices
Anvisa approves Brazil's first generic semaglutide pen
EMS won approval for Ozivy, to be produced in Sao Paulo state with capacity for up to 40 million pens a year, pending a price cap from Brazil's medicine pricing chamber.
- Business
Lilly buys three companies in one day to build an infectious disease business
Curevo (up to $1.5 billion, shingles vaccine), LimmaTech Biologics (up to $780 million, bacterial vaccines) and Vaccine Company (up to $1.55 billion, nanoparticle platform with an Epstein-Barr candidate). A new therapeutic area created from nothing in a single announcement.
- Research
Nurse practitioner commentary frames microdosing as an access and trust problem
The Journal of the American Association of Nurse Practitioners published a commentary arguing that affordability barriers continue to drive patients toward unsupervised microdosing and illicit research-grade peptides despite federal pricing agreements. It identified gastrointestinal tolerability and 'vanity weight' goals as the two drivers of deliberately sub-therapeutic dosing, and named provider weight bias as a reason patients seek unregulated alternatives rather than raising the subject with a clinician.
- Research
GLP-1 drugs linked to lower macular degeneration risk in a 157,880-patient analysis
A target trial emulation in Diabetes, Obesity and Metabolism compared adults aged 60 and over with obesity and no diabetes who started a GLP-1 receptor agonist against new users of other weight-loss drugs. After 1:1 propensity matching, GLP-1 use was associated with lower incident age-related macular degeneration (HR 0.82, 95% CI 0.68-0.98). Follow-up was markedly shorter in the GLP-1 group (median 1.11 versus 2.56 years), which complicates a slowly developing outcome, and the class was analyzed together rather than by molecule.
- Culture
Penn researchers mine 400,000 Reddit posts for GLP-1 side effects
A University of Pennsylvania study used AI to analyze GLP-1 patient communities and surfaced frequently discussed symptoms such as menstrual irregularities, chills and hot flashes, arguing online peer communities function as an early-warning system.
- Research
BARI-STEP: first randomized trial of semaglutide after bariatric surgery reports 18 percent weight loss
Nature Medicine published BARI-STEP online, a double-blind placebo-controlled trial in 70 adults recruited at University College London Hospitals and Homerton University Hospitals at least one year after gastric bypass or sleeve gastrectomy with a suboptimal response. Mean weight change at week 68 was -18.0 percent with semaglutide 2.4 mg versus +0.4 percent with placebo, an adjusted difference of -19.18 percentage points (95 percent CI -23.4 to -14.8). It appeared in the July 2026 issue, 32(7):2662-2672.
- Competition
NARB upholds that 'clinically proven' claims must be substantiated regardless of supplement status
In the Tru Niagen matter, the National Advertising Review Board upholds the National Advertising Division's recommendation to discontinue 'clinically proven' claims. NAD adheres to FTC guidance that a product's DSHEA status is a regulatory matter for the FDA and not relevant to whether a health claim is misleading or properly supported. The most important recent precedent for GLP-1 supplement marketing.
- Competition
Retatrutide sets a new weight-loss benchmark at 28.3%
Eli Lilly reported that in the phase 3 TRIUMPH-1 trial, participants on the 12 mg dose of its triple hormone agonist retatrutide lost an average of 28.3% of body weight, or about 70 pounds, over 80 weeks. It was the largest late-stage obesity trial result recorded to date and reset the competitive bar for semaglutide.
- Research
TRIUMPH-1 retatrutide topline raises the ceiling above tirzepatide's trial numbers
In 2,335 adults over 80 weeks, retatrutide 12 mg produced 28.3% average weight loss on the efficacy estimand and 25.0% on the treatment-regimen estimand, with 45.3% of the 12 mg group losing at least 30% of body weight. A blinded extension reached 30.3% at 104 weeks. Discontinuation for adverse events was 11.3% at 12 mg and dysesthesia was reported in 12.5%.
- FDA & regulation
EMA committee backs the Wegovy pill and the 7.2 mg pen for Europe
The European Medicines Agency's human medicines committee adopted positive opinions recommending oral Wegovy tablets in 1.5, 4, 9 and 25 mg strengths and the higher-dose Wegovy injection. The recommendations put Europe on track for its first oral GLP-1 for weight management.
- Safety
FDA reports more than 1,700 adverse events tied to compounded GLP-1 products
The agency disclosed the running count of adverse event reports associated with compounded semaglutide and tirzepatide, while noting that 503A pharmacies are not legally required to report, so the true number is likely higher.
- Competition
NARB affirms NAD in the Tru Niagen matter
A National Advertising Review Board appellate panel affirms the National Advertising Division's 2026-03-16 recommendations that Niagen Bioscience discontinue 'clinically proven' establishment claims and certain health-benefit claims for Tru Niagen. The panel rejects the argument that DSHEA structure/function status lowers the substantiation bar, holding that required substantiation depends on the message conveyed to consumers rather than the advertiser's regulatory classification. This is the most directly applicable recent authority for GLP-1 supplement advertising.
- Safety
PLOS Medicine pooled analysis puts the NAION risk in absolute terms
Researchers estimated an absolute risk difference of about 0.014% per year, roughly one additional NAION case per 7,000 people treated for a year, close to the regulatory framing of one extra case per 10,000 person-years.
- Culture
Restaurant survey finds GLP-1 users eat out more often, not less
A National Restaurant Association survey of 1,400 US adults, 509 of them current GLP-1 users, fielded March 6-11, 2026, found GLP-1 users bought restaurant food an average of 7.6 times in the prior week against 5.1 for non-users - cutting against the assumption that the drugs would empty dining rooms.
- Safety
Eli Lilly files its roadmap brief seeking summary judgment across every injury category
Lilly's brief identifies Trulicity, Mounjaro and Zepbound as its medicines at issue and sets out nine motions: excluding plaintiffs' experts on gastroparesis, warning adequacy, ileus and obstruction, gallbladder claims, class-effect opinions and animal studies, plus summary judgment on gastroparesis, ileus and obstruction, gallbladder and other gastrointestinal claims. Its preemption argument includes the assertion that the FDA considered and rejected additional gastroparesis warnings.
- Business
Supreme Court ends Novo Nordisk's Inflation Reduction Act challenge
The US Supreme Court denied Novo Nordisk's petition for certiorari over the Third Circuit's dismissal of its challenge to the IRA's drug pricing provisions, closing the matter with no appeals left.
- Science
Lilly starts a Phase 2 obesity trial of the selective GIP agonist macupatide
NCT07589608 begins, testing macupatide alone and in combination in obesity - the first Phase 2 obesity program for a molecule that isolates tirzepatide's GIP half.
- Safety
American Academy of Ophthalmology says tirzepatide's NAION risk is under-studied
The Academy's clinical statement concluded that the available evidence suggests a possible association between semaglutide and NAION of roughly two-fold, that causality is not established, and that even a several-fold relative risk is a small absolute risk on a rare condition. It said the association with other GLP-1 drugs has been less frequently studied and warrants further investigation, particularly for tirzepatide, which is more potent than semaglutide.
- Science
Apotex launches generic semaglutide injection in Canada
Apo-Semaglutide Injection went on sale as a generic equivalent of Ozempic, the first generic semaglutide to reach pharmacy shelves in a G7 country. It is not available in the United States.
- Business
Teva posts a discontinuation notice for its generic Saxenda NDC
The FDA drug discontinuation database records a Teva posting dated 2026-05-14 for NDC 0480-7250-46, the five-pen generic Saxenda carton. The FDA's NDC directory separately lists a marketing end date of 2027-09-30 for the same product, and the shortage database still shows Teva-distributed liraglutide as Available, so the status is contradictory across FDA records.
- Research
ATTAIN-MAINTAIN tests switching from an injection to an oral GLP-1 for maintenance
Nature Medicine published the phase 3b ATTAIN-MAINTAIN trial, which moved people who had lost weight on injectable tirzepatide or semaglutide onto oral orforglipron or placebo. At week 52, orforglipron maintained 74.7% of the weight reduction in the tirzepatide-treated cohort versus 49.2% on placebo, and 79.3% in the semaglutide-treated cohort versus 37.6% on placebo. It is the first randomized evidence that a switch to a pill can hold most of an injectable's result through the maintenance phase.
- Culture
ECO 2026: adding a GLP-1 to behavioral treatment cuts food noise measurably more
Research presented at the European Congress on Obesity compared 417 adults in a digital weight-management program. Over one month, adjusted food noise scores fell 4.05 points in people who started a GLP-1 alongside behavioral treatment versus 1.15 points with behavioral treatment alone — a between-group difference of 3.0 on a 20-point scale, and the best controlled evidence to date on a construct that was patient slang two years earlier.
- Prices
Tirzepatide reaches its NCE-1 date, opening the door to generic filings
Four years after Mounjaro's approval, generic manufacturers could for the first time file an abbreviated new drug application with a Paragraph IV certification challenging Lilly's Orange Book patents. New Chemical Entity exclusivity itself still runs to May 13, 2027.
- Research
Wegovy pill delivers 21.6% weight loss in early responders
New analyses presented at ECO 2026 showed the Wegovy pill produced 21.6% weight loss among early responders and doubled improvement in mobility measures. Novo used the data to argue the pill belongs in the same efficacy conversation as injections.
- Research
SURMOUNT-MAINTAIN results published: staying on the full dose held all the weight loss
The Lancet published the first randomized test of lowering the tirzepatide dose instead of stopping. After 60 weeks of open-label treatment at the maximum tolerated dose, 378 adults were randomized to continue at that dose, reduce to 5 mg, or switch to placebo for 52 more weeks. At week 112, total weight change from baseline was -21.9 percent on the maintained dose, -16.6 percent on 5 mg and -9.9 percent on placebo. The authors concluded that reducing to 5 mg 'might provide a valuable alternative to discontinuation.' The lowest dose tested was 5 mg, a fully approved maintenance dose, so the trial supports a lower approved dose rather than microdosing.
- Research
Detailed ATTAIN-MAINTAIN results published in Nature Medicine
Mount and colleagues report in Nature Medicine that after an 8-week low-energy diet, 90 adults entered a 24-week maintenance phase; those given pasteurized Akkermansia muciniphila MucT regained 1.2 kg versus 3.2 kg on placebo (P=0.012), a difference of about 2 kg, with better preserved insulin sensitivity. Benefits appeared largest in people with low baseline Akkermansia and prediabetes. Independent experts called the randomized, double-blind design sound, while noting it is a maintenance trial, not a weight-loss trial, and that GLP-1 and other appetite hormones did not change meaningfully. CORRECTION 2026-09-14: the manufacturer press release described the benefit as about 3 kg; the published figures give about 2 kg.
- Business
Lilly marks 150 years with a ceremony in Indianapolis
Three governors, two former chief executives, 25 descendants of Colonel Eli Lilly and Peyton Manning as emcee. An Indiana University study released the same week put Lilly's direct contribution to state GDP at nearly $15.6 billion, about 2.7% of Indiana's economy, with every Lilly job supporting 2.17 more.
- Research
Lilly reports that Foundayo and lower-dose Zepbound maintain weight loss after stepping down
Two late-phase trials showed people maintained weight loss after switching from higher doses of injectable incretin therapy to orforglipron or to a lower Zepbound dose. It is the strongest public evidence yet that step-down maintenance can work, and it is the clearest signal that Lilly's plan is stepping down rather than building a higher-dose Zepbound.
- Research
ECO 2026: Wegovy HD shows nearly 28% weight loss in early responders
At the European Congress on Obesity, Novo Nordisk presented analyses showing semaglutide 7.2 mg produced nearly 28% weight loss in participants who responded early in the STEP UP program. Early-responder analyses are exploratory and describe a subgroup, not the average patient.
- Compounding
Hims & Hers posts a $92 million first-quarter loss on the branded pivot
Revenue rose to about $608 million but the shift from self-compounded semaglutide to purchased branded GLP-1s turned a year-earlier profit into a loss, showing the margin cost of leaving the compounded market.
- Science
Novo reports Wegovy results across menopause stages
Novo Nordisk presented data at the European Congress on Obesity showing substantial weight loss with Wegovy in women at every stage of menopause, along with signals on heart and migraine outcomes. Eli Lilly published comparable menopause analyses for Foundayo a month later.
- Competition
Oral VK2735 shows 12.2% weight loss at 13 weeks at ECO 2026
Viking presented additional Phase 2 VENTURE-Oral data and said it aimed to become the first oral dual GLP-1/GIP agonist on the market.
- FDA & regulation
FDA Commissioner Marty Makary resigns; Kyle Diamantas named acting commissioner
Makary, quoted in the Wegovy HD approval and the 503B bulks list proposal, left after about 13 months. The Deputy Commissioner for Food took over in an acting capacity.
- Research
SURPASS-CVOT kidney analysis reports a 23% lower rate of major kidney events
In a prespecified exploratory analysis, the composite kidney outcome occurred in 6.0% on tirzepatide versus 7.6% on dulaglutide (hazard ratio 0.77; 95% CI 0.68 to 0.88), driven mainly by fewer cases of new persistent macroalbuminuria.
- Prices
Omada Health joins Lilly Employer Connect as an independent program administrator
Omada said it would offer its GLP-1 Care Track, including clinical evaluation, prescribing and ongoing medication management, to employers through Lilly's platform, adding a direct-to-employer channel alongside its PBM and cash-pay routes. Omada's 2026 survey of GLP-1 patients found only 18 percent had full insurance coverage for weight-loss GLP-1s and 44 percent paid more than $250 a month.
- Policy
CMS unveils the Medicare GLP-1 Bridge at $50 a month
The Centers for Medicare & Medicaid Services announced that eligible Medicare Part D beneficiaries would be able to get certain GLP-1 medicines for $50 a month from July 1, 2026 through December 31, 2027. It was the first time Medicare would provide a pathway to coverage for weight management.
- Culture
Mounjaro passes Keytruda as the world's best-selling drug
Mounjaro's $8.7 billion first quarter beat Keytruda's $7.9 billion, ending a run at the top that began in early 2023. It is the first time a diabetes and weight medicine has held the position.
- Prices
Business Group on Health finds 67% of large employers cover GLP-1s for weight management
A survey of large employers found nearly eight in ten saying GLP-1s are a major contributor to rising health care costs, that 87% expect oral GLP-1s to raise demand, and that only 9% expect an accompanying price decrease.
- Prices
Lilly adds $4.5 billion in Indiana, where tirzepatide active ingredient will be made
Lilly's Indiana commitments passed $21 billion and its total US commitments passed $50 billion. The Lebanon API site, which will produce tirzepatide for both Mounjaro and Zepbound, is due to open in 2027 and is described by the company as the largest API production site in US history.
- Business
Q1 2026: Wegovy pill posts DKK 2.26 billion in its first quarter; guidance raised
Novo Nordisk said the Wegovy pill had been prescribed about 1.3 million times in the quarter and more than 2 million times since launch, the strongest GLP-1 volume launch in US history. It raised full-year guidance to -4% to -12% and the shares rose about 7%.
- Business
Doustdar says Novo Nordisk is hunting for deals 'more than ever before'
In a CNBC interview the CEO said the company needs 'not just the best, but the broadest pipeline in the world' and promised more acquisitions, pushing back on analyst doubts about the pipeline.
- Science
Lilly starts RENEW-IBS-D, a Phase 2 trial of brenipatide in irritable bowel syndrome
NCT07545759 begins enrolling a planned 531 adults with IBS-D, evidence that Lilly is pushing incretin chemistry into gastrointestinal indications rather than only metabolic ones.
- Business
Ozempic tablets reach US pharmacies, replacing Rybelsus
The rebranded Ozempic tablets became available in the United States on May 4, 2026 in 1.5 mg, 4 mg and 9 mg strengths, replacing the Rybelsus brand in the US. Novo Nordisk said it would discontinue all US strengths of Rybelsus, with shipments to wholesalers ceasing in May 2026. Patients on Rybelsus needed a new prescription written with the Ozempic name and national drug code, because the strengths are not interchangeable milligram for milligram: Rybelsus 3 mg, 7 mg and 14 mg correspond to Ozempic tablets 1.5 mg, 4 mg and 9 mg. Rybelsus continues to be marketed outside the United States.
- Compounding
Rybelsus relaunches in the US as the reformulated Ozempic pill
Novo Nordisk oral semaglutide for type 2 diabetes became available nationwide under the Ozempic pill name in 1.5 mg, 4 mg and 9 mg strengths, replacing the 3 mg, 7 mg and 14 mg Rybelsus tablets. Novo says the new formulation is smaller and more bioavailable with the same efficacy and safety profile. Self-pay pricing runs $149 to $299 a month through NovoCare Pharmacy.
- Prices
Apotex wins Canadian approval for Apo-Semaglutide
The second Canadian generic approval came three days after Dr. Reddy's, developed through a partnership with India's Orbicular Pharmaceutical Technologies.
- Prices
BALANCE opens to state Medicaid programs on a rolling basis
States could begin joining the model, adopting standardized coverage criteria and supplemental rebate agreements covering all formulations of Mounjaro plus the Zepbound KwikPen. Applications were due July 31, 2026 and start dates ran through January 1, 2027.
- Prices
Colorado restores GLP-1 weight-loss coverage for state employees
Effective May 1, 2026, Colorado state employee health plans cover GLP-1s for weight loss for employees who meet plan criteria and hold a valid prescription, reversing the July 2025 cut. The grandfathering rule that had required existing users to fill at least every 120 days terminated the same day.
- Business
Novo Nordisk announces the US launch date for Ozempic tablets
The company confirmed that Ozempic tablets 1.5, 4 and 9 mg would be available from May 4, 2026 at more than 70,000 pharmacies, with self-pay prices of $149, $199 and $299 a month.
- Compounding
The 503B bulks list proposal publishes in the Federal Register
Publication at 91 FR 23431 opens the formal comment period on excluding semaglutide, tirzepatide and liraglutide.
- Research
Phase 2a smoking trial misses its main endpoint but cuts cigarette craving
JAMA Network Open published a trial in which semaglutide monotherapy did not significantly improve laboratory smoking resistance in daily smokers, but did significantly reduce weekly cigarette craving, body weight and hemoglobin A1c.
- Compounding
FDA proposes permanently barring semaglutide from 503B bulk compounding
The FDA proposed excluding semaglutide, tirzepatide and liraglutide from the list of drugs that 503B outsourcing facilities may compound in bulk. The agency later extended the public comment deadline from June 30 to July 30, 2026.
- Culture
IU study: Lilly supports 47,520 Indiana jobs and 3.6% of state GDP
The Indiana Business Research Center put Lilly's direct Indiana employment at about 14,700, its total economic impact at $20.7 billion, and average supported-job compensation at about $142,130.
- Safety
Ozempic prescribing information revised, still with no NAION warning
The Ozempic label carries a revision date of May 2026 and lists ten Warnings and Precautions, from thyroid C-cell tumors through pulmonary aspiration. NAION, which European and UK regulators added to their product information in mid-2025, is still absent from the US label.
- FDA & regulation
FDA approves an Instructions for Use for a single-dose Ozempic prefilled syringe
A new Ozempic presentation appeared on the label: a single-dose prefilled glass syringe with an integrated needle in 0.25 mg, 0.5 mg and 1 mg, four to a carton, with its own Instructions for Use marked approved 05/2026. It is the first Ozempic presentation that is not a dial pen, it uses a pinched skinfold and a 45-degree angle rather than a dose counter, and its storage window is 28 days at 8 to 30 C rather than the pen's 56 days.
- Science
Novo Nordisk launches AMAZE-12, a Phase 3 trial of amycretin in obesity
The dual GLP-1/amylin molecule entered pivotal testing for weight management, with both weekly injectable and daily oral formats in development.
- Compounding
FDA proposes excluding tirzepatide from the 503B bulks list
The FDA published a Federal Register notice under docket FDA-2018-N-3240 identifying three bulk drug substances it proposes not to include on the list of substances for which there is a clinical need for outsourcing facilities to use in compounding: semaglutide, tirzepatide and liraglutide. This is the formal regulatory record behind the trade coverage that preceded it. If finalized, it would end large-scale 503B compounding of these molecules, which is the supply channel most below-label and microdosing practice has relied on.
- Research
NIH announces the first randomized win for a GLP-1 drug in alcohol use disorder
In 108 treatment-seeking adults with alcohol use disorder and obesity, 26 weeks of weekly semaglutide added to cognitive behavioral therapy cut heavy drinking days by 41.1 percentage points versus 26.4 on placebo, a difference of 13.7 percentage points, with a number needed to treat of 4.3.
- Culture
Eating-disorder clinicians warn of a cultural swing back to the thin ideal
USA TODAY reported treatment-center clinicians drawing parallels between 1990s diet-pill culture and the GLP-1 boom, warning that appetite-suppressing medication is reaching people with restrictive eating patterns.
- Safety
Lancet trial: semaglutide cuts heavy drinking days in alcohol use disorder
In a randomized, double-blind, placebo-controlled trial in adults with alcohol use disorder and comorbid obesity, heavy drinking days fell from about 17 per 30 days at baseline to about 5 with once-weekly semaglutide versus about 9 with placebo, on top of cognitive behavioral therapy (a 41.1 versus 26.4 percentage-point fall in the share of days that were heavy drinking days). The trial randomized 108 adults at a single center in Copenhagen over 26 weeks. Gastrointestinal side effects predominated and five participants discontinued.
- Business
Lilly reports Q1 2026 revenue of $19.8 billion, up 56%, and raises guidance to $82 to $85 billion
Mounjaro reached $8.66 billion, with international sales of $4.43 billion passing US sales of $4.23 billion for the first time. Zepbound was $4.16 billion. Shares rallied nearly 10%.
- Safety
MDL 3094 sets the expert evidence hearing that will decide the litigation's direction
Case Management Order 32 set deadlines for Rule 702 expert challenges and summary judgment motions on warning adequacy, federal preemption and general causation, and reserved the September 2026 hearing window; the court's own MDL 3094 page states the hearing runs September 14 through 18, 2026. The outcome applies to the Eli Lilly tirzepatide claims as much as to the semaglutide claims.
- Safety
Summary judgment briefing filed in MDL 3094 on warnings adequacy and preemption
The manufacturers pressed cross-cutting defenses, including that federal law preempts state failure-to-warn claims. Briefing continued through July 2026.
- Science
Systematic review quantifies the incretin-contraceptive interaction
A PRISMA review in Obstetrics & Gynecology covering 10 studies and 305 participants finds estrogen exposure unchanged across agents while progestin effects vary. Tirzepatide reduced levonorgestrel peak concentration by 45-66% and exposure by 18-23%, against essentially no change for semaglutide and dulaglutide.
- Science
Study finds weekly GLP-1 added to therapy further cuts heavy drinking
Researchers reported that adding a weekly GLP-1 to cognitive behavioral therapy produced greater reductions in heavy drinking than therapy alone. No GLP-1 is approved for alcohol use disorder, and the work remains investigational.
- Compounding
A court trims but does not dismiss Lilly's case against compounder Empower
The judge threw out part of Lilly's claims while letting others proceed, a mixed result in the longest-running of the company's compounding suits.
- Compounding
Court rules in Lilly v. Empower Clinic Services on compounded tirzepatide
The opinion addresses Lilly's trademark and false-advertising claims against one of the largest compounders selling tirzepatide.
- Research
Zealand Pharma and Roche take petrelintide to Phase 3
The partners announced a Phase 3 program in chronic weight management starting in the second half of 2026 for petrelintide, a weekly amylin analog whose Phase 2 showed up to 10.7% at 42 weeks with tolerability the sponsors described as close to placebo.
- Prices
Health Canada approves the first generic semaglutide in the G7
Health Canada approved Dr. Reddy's generic semaglutide injection on April 28, 2026, the first generic semaglutide cleared in a G7 country, after a Novo Nordisk Canadian patent lapsed for a missed maintenance fee. Apotex followed on May 1, 2026. US patents remain in force: Orange Book compound patents to December 5, 2031 and method-of-use patents to June 21, 2033, with Novo Nordisk's 2025 Form 20-F citing 2032.
- Safety
Daubert motions deadline passes in the GLP-1 stomach injury MDL
Expert depositions wrapped and the deadline for motions challenging expert testimony passed on April 28, 2026 in MDL 3094. Summary judgment briefing continued through July, with bellwether trials possible in late 2026 at the earliest.
- Research
Meta-analysis of 49,395 pregnancies finds no clear malformation signal for GLP-1 drugs
Pooling 22 studies of periconceptional exposure, researchers found no statistically significant association with major congenital malformations, cardiac malformations, preterm delivery, live birth, miscarriage, hypertensive disorders or cesarean delivery. A small renal malformation association (odds ratio 1.23) was attributed largely to one imbalanced cohort. The tirzepatide-specific pregnancy registry has not reported.
- Research
Survodutide SYNCHRONIZE-1 reports 16.6% weight loss plus large liver and visceral fat reductions
Boehringer Ingelheim reported up to 16.6% average weight loss at 76 weeks on the efficacy estimand, alongside about a 63% reduction in liver fat and 34% reduction in visceral fat with limited lean mass loss. The obesity results were published in the New England Journal of Medicine. Reported gastrointestinal discontinuation near 19% is the open question.
- Science
Survodutide posts the first Phase 3 readout for a dual GLP-1/glucagon agonist
SYNCHRONIZE-1 topline reported 16.6% mean weight loss at 76 weeks versus 3.2% with placebo. The glucagon arm is aimed particularly at liver fat.
- Compounding
Hims & Hers adds Zepbound, the Zepbound KwikPen and Foundayo via LillyDirect
Hims announces that prescribers on its platform can route prescriptions to LillyDirect Pharmacy at Lilly self-pay prices, listing Zepbound from $299 a month. Hims had previously listed branded tirzepatide at roughly $1,899 a month, which Lilly publicly contrasted with its own price while stating it had no affiliation with Hims.
- Research
Oral semaglutide shows promise in children and teens with type 2 diabetes
Novo Nordisk reported data suggesting oral semaglutide could become the first oral GLP-1 receptor agonist therapy for children and adolescents with type 2 diabetes. Pediatric options for type 2 diabetes remain limited.
- Prices
White House announces a most-favored-nation deal with Regeneron
Another manufacturer joined the MFN program, expanding the roster of drugs carried on TrumpRx.
- Prices
GoodRx and NPR document 12 million people losing Zepbound coverage
Research using MMIT formulary data covering more than 190 million lives found that from 2025 to 2026, 12 million people lost coverage for Zepbound and 12 million for Wegovy, and that the overwhelming majority of those who retained coverage faced prior authorization or step therapy.
- Research
LEAN-PREP protocol published: the first randomized trial of lifting weights on semaglutide or tirzepatide
BMJ Open published the protocol for a six-month randomized controlled trial enrolling 232 adults on semaglutide or tirzepatide, randomized to control, resistance exercise, protein supplementation, or both, with quadriceps cross-sectional area on MRI as the primary outcome. Until it reports, all exercise guidance for this class is extrapolated from other literature.
- FDA & regulation
FDA approves 21-day in-use storage for single-dose tirzepatide
A joint Mounjaro and Zepbound supplement accepted stability data covering repeated cycling between refrigeration and room temperature.
- Search trends
Multi-dose tirzepatide presentations get their own 30-day in-use window, splitting the storage answer by device
The 21-day room-temperature limit for single-dose pens and single-dose vials has been in the tirzepatide labeling since the 2022 Mounjaro approval and did not change. What changed in 2026 is that the multi-dose vial and the KwikPen carry a separate 30-day in-use limit, discarded after 30 days at room temperature, 30 days after first use, or four weekly doses, whichever comes first. Storage questions are high volume and high anxiety, and the answer now depends on which device the prescription named. A dated storage table covering all three presentations is a genuine utility asset and the kind of page that earns links.
- FDA & regulation
Zepbound single-dose pen and single-dose vial Instructions for Use revised
Lilly issued revised FDA-approved Instructions for Use for the Zepbound single-dose pen (ZEP-0003-PEN-IFU-20260422) and single-dose vial (ZEP-0002-VL-IFU-20260422). The pen document carries the commonly-asked-questions section that confirms air bubbles are normal, that it is not necessary to warm the pen to room temperature, and that a soft click before the second loud click is normal operation. The vial document confirms the needle and syringe are not included and gives the 1 mL syringe example.
- Prices
CMS says BALANCE will not launch in Medicare Part D for 2027
Part D plan applications for the BALANCE Model were due April 20, 2026, against a requirement that applying plans cover at least 80% of the relevant Part D enrollment measured from February 2026 data. CMS announced the following day that the model would not proceed in Medicare for 2027, and it has since been described as delayed to 2028 at the earliest. CMS extended the Medicare GLP-1 Bridge through December 31, 2027 instead. The Medicaid component was unaffected.
- Compounding
Amazon launches a nationwide GLP-1 program through One Medical
The branded-only program bundles clinical screening, prescribing and Amazon Pharmacy delivery, with cash-pay oral products from $149 a month and injectables from $299, and same-day delivery in nearly 3,000 cities.
- Competition
IQVIA sizes the global obesity medicines market at $66 billion for 2025
IQVIA's ForecastLink put 2025 list-price sales at $66 billion, forecast $92 billion for 2026, and a range of $105 billion to $200 billion from 2027 onward, with oral therapies and off-patent semaglutide as the swing factors.
- Science
Compounded tirzepatide impurity described in a peer-reviewed journal
Expert Opinion on Drug Safety publishes the analytical work behind Lilly's March warning. The authors, who are Lilly-affiliated, report the impurity is widespread in mass-compounded tirzepatide/B12 products and note that its clinical effects are unknown.
- Culture
Trade press reports that food brands are adopting 'GLP-1 friendly' claims cautiously
FoodNavigator reported that consumer-packaged-goods companies were approaching GLP-1 packaging claims carefully, because no regulatory definition exists and the line between a marketing descriptor and an implied health claim remains unsettled.
- Business
Lilly agrees to acquire Kelonia Therapeutics in a deal worth up to $7 billion
About $3.25 billion upfront for engineered lentiviral delivery of CAR constructs to T cells in the body, led by a Phase 1 BCMA-directed in vivo CAR-T for multiple myeloma. It is Lilly's largest 2026 deal by headline value.
- Safety
A second court lets Lilly's compounded tirzepatide advertising claims proceed
The Northern District of California largely denied dismissal in Eli Lilly & Co. v. Mochi Health Corp., allowing Lanham Act claims that Mochi misrepresented compounded tirzepatide as FDA-approved and as 'personalized' when, Lilly alleges, formulations and doses changed en masse for business reasons rather than clinical indication. The court expressly declined to follow the Willow Health proximate-cause holding.
- Prices
Deadline passes for Medicare Part D plans to join the BALANCE Model
Plan sponsors had to apply by this date. CMS had set an 80% enrollment participation threshold for the model to proceed in 2027.
- Safety
India seizes suspected counterfeit Mounjaro pens sourced through online marketplaces
Investigators said raw materials had been bought through an e-commerce platform, an illustration of how quickly a counterfeit supply chain formed around the fastest-growing incretin market.
- Research
ADJUST-T1D post hoc analysis shows early insulin cuts are independent of weight loss
A Diabetes Care analysis found semaglutide produced rapid, sustained and mainly bolus-driven insulin dose reductions in adults with type 1 diabetes and obesity, with early effects largely independent of weight loss.
- Safety
Indian regulators seize more than 260 counterfeit Mounjaro pens
Officials in Haryana recovered suspected counterfeit Mounjaro KwikPen injections in strengths from 2.5 mg to 15 mg and arrested two people. The main accused had no pharmaceutical license and had ordered raw peptides from vendors on a Chinese e-commerce platform. The pens had not been stored at the required 2 to 8 degrees Celsius and showed font and labeling discrepancies against genuine product.
- Science
A preprint suggests Wegovy preserves lean mass better than Zepbound
Researchers reported that tirzepatide produced more total weight loss but also more lean-mass loss than semaglutide. The work had not been peer reviewed, and both companies disputed how to interpret body-composition endpoints.
- Research
ACHIEVE-4 reaffirms orforglipron's cardiovascular safety profile
In the largest and longest Foundayo trial, 2,749 people with type 2 diabetes at high cardiovascular risk, Foundayo met non-inferiority for major adverse cardiovascular events (hazard ratio 0.84) and showed a 57% lower risk of all-cause death than insulin glargine in a pre-planned analysis. A thorough drug-induced liver injury analysis found no hepatic safety signal, two days after the FDA's concerns became public.
- Prices
CMS proposes extending electronic prior authorization standards to drugs
CMS published a proposed rule that would require Medicare Advantage, Medicaid, CHIP and Exchange payers to make electronic prior authorization available for drugs, and would extend existing interoperability requirements for non-drug items and services to drug prior authorizations. Comments closed June 15, 2026, with an October 1, 2027 proposed compliance date for bringing drugs into the Prior Authorization API and for the NCPDP pharmacy-benefit standards (a separate January 1, 2028 date applies to small group market QHP issuers on the FF-SHOPs). If finalized it would be the first federal rule putting standardized electronic timelines around a GLP-1 prior authorization.
- Business
FDA asks Lilly for heart and liver data on the newly approved Foundayo
The FDA's NDA 220934 approval letter, signed April 1 and posted April 14, determined that "only a clinical trial (rather than a nonclinical or observational study) will be sufficient to assess a signal of a serious risk of retained gastric contents and to identify an unexpected serious risk for major adverse cardiovascular events (MACE), drug-induced liver injury (DILI), and exposure to orforglipron during lactation." It also required a milk-only lactation study, an ultrasound trial of dose withholding and fasting duration to inform pulmonary aspiration guidance, and completion of the ongoing adolescent obesity trial. A Lilly spokesperson told Reuters there had been no indications of liver damage in late-stage testing.
- FDA & regulation
Foundayo's approval letter carries postmarketing safety requirements
The NDA approval letter, posted April 14, required Lilly to study cardiovascular events, drug-induced liver injury and delayed gastric emptying, and to submit pediatric data. Postmarketing requirements of this kind are a standard condition of approval rather than a special intervention, though the request drew attention after reporting about a compressed review. Lilly published ACHIEVE-4 safety data two days later.
- Compounding
FDA warning letter to New Life Pharma over unapproved GLP-1 marketing
Another letter in the 2026 run against sellers of unapproved tirzepatide-containing products.
- Research
Review maps the psoriasis and psoriatic arthritis research pipeline for GLP-1 drugs
A Frontiers in Immunology review collected randomized and cohort evidence showing PASI improvements with liraglutide and semaglutide and listed active trials including TOGETHER-PsA testing ixekizumab with and without tirzepatide.
- FDA & regulation
Apotex wins the first US FDA tentative approval for generic semaglutide
Apotex announced the first FDA tentative approval of an abbreviated new drug application for semaglutide injection, a generic of Ozempic. Tentative approval means the product meets FDA standards but cannot be marketed in the US until Novo Nordisk's patents and exclusivities expire.
- Competition
Generic competition in India starts eating into Lilly's share
With semaglutide off patent in India, a wave of low-cost generics arrived and Lilly's share of the Indian GLP-1 market slipped, even as tirzepatide volumes kept growing.
- Business
Foundayo goes on sale in the United States
Lilly's obesity pill launched with LillyDirect self-pay pricing from $149 a month at the starting dose. Prescriptions were accepted from approval on April 1 and LillyDirect shipping began April 6, with broad US availability on April 9. First-week prescriptions were 1,390 against more than 3,000 in the first days of Novo Nordisk's Wegovy pill in January.
- Business
Foundayo reaches US retail pharmacies and telehealth providers
Lilly announced broad availability through retail pharmacies and telehealth providers, with free home delivery through LillyDirect. Self-pay started at $149 a month; commercially insured patients could pay as little as $25.
- Culture
Georgetown study finds GLP-1 weight loss draws more stigma than dieting
Published in APA's Stigma & Health, the study found higher fat phobia, blame and desire for social distance toward a woman who lost weight with a GLP-1 than one who lost the same weight through diet and exercise, driven by "shortcut" beliefs.
- Compounding
Partnership for Safe Medicines compiles FDA's research-chemical warning letters
The compilation gives a usable index of which peptide sellers FDA cited for tirzepatide and related molecules.
- Business
Foundayo begins shipping through LillyDirect
Eli Lilly began shipping Foundayo through its LillyDirect channel, with some commercially insured patients paying as little as $25 a month and self-pay options starting at $149. Broader pharmacy and telehealth distribution followed.
- Prices
CMS adds Foundayo to the Medicare GLP-1 Bridge and clarifies that only the Zepbound KwikPen qualifies
CMS updated the Bridge's eligible-product list to include all formulations of Foundayo (orforglipron) following its April 1, 2026 FDA approval, and clarified that among Zepbound products only the KwikPen is covered. The single-dose Zepbound pen and Zepbound vials are excluded.
- Research
Imputed-placebo analysis estimates a 28% MACE reduction for tirzepatide versus no drug
Chaining SURPASS-CVOT with matched REWIND data, researchers estimated a hazard ratio of 0.72 for MACE-3 and 0.61 for all-cause death versus a putative placebo. It is an indirect statistical construction, not a randomized comparison.
- Research
Multinational study of 1.8 million older adults compares GLP-1 safety against other diabetes drugs
Nature Communications published a nine-database cohort study in adults 65 and older with type 2 diabetes. GLP-1 receptor agonists and SGLT2 inhibitors both showed significantly lower risks of hypoglycemia and hyperkalemia than sulfonylureas, and GLP-1 drugs showed lower peripheral edema risk than DPP-4 inhibitors.
- Business
Section 232 proclamation imposes 100% tariffs on patented pharmaceuticals
The President signed a proclamation imposing up to 100% ad valorem tariffs on imported patented pharmaceuticals, active ingredients and key starting materials, effective July 31, 2026 for 17 named companies and September 29, 2026 for others, with zero rates for companies holding both onshoring plans and most-favored-nation pricing agreements.
- Compounding
New York Times profiles MEDVi as a $1.8 billion AI-built startup
The profile described $401 million in 2025 revenue and 250,000 customers without noting the FDA warning letter the company had received six weeks earlier, prompting a wave of critical follow-up coverage.
- Research
Novo publishes an indirect comparison favoring the Wegovy pill over orforglipron
One day after Foundayo's approval, Novo Nordisk announced a population-adjusted indirect treatment comparison using OASIS 4 and ATTAIN-1 data reporting that oral semaglutide 25 mg produced significantly greater mean weight loss than orforglipron 36 mg, with roughly 14 times higher odds of stopping for gastrointestinal side effects. It is a company-sponsored cross-trial analysis, not a head-to-head trial.
- Prices
FDA approves Foundayo (orforglipron), the first once-daily GLP-1 pill for obesity without food or water restrictions
The FDA approved Foundayo (orforglipron) for adults with obesity, or adults with overweight plus at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. It was the fifth approval and the first new molecular entity under the Commissioner's National Priority Voucher pilot, issued 50 days after filing and 294 days before the January 20, 2027 PDUFA date. Dosing starts at 0.8 mg once daily and escalates at minimum 30-day intervals to a maximum of 17.2 mg. Unlike oral semaglutide it is taken with or without food and has no water or 30-minute waiting rule.
- Prices
FDA clarifies compounding rules as GLP-1 supply stabilizes
The agency restated that semaglutide and tirzepatide are on neither the 503B bulks list nor the shortage list, said it would not act against 503A pharmacies filling four or fewer essentially-a-copy prescriptions a month, and warned that adding vitamin B12 does not avoid the copy rule.
- Compounding
FDA clarifies the 'essentially a copy' rule and a four-prescription threshold
FDA's updated compounding guidance says it does not currently intend to act against a 503A compounder that fills four or fewer prescriptions of a given essentially-a-copy product in a calendar month, and gives a worked example on B12 combinations — the strategy compounders used to keep tirzepatide products on the market.
- FDA & regulation
FDA sets a four-prescriptions-a-month yardstick for copy compounding
The agency said it does not intend to act against a 503A compounder filling four or fewer prescriptions a month of a product that is essentially a copy, and restated that tirzepatide is on neither the shortage list nor the 503B bulks list.
- Compounding
FDA spells out what counts as "essentially a copy" for compounded GLP-1s
In a clarifying statement FDA said a compounded product with the same active ingredient at the same, similar or easily substitutable strength and the same route of administration is essentially a copy, gave a semaglutide plus B12 example using a 10 percent strength test, and said it would not pursue 503A compounders filling four or fewer such prescriptions a month.
- Search trends
Foundayo (orforglipron) approval creates the year's biggest new comparison opportunity
The FDA approved Eli Lilly's oral GLP-1 for weight management 50 days after filing. Searchers immediately began comparing it to the Wegovy pill, and the comparison demands strict molecule disambiguation because orforglipron is not semaglutide.
- Prices
FDA restates that tirzepatide is on neither the shortage list nor the 503B bulks list
The FDA reminded compounders that the 503A and 503B exemptions require specific conditions, confirmed tirzepatide's absence from both lists, and said it does not intend to act against a compounder filling four or fewer prescriptions of an essentially-a-copy product per calendar month.
- FDA & regulation
Foundayo is the fastest new molecular entity approval since 2002
Coverage of the orforglipron decision described it as the fastest approval of a new molecular entity since 2002, granted under the FDA's priority voucher pilot. The pace itself became a story about how the agency is handling obesity medicines.
- Business
NHS England moves tirzepatide prescribing into the GP contract
From April 1, 2026 NHS England incorporated tirzepatide prescribing for obesity into the 2026/27 GP contract as optional Quality and Outcomes Framework indicators, with GBP 25 million ring-fenced and up to GBP 3,000 per practice. Participation is voluntary, so access varies by area.
- Business
Novo Nordisk pushes back on Foundayo comparisons the same day
Novo Nordisk's US operations head Jamey Millar said that any reports claiming orforglipron is more effective than the Wegovy pill for weight management were 'inaccurate and misleading,' framing the two oral GLP-1s as clinically distinct.
- Science
Foundayo dosing starts at 0.8 mg and steps up over months
The FDA said Foundayo begins at 0.8 mg daily, increasing to 2.5 mg after at least 30 days and 5.5 mg after another 30, with further steps to a maximum of 17.2 mg. Slow titration is standard across the class to limit nausea and other gut side effects.
- Research
TOS, OMA and OAC give continuing medication during maintenance a strong recommendation
The Obesity Society, the Obesity Medicine Association and the Obesity Action Coalition published a joint GRADE-based expert guidance statement in Obesity. Alongside strong recommendations for semaglutide and tirzepatide on moderate-certainty evidence, continuing obesity medications during weight maintenance received a strong recommendation. It is now the document most often cited in coverage appeals when a plan proposes stopping a drug that is working.
- Competition
Eight markets lose semaglutide exclusivity in the first wave
IQVIA identified Canada, Brazil, China, India, Mexico, Turkey, Saudi Arabia and South Africa as the first wave of 2026 patent and data protection expiries. Both diabetes and obesity uses, including oral forms, lose protection in those markets.
- Policy
Medicare Part D plans must cover at least one weight-management GLP-1
Reporting on the 2026 coverage changes described a requirement that Part D plans cover at least one GLP-1 for weight management from April 1, 2026, with a $50 copay cap and an exemption from the deductible. CMS estimated modest premium effects of $2 to $7 a month.
- Research
Swedish national cohort finds semaglutide linked to lower risk of worsening mental illness
The Lancet Psychiatry published a within-individual analysis of 95,490 people with depression or anxiety using antidiabetic medication between 2009 and 2022. Semaglutide was associated with lower risk of worsening mental illness (adjusted hazard ratio 0.58) and liraglutide 0.82, while exenatide and dulaglutide showed no association.
- Prices
Wegovy HD 7.2 mg reaches US pharmacies
Novo Nordisk launched Wegovy HD in a single-dose pen in April 2026, priced at $399 a month for self-paying patients after the introductory period. The label requires patients to have tolerated the 2.4 mg dose for at least four weeks before stepping up.
- Compounding
FDA warning letter to Gram Peptides citing tirzepatide
The letter rejects research-use-only labeling as a defense where the surrounding marketing signals human use, including selling bacteriostatic water alongside the peptide.
- Business
Lilly agrees to acquire Centessa Pharmaceuticals for about $6.3 billion upfront
With up to $1.5 billion more in contingent value rights, for cleminorexton and a family of orexin-2 receptor agonists that give Lilly a sleep-wake disorder franchise. The deal completed June 24, 2026.
- Prices
Novo launches multi-month Wegovy subscriptions
Novo Nordisk introduced its first multi-month subscription program for FDA-approved Wegovy, offering savings of up to $1,200 a year for cash-paying patients. The program was part of an effort to hold customers against Eli Lilly's direct channel.
- Prices
OPM Carrier Letter 2026-07 sets plan year 2027 FEHB rules: anti-obesity medication requirement kept, intensive behavioral therapy condition added
OPM issued FEHB/PSHB Carrier Letter 2026-07 on March 31, 2026, the call letter for PLAN YEAR 2027. It continues to require carriers to carry a range of FDA-approved anti-obesity medications on formulary, including at least one from the GLP-1 class for weight loss and at least two additional oral options. For plan year 2027 it adds that prior authorization and utilization management for any anti-obesity medication must ensure the member has demonstrated and will continue participation in lifestyle interventions meeting the rigor of intensive behavioral therapy, and that anti-obesity medications must only be covered when used concurrently with that therapy.
- Business
Lilly spends up to $7.8 billion on a narcolepsy drugmaker
The deal extended Lilly's move into sleep medicine, a field it had entered commercially through Zepbound's sleep apnea indication.
- Research
SURPASS-CVOT post hoc finds a broad cardiorenal benefit for tirzepatide over dulaglutide
Widening the endpoint to six components — death, heart attack, stroke, revascularization, heart failure and kidney outcomes — the composite occurred in 23.7 percent on tirzepatide versus 27.4 percent on dulaglutide, a number needed to treat of 27. Every component contributed, and the kidney composite alone had a hazard ratio of 0.79.
- Safety
A FAERS analysis finds tirzepatide negatively associated with hair loss reporting
An adjusted disproportionality analysis of FAERS from Q2 2022 to Q2 2025 found semaglutide positively associated with alopecia reporting (adjusted reporting odds ratio 1.23) but tirzepatide negatively associated (0.78). The result directly contradicts several other analyses that place tirzepatide alongside semaglutide as the two agents with the strongest hair loss signals, and the disagreement remains unresolved.
- Culture
Destination XL blames GLP-1s for size "volatility" as apparel demand shifts
The big-and-tall retailer reported fourth-quarter sales down 6% and a $29.6 million net loss, with its CEO citing GLP-1 use by an estimated quarter of its customers. Circana reported broad wardrobe replacement among GLP-1 households.
- Culture
KFF puts current US GLP-1 use at 12% of adults
KFF's March 2026 tracking poll found 12% current and 6% former users. The poll names Mounjaro and Zepbound in its question wording but publishes no brand-by-brand split, a standing gap in US polling.
- Competition
UBT251 reduces HbA1c by up to 2.16% in Chinese Phase 2 diabetes trial
Novo Nordisk's in-licensed triple agonist also produced up to 9.8% weight loss, with Chinese Phase 3 and a global Phase 2 planned.
- Research
Meta-analysis puts a number on what resistance training changes about lean mass
A systematic review and meta-analysis of 20 randomized trials and 15,782 participants found lean mass made up 25% to 39% of weight lost on incretin drugs (semaglutide 35.2%, tirzepatide 25.4%, liraglutide 26.8%) and 26.2% with lifestyle alone — while lifestyle plus resistance training came in at 17.5%, the most favorable profile in the analysis.
- Compounding
FTC creates an internal Healthcare Task Force
Chairman Andrew Ferguson's memo named misleading telehealth and weight loss programs among the agency's consumer protection priorities, putting claims substantiation, disclosures, endorsements and steering on notice.
- Competition
Novo faces an Indian price war it cannot match
CNBC reported that Dr. Reddy's had launched semaglutide for diabetes in India at about 4,200 rupees a month, with plans to expand to Canada, Turkey and Brazil. Analysts said Novo could hold its position if generics stayed inside markets where the patent has expired.
- Culture
NPR covers what to eat on GLP-1 drugs, taking the nutrition gap mainstream
National coverage of nutrition during GLP-1 therapy brought dietitian guidance on protein, fiber and hydration to a general US audience, reflecting how far ahead of clinical support the prescribing volume had moved.
- Competition
A dozen Indian generic semaglutide brands launch on day one
Dr. Reddy's, Sun Pharma, Zydus, Alkem, Glenmark, Natco and others launched within days of patent expiry, with prices reported from about 325 rupees per weekly injection to 4,200 rupees per month against Novo's 8,800 to 10,000 rupees.
- Culture
CNBC quantifies the GLP-1 hit to US restaurant dinner traffic
Dinner traffic among consistent GLP-1 users was reported down about 6%, translating to roughly a 0.4% decline in overall restaurant dinner sales, with breakfast pastries and sugary coffee drinks also under pressure.
- Competition
Semaglutide patents lapse in China and Brazil
Patent protection for semaglutide also ended in China and Brazil during 2026, part of a first wave covering eight markets including Canada, Mexico, Turkey, Saudi Arabia and South Africa. IQVIA estimated that at least one in three people with obesity worldwide would live in a country with off-patent semaglutide from 2026.
- Competition
Semaglutide's Indian patent expires
The main Indian patent on semaglutide expired on March 20, 2026. Within days more than five domestic manufacturers had launched generic versions, several priced 70% to 90% below the originator, and industry watchers expected dozens of branded generics.
- Business
Lilly discloses David Ricks's 2025 pay package of $36.7 million
Up 26% on 2024, with $23.3 million in stock awards. Lilly justified it in the proxy with 207% revenue growth and 571% five-year total shareholder return since Ricks took over. The company disclosed a CEO-to-median-worker pay ratio of 367 to 1. At the May 4, 2026 annual meeting, shareholders approved the package on an advisory basis with 731,998,717 votes for and 30,467,278 against, about 96% of votes cast.
- FDA & regulation
FDA approves Wegovy HD 7.2 mg, adding a sixth single-dose pen strength
FDA approved Wegovy HD (semaglutide) injection 7.2 mg for adults with obesity who have tolerated the 2.4 mg dosage for at least 4 weeks. The device is the same single-dose autoinjector as the lower strengths with its own Instructions for Use and NDC 0169-4572-14, so the operating steps, the two clicks and the yellow-bar confirmation are unchanged, but it adds a sixth pen a patient could be handed at the counter.
- Business
Imcivree becomes the first approved treatment for acquired hypothalamic obesity
The FDA approves an expanded indication for setmelanotide covering adults and children aged 4 and older with acquired hypothalamic obesity, based on the phase 3 TRANSCEND trial. Participants on setmelanotide saw BMI fall 15.8 percent at 52 weeks while placebo patients gained 2.6 percent, an 18.4 percentage point difference. Rhythm estimates about 10,000 people in the US live with the condition.
- Research
evoke and evoke+ results published in The Lancet
The Lancet published the full evoke and evoke+ results online on the day they were presented at AD/PD 2026 (print issue 30 May 2026). In 3,808 people with early Alzheimer's disease, once-daily oral semaglutide 14 mg did not slow decline: the CDR-SB difference was -0.08 (p=0.57) in evoke and 0.10 (p=0.46) in evoke+. Both trials and their one-year extensions were discontinued.
- Research
Lancet Psychiatry: semaglutide linked to 42 percent lower risk of worsening mental illness
A Swedish national cohort of nearly 100,000 people with depression or anxiety found periods of semaglutide use carried a 42 percent lower risk of psychiatric hospital care or sick leave, with depression down 44 percent, anxiety 38 percent and substance use disorder 47 percent.
- Research
Retatrutide's first diabetes phase 3 shows 16.8% weight loss alongside A1C drops
TRANSCEND-T2D-1 reported large reductions in blood sugar and weight in adults with type 2 diabetes, with up to 40% of participants reaching a normal A1C. Reporters also noted discontinuation rates that analysts were watching closely.
- Search trends
Wegovy HD approval creates a dose-upgrade query cluster with almost no ranking content
Approval of semaglutide 7.2 mg for adults who had tolerated 2.4 mg generated searches about eligibility, added weight loss and the dysesthesia signal. Most existing Wegovy dosing pages predate the dose entirely.
- FDA & regulation
Wegovy HD becomes the fourth approval under the FDA's priority voucher pilot
The FDA said Wegovy HD was the fourth product cleared under the Commissioner's National Priority Voucher program, which grants rapid review to medicines aligned with national health priorities. Foundayo followed under the same program two weeks later.
- Competition
FDA approves setmelanotide for acquired hypothalamic obesity
Rhythm Pharmaceuticals won an expanded Imcivree indication for adults and children aged 4 and older, the first and only approved therapy for acquired hypothalamic obesity, based on an 18.4% placebo-adjusted BMI reduction.
- Science
Wegovy HD requires four weeks at the 2.4 mg dose first
The Wegovy HD label states the 7.2 mg dose is for adults who have tolerated 2.4 mg for at least four weeks. In the STEP UP trial, gastrointestinal side effects were more common at 7.2 mg than at 2.4 mg, at 70.8% versus 61.2%.
- Business
A rare Wall Street downgrade questions the obesity pill story
HSBC cut its rating, arguing that oral GLP-1 enthusiasm and Zepbound's growing cash-pay mix were both being valued too generously. The note was widely circulated because sell-side skepticism on Lilly had been almost absent for three years.
- Science
Lilly starts a Phase 1b study of brenipatide in overweight and obesity
NCT07476118 begins, a 150-participant pharmacodynamics study of the incretin LY3537031, which Lilly describes as aimed at indications beyond the core obesity and diabetes programs.
- Prices
Zepbound KwikPen self-pay pricing reaches pharmacies nationwide
Lilly introduced a KwikPen Self-Pay Savings Card available to all patients including the uninsured, letting anyone with a valid on-label KwikPen prescription get LillyDirect prices from $299 at major pharmacies. The card does not apply to vials or single-dose pens and expires December 31, 2026.
- Safety
OCULUS trial stops early after residual stomach contents rise in the continue group
The first randomized trial on whether to hold a GLP-1 or GIP agonist before upper endoscopy stopped at a 60-patient interim analysis. Clinically significant residual gastric volume occurred in 3.1% of those who held one dose versus 25.0% of those who continued. No aspiration or intubation occurred in either arm. Among the 25 patients who had clear liquids the day before, none had clinically significant residual volume regardless of whether the drug was held, which points at the diet lever as much as the drug hold.
- Culture
The Oscars red carpet reignites the Hollywood thinness debate
Coverage of the 2026 Academy Awards turned into a broad argument over whether Hollywood had pushed GLP-1 use too far, with outlets naming actors who had made no disclosure - a practice eating-disorder clinicians criticize.
- Business
All 15 IPAY 2028 manufacturers agree to negotiate, Lilly included
CMS confirms that every drug company with a selected drug for the third negotiation cycle has chosen to participate, and that the manufacturer of the one drug selected for renegotiation continues to participate.
- Prices
All 15 drugmakers agree to join the third Medicare negotiation cycle
CMS confirmed participation for the drugs selected for initial price applicability year 2028, keeping the negotiation program on track.
- Business
Kroger adds the Zepbound pen to its retail self-pay program
A third national retailer joined the direct-pay channel, which by this point accounted for a large share of new Zepbound starts.
- Research
Cleveland Clinic finds most people who stop GLP-1s switch or restart rather than simply regain
In 7,938 adults who discontinued semaglutide or tirzepatide, average weight change in the following year was only +0.5% for those treated for obesity — largely because 19.6% restarted the drug and 35.2% began another obesity treatment. Individual variation was large.
- Culture
Lilly publishes an open letter on compounded tirzepatide mixed with vitamin B12
The company publishes a letter, reported by Reuters, saying its testing of compounded tirzepatide/B12 samples found a previously unidentified impurity produced by a chemical reaction between the two ingredients, and calling for a recall. Compounders dispute the characterization.
- Business
Novo Holdings reports assets down 34% for 2025
The Foundation's holding company said assets under management fell from DKK 1,060 billion to DKK 694 billion, almost entirely because of the fall in Novo Nordisk's market value, even though its own investment portfolio returned 9.2% in constant currency.
- Safety
FDA retires FAERS and launches the Adverse Event Monitoring System
AEMS replaced FAERS, VAERS and AERS in a single public lookup tool, with other databases following by the end of May 2026. Anyone checking historical GLP-1 adverse event reports now uses AEMS, including the quarterly potential-signals list that has previously flagged GLP-1 hair loss and aspiration.
- FDA & regulation
FDA approves Biocon's generic Victoza, the fifth such application
ANDA215245 was approved on 2026-03-11 and first marketed on 2026-04-25, bringing the number of Victoza-referenced abbreviated applications to five alongside Teva's authorized generic.
- Safety
Preprint reports an uncharacterized impurity in compounded tirzepatide plus B12 products
Researchers reported a previously uncharacterized impurity, formed by a chemical interaction between tirzepatide and vitamin B12, in ten compounded samples obtained from multiple compounding pharmacies, med spas and telehealth networks, at levels up to 10% of total protein content. There are no data on its effect on safety or efficacy. The paper is a preprint and has not been peer reviewed.
- Compounding
Novo Nordisk and Hims & Hers settle; Hims goes branded
Novo dismissed its patent suit without prejudice and Hims agreed to stop advertising compounded GLP-1s and to sell branded Wegovy, the Wegovy pill and Ozempic, while reserving the option to supply compounded product where a provider deems it clinically necessary. HIMS shares surged.
- Prices
CMS issues BALANCE implementation details naming Zepbound and Mounjaro
Lilly said that from January 1, 2027 Zepbound, Mounjaro and orforglipron would be available through participating Medicare Part D plans under BALANCE, with most beneficiaries capped at $50 a month after the deductible and cost sharing limited to $245 plus a dispensing fee before it. State Medicaid programs could apply from May 1, 2026.
- Prices
Amazon Pharmacy begins selling the Zepbound KwikPen at $299
Amazon Pharmacy announced transparent cash pricing from $299 per month for the 2.5 mg KwikPen with same-day delivery to more than half of US households, and said customers had saved more than $200 million through its automatic manufacturer-coupon program, with GLP-1s the largest category.
- Compounding
Hims keeps a narrow path to compounded GLP-1s under the settlement
Under the Novo Nordisk settlement, Hims & Hers may still supply compounded semaglutide, but only where a branded product cannot meet a specific patient's clinical need and only when made for that patient. The company agreed to stop advertising compounded GLP-1s.
- Policy
Lilly warns that some Medicare plans may charge more than the promised $50
Commenting on the CMS BALANCE model and the Medicare GLP-1 Bridge, Lilly said plan design could push patient cost above the headline copay. Consumer groups picked the caveat up as the Bridge rolled out in July.
- Culture
Axios-Ipsos finds 18% of Americans have a weight-loss drug user in their circle
The poll of 1,225 adults found only 16% of uninterested non-users cited cost, while 51% simply preferred diet and exercise. Familiarity with the new Wegovy pill stood at 39%.
- Competition
China approves ecnoglutide for chronic weight management
Sciwind's injectable GLP-1 gained a second Chinese indication, adding another approved domestic competitor to semaglutide in China.
- Policy
Lilly and the WHO Foundation announce an obesity care collaboration
The partnership focuses on health system capacity in lower-income countries, where obesity rates are rising fastest and almost no one can afford incretins.
- Prices
Eli Lilly launches Employer Connect, selling Zepbound to employers at $449 a month
Lilly's direct-to-employer platform offers the single-patient-use Zepbound KwikPen to network pharmacies at a set $449 price across all doses, with no rebates, through more than fifteen independent program administrators. Employees pay whatever their employer does not subsidize. The design lets employers add access outside traditional formulary controls.
- FDA & regulation
FDA warns Novo Nordisk over adverse event reporting failures
The FDA sent a warning letter to Novo Nordisk's Plainsboro, New Jersey headquarters citing serious violations of postmarketing adverse drug experience rules, including three unreported deaths among semaglutide patients, one by suicide. The agency did not link the deaths to the drug, but said the lapses raised concerns about the company's ability to monitor product safety.
- Business
Lilly launches Employer Connect to widen workplace obesity coverage
More than fifteen independent program administrators offering tailored obesity coverage options to employers, addressing the coverage gap that keeps many people from filling weight-management prescriptions.
- Research
Meta-regression maps the shape of weight regain after stopping GLP-1 drugs
eClinicalMedicine published a systematic review and meta-regression pooling 48 studies and using six randomized trials with 3,236 participants to fit a regain curve. One year after stopping, 60% of the weight lost during treatment had been regained, following an exponential curve with a half-life of about 23 weeks, with the model projecting a plateau at 75.3% of the loss. It became the single best summary estimate for what stopping does.
- Research
BMJ study examines GLP-1 drugs and substance use disorders in US veterans
Researchers emulated eight parallel target trials in Department of Veterans Affairs records to test whether starting a GLP-1 receptor agonist lowered the risk of new alcohol, cannabis, cocaine, nicotine, opioid and other substance use disorders, and improved outcomes in people who already had one.
- Research
VA analysis of 600,000 people reports GLP-1 drugs reduce overdose and substance-related death
Comparing veterans with type 2 diabetes who started a GLP-1 drug with those who did not, researchers reported 50 percent fewer substance-related deaths, 39 percent fewer overdoses and 25 percent fewer suicide attempts among people already living with addiction, plus lower rates of new alcohol, opioid, cocaine and nicotine use disorders. Tirzepatide was pooled with other drugs.
- Compounding
FDA releases 30 warning letters to telehealth firms over compounded GLP-1 claims
The FDA publicly released a batch of 30 warning letters to telehealth companies and online wellness clinics accused of false or misleading claims about compounded GLP-1 medicines. Regulators objected in particular to claims implying compounded products were comparable to FDA-approved drugs.
- Prices
CMS publishes Medicare GLP-1 Bridge frequently asked questions
The guidance set out prior authorization rules, clinical criteria and the flat $50 copay ahead of the July 1 start, and confirmed the copay would not count toward the Part D out-of-pocket cap.
- Research
AAOS 2026 reports mixed musculoskeletal findings for GLP-1 users
Research presented at the American Academy of Orthopaedic Surgeons annual meeting associated GLP-1 use with fewer postoperative emergency department visits and lower surgical site infection rates after joint replacement, while a separate analysis linked GLP-1 use to higher osteoporosis, gout and osteomalacia risk.
- Compounding
March enforcement wave accelerates the shift away from compounded GLP-1s
The combination of 30 FDA warning letters, the Novo Nordisk patent suit and the Hims settlement made March 2026 the turning point for compounded semaglutide. Analysts described the 503B pathway as effectively closing, with patient-specific 503A compounding the only remaining route.
- Safety
Ozempic's US label still carries no NAION warning
As of the May 2026 revision, the US Ozempic prescribing information did not include a warning about non-arteritic anterior ischemic optic neuropathy, even though European, UK and Australian regulators had acted. That gap is central to the vision-loss lawsuits in MDL 3163.
- Research
Prime Therapeutics claims data show real-world one-year persistence on tirzepatide around 65%
Among 33,607 commercially insured US adults without diabetes, one-year persistence on tirzepatide was 64.0% in 2023 and 64.8% in the first half of 2024, versus 39.8% and 58.6% for semaglutide. Overall persistence nearly doubled from 33.2% in 2021.
- Research
Two large claims studies disagree on tirzepatide versus semaglutide for heart events
The STEER analysis of Komodo data in obesity with cardiovascular disease and no diabetes found a 29% lower 3-point MACE rate on semaglutide. A TriNetX analysis in older adults with type 2 diabetes and obesity found lower MACE and mortality on tirzepatide. Neither is randomized, and no head-to-head cardiovascular trial exists.
- Research
Pooled SURPASS-5 and SURPASS-6 analysis supports adding tirzepatide to basal insulin
Across 1,072 participants, adding tirzepatide to titrated basal insulin lowered HbA1c, fasting glucose and insulin dose in every subgroup examined, with no significant heterogeneity and low rates of clinically significant hypoglycemia.
- Compounding
HHS Secretary says most restricted peptides will return to Category 1 compounding
Robert F. Kennedy Jr. said on a podcast that roughly 14 of 19 peptides on FDA's Category 2 restricted list would move back to Category 1. No Federal Register notice followed immediately, and the peptides were not named.
- Research
Small real-world study raises a CPAP adherence question when tirzepatide is added
In a 20-patient Italian study, adding tirzepatide to CPAP produced far greater weight loss and better sleep apnea control than CPAP alone. But CPAP adherence at six months was 60 percent in the combination group versus 90 percent on CPAP alone — a difference that did not reach statistical significance in such a small sample but that mirrors the claims-based signal seen in the United States.
- Research
ACHIEVE-3 published in The Lancet with a 73.6% greater relative weight loss
Full results showed orforglipron 17.2 mg produced 19.7 pounds (9.2%) of weight loss versus 11.0 pounds (5.3%) with oral semaglutide 14 mg, and 37.1% versus 12.5% reached a normal A1C. The trade-off was tolerability: discontinuation for adverse events was 8.7% and 9.7% versus 4.5% and 4.9%.
- Prices
Massachusetts Group Insurance Commission votes to eliminate GLP-1 coverage for obesity alone
The GIC voted to end coverage of GLP-1 medications when used solely for weight management, following a call from the governor to cut more than $100 million from state and municipal employee health care costs. Unions including the Massachusetts Teachers Association organized against the change.
- Business
Walgreens adds weight management to its virtual healthcare service
Walgreens Virtual Healthcare began offering weight management services with on-demand follow-up visits by chat or video for medication adjustments and side effect management, part of the retail pharmacy push into GLP-1 care.
- Culture
General Mills CEO says anti-obesity drugs will have a "lasting influence" on food
At the Consumer Analyst Group of New York conference, Jeff Harmening gave the most direct acknowledgment yet from a major US packaged-food CEO, while Mondelez's CEO argued the volume effect would be minimal.
- FDA & regulation
Zepbound label drops the suicidality warning and adds intestinal obstruction
NDA 217806 supplement S-042 removed subsection 5.9 Suicidal Ideation and Behavior and the matching Medication Guide text, added a line to Severe Gastrointestinal Adverse Reactions about postmarketing reports across the GLP-1 class, and listed intestinal obstruction and severe constipation including fecal impaction under Postmarketing Experience.
- Safety
UK raids seize nearly 2,000 doses labeled as tirzepatide and retatrutide
MHRA enforcement operations in Lincolnshire and Nottinghamshire seized almost 2,000 doses of illegal weight-loss drugs along with manufacturing equipment, packaging materials and commercial vehicles. The seized products were labeled as containing tirzepatide and retatrutide, the latter an investigational drug that is not approved anywhere.
- Compounding
Novo Nordisk announces a $675 US list price for Wegovy, Ozempic and Rybelsus effective January 2027
The wholesale acquisition cost of Wegovy injection 2.4 mg and tablets 25 mg, Ozempic injection 0.5 / 1 / 2 mg and Rybelsus 7 mg and 14 mg drops to $675 a month on January 1, 2027, a cut of roughly 50 percent for Wegovy and 35 percent for Ozempic. Self-pay prices through NovoCare Pharmacy are unaffected because they already sit far below list.
- Search trends
Announced 2027 list price cut guarantees that undated cost pages will go stale
Novo Nordisk announced that Wegovy, Ozempic and Rybelsus list prices would drop to $675 per month on January 1, 2027. Any cost page without a visible verification date is now scheduled to be wrong, which makes dated pricing a durable ranking advantage.
- Safety
Falsified Mounjaro KwikPen 15 mg pens found in the UK supply chain
The MHRA warned that falsified Mounjaro KwikPen 15 mg pre-filled pens labeled with batch D873576 had been supplied through one online pharmacy. Five were identified, all faulty, most with a dose knob that came off during use. Testing confirmed they did contain tirzepatide, but because the manufacturing route was unknown sterility could not be assured, raising infection and hypersensitivity risk. The counterfeit batch number and expiry matched a genuine 7.5 mg pen.
- Competition
Novo Nordisk's licensed triple agonist UBT251 shows 19.7% weight loss in Chinese Phase 2
The GLP-1/GIP/glucagon triple agonist licensed from The United Laboratories delivered up to 19.7% mean weight loss at 24 weeks, giving Novo Nordisk a direct answer to retatrutide.
- Research
Reduced-frequency dosing case series published in Obesity
Obesity published a retrospective case series of 30 adults who had reached a weight plateau on weekly semaglutide or tirzepatide and then moved to reduced-frequency dosing, usually every other week, at their existing dose. Over a mean 36 weeks they maintained weight, body composition and metabolic syndrome improvements, though four returned to weekly dosing after regaining. JAMA covered the finding in April 2026. It is the first real clinical data behind spaced dosing, and it is not a randomized trial.
- Prices
Employers and benefit consultants weigh the list-price reset
Benefits advisers told employers the $675 list price taking effect in 2027 would mostly help members in high-deductible and coinsurance plans, while rebate-driven net costs could move differently. The change affects what patients see at the counter more than what plans ultimately pay.
- Policy
England offers general practitioners a bonus for prescribing Mounjaro
The incentive was designed to speed the NHS rollout after a slow start. For US readers it is a reminder that the same molecule reaches patients through completely different machinery abroad.
- Business
Drugs.com records the Zepbound KwikPen as the brand's newest presentation
The reference site's approval history was updated to list the multi-dose KwikPen alongside the single-dose pen, single-dose vial and multi-dose vial, with all six strengths in each.
- Research
CagriSema misses its head-to-head goal against Zepbound
In the open-label 84-week head-to-head, CagriSema 2.4/2.4 mg produced 23.0 percent weight loss against 25.5 percent for tirzepatide 15 mg on the efficacy estimand (20.2 versus 23.6 percent on the treatment-regimen estimand), and the prespecified non-inferiority endpoint was not met. That is a missed endpoint, not a rout, and pages that report it as either need the numbers. The readout reset expectations for the next generation of obesity drugs and pushed 'what comes after Zepbound' searches toward retatrutide.
- Prices
Lilly launches the Zepbound KwikPen at the same self-pay price as the vial
The KwikPen went on sale through LillyDirect starting at $299 per month, and Lilly's purchase-offer terms applied the $449 price to 7.5 mg and above for the KwikPen as well as the vial from this date. The price gap between the two presentations closed.
- FDA & regulation
FDA approves the four-dose Zepbound KwikPen, putting a month of tirzepatide in one device
FDA approved a Zepbound label expansion to include the four-dose single-patient-use KwikPen, replacing four separate weekly autoinjectors with a single dial pen. Lilly made it available through LillyDirect self-pay at the same price as vials, starting at $299 per month for 2.5 mg. The change matters practically because it moves patients from a no-priming autoinjector to a device that must be primed before every dose and needs separately purchased pen needles.
- Culture
Lilly calls Zepbound the most prescribed weight management medication of 2025
The claim, citing IQVIA National Prescription Audit data, came in the launch release for the multi-dose Zepbound KwikPen. Lilly also said one in three new branded weight-management patients started on Zepbound self-pay vials.
- Business
Eli Lilly signs a company-specific Section 232 tariff agreement
Annex II of the April 2026 pharmaceutical tariff proclamation lists an agreement between Eli Lilly and the Secretary of Commerce dated February 23, 2026, one of the deals providing tariff relief in exchange for onshoring and most-favored-nation pricing commitments.
- Research
Novo sets up higher-dose CagriSema and a full-potential trial
After the REDEFINE 4 miss, Novo Nordisk said REDEFINE 11, testing CagriSema 2.4/2.4 mg for full weight-loss potential, would report in the first half of 2027, and that a higher-dose trial combining 2.4 mg and 7.2 mg would begin in the second half of 2026. It also withdrew a phase 2 study of alternative injection devices.
- Science
Zepbound KwikPen launches through LillyDirect at $299 a month for 2.5 mg
Lilly makes the four-dose pen available to self-pay patients, matching the single-dose vial price. Reuters reports availability in all six doses. Lilly cites IQVIA data describing Zepbound as the most prescribed weight management medication in 2025.
- Compounding
FDA warns MEDVi over misbranded compounded GLP-1 products
The letter said MEDVi's website labeling implied the company was the compounder and cited "same active ingredient as Wegovy and Ozempic" claims as false or misleading. Six weeks later The New York Times profiled MEDVi as an AI success story.
- Prices
First Circuit upholds a health plan's weight-loss drug exclusion against a Section 1557 discrimination claim
In Whittemore v. Cigna, the US Court of Appeals for the First Circuit affirmed dismissal of a putative class action alleging that excluding weight-loss drugs discriminated against plan members with obesity. The court did not decide whether obesity can be a disability, holding instead that the complaint failed to plausibly allege that the plaintiff's obesity substantially limits a major life activity.
- Compounding
Hims & Hers agrees to acquire Eucalyptus for up to $1.15 billion
The Australian digital health company brought Australia, Japan, the United Kingdom, Germany and Canada into the Hims footprint, signaling a strategic pivot toward international growth as the U.S. compounded business closed.
- Culture
Analysis finds bariatric surgery volume down 13% as GLP-1 use climbs 67%
A Cedar Gate Technologies (IQVIA) analysis documented one of the clearest substitutions caused by the drugs, with average bariatric surgery costing $24,215 against about $5,200 a year for GLP-1 prescriptions.
- Research
Tirzepatide associated with fewer asthma flare-ups in adults with obesity
A retrospective cohort found asthma exacerbations in 3.0 percent of tirzepatide users versus 3.8 percent of matched non-users, and fewer events per affected patient. A separate head-to-head analysis published later in 2026 found no difference between tirzepatide and semaglutide, tempering the claim that dual agonism adds a respiratory advantage.
- FDA & regulation
European Commission approves Wegovy 7.2 mg
The EU cleared the higher maintenance dose after a CHMP positive opinion on December 12, 2025.
- Safety
Largest NAION study to date: VA cohort finds double the risk with semaglutide
A JAMA Ophthalmology target trial emulation of 102,361 US veterans with type 2 diabetes found 173 incident NAION events and a weighted cumulative risk of 0.29% with semaglutide versus 0.13% with SGLT2 inhibitors over a median 2.1 years. The authors said counseling about the risk may be warranted even though absolute incidence is low.
- Business
Novo Nordisk signals plans for Wegovy vials
Reuters reported that Novo Nordisk intends to add a Wegovy vial presentation, following Lilly's success with Zepbound vials. No Wegovy vial appears in the US label as of September 2026.
- Competition
AstraZeneca says its oral GLP-1 won both Phase 2b trials but withholds the data
AstraZeneca announced that elecoglipron met its endpoints in the VISTA obesity and SOLSTICE diabetes studies and would advance to Phase 3, without releasing weight-loss figures until June.
- Research
Lilly begins phase 3 testing of an amylin drug on top of weekly incretins
ENLIGHTEN-6 started enrolling 900 adults with persistent obesity or overweight who are already on stable weekly incretin therapy, randomizing them to eloralintide, a selective amylin receptor agonist, or placebo for about 80 weeks. It is the clearest sign that the next phase of obesity treatment is add-on therapy layered on top of tirzepatide rather than replacement of it.
- Competition
Oral ribupatide posts 12.1% weight loss at 26 weeks in Chinese Phase 2
Hengrui and Kailera reported that the once-daily tablet form of their GLP-1/GIP dual agonist reached 12.1% mean weight loss at both 25 mg and 50 mg with no plateau, supporting a Chinese Phase 3 and a global Phase 2.
- Compounding
Novo Nordisk sues Hims & Hers for patent infringement
Novo Nordisk filed suit alleging Hims & Hers infringed US Patent 8,129,343 with its compounded semaglutide products and sought a permanent injunction plus damages. Novo said its own testing found impurities of up to 86% in compounded injectable semaglutide and up to 75% in compounded oral products.
- Business
Hims & Hers shares fall 29% after the lawsuit and DOJ referral
Hims & Hers stock dropped about 29% as investors absorbed the Novo Nordisk patent suit, the withdrawn compounded pill and the HHS referral to the Justice Department. The episode put the durability of the company's weight-loss business in question.
- Safety
TriNetX cohort links GLP-1 use to higher hair loss risk
A retrospective study of 547,993 matched adults found that at 12 months GLP-1 receptor agonist users had higher odds of telogen effluvium (1.76), androgenetic alopecia (1.64) and non-scarring hair loss overall (1.40). Alopecia areata was consistently higher in controls, which the authors read as evidence these drugs do not affect autoimmune hair loss.
- Culture
Lady Gaga's halftime cameo revives celebrity GLP-1 speculation
Lady Gaga's surprise appearance during Bad Bunny's Super Bowl LX halftime show triggered a wave of online speculation using the phrase "Ozempic face." She has not confirmed using the drug and no evidence supports the claims, which illustrates how routine the gossip has become.
- Compounding
FDA says it will restrict GLP-1 ingredients used in compounded drugs
The FDA announced plans to restrict the GLP-1 active ingredients used by compounders, citing quality, safety and potential violations of federal law. The Department of Health and Human Services said it would refer Hims & Hers to the Department of Justice.
- FDA & regulation
FDA threatens seizure and injunction over compounded GLP-1 marketing
Commissioner Makary announced plans to restrict GLP-1 active ingredients headed for mass-marketed compounded products and named Hims & Hers.
- Policy
TrumpRx.gov launches with discounted GLP-1 listings
The White House launched TrumpRx.gov, a referral site connecting patients to manufacturer discount programs rather than selling drugs directly. Monthly prices for Ozempic and injectable Wegovy dropped from $1,028 and $1,349 to an average of $350 and as low as $199 depending on dose, with the Wegovy pill as low as $149.
- Research
Bone density study finds greater hip bone loss on incretin drugs in people without diabetes
A single-center retrospective study matched 255 semaglutide or tirzepatide users with 255 non-users and found greater annualized total hip bone loss among users without diabetes (-1 versus -0.6 percent) but no difference among those with diabetes. Bone loss tracked the amount of weight lost. Fracture studies point the opposite way.
- Competition
Eli Lilly posts 43% revenue growth and guides well above Novo for 2026
Eli Lilly reported fourth-quarter 2025 revenue of $19.3 billion, up 43%, with Mounjaro at $7.4 billion and Zepbound at $4.3 billion. Lilly guided to $80 billion to $83 billion in 2026 revenue, a sharp contrast with Novo Nordisk's projected decline.
- Safety
MHRA issues a UK drug safety update on semaglutide and NAION
Britain's Medicines and Healthcare products Regulatory Agency published a drug safety update on the risk of non-arteritic anterior ischemic optic neuropathy with semaglutide products, saying product information would be updated in the coming months.
- Prices
TrumpRx.gov launches with Zepbound and Mounjaro listings
The federal most-favored-nation price site went live displaying cash prices and routing buyers to manufacturers. Its Zepbound vial listing shows $1,087.00 original, $788.00 savings and $299.00 final; its Mounjaro listing shows $1,112.16 original, $613.16 savings and $499.00 final.
- Search trends
TrumpRx.gov launches and becomes a .gov competitor for drug-pricing queries
A federal site displaying discounted cash prices and issuing coupons entered a SERP previously dominated by GoodRx, SingleCare and telehealth blogs. It also created a new explainer gap, because most consumers did not know it is a coupon site rather than a pharmacy.
- Business
Two senior Novo executives head for the exit
Reporting on the guidance warning noted that two top Novo Nordisk executives were leaving as the company absorbed the 2026 outlook. The departures added to the leadership churn that began with the CEO change in May 2025.
- Culture
Lilly reports 2025 results: Mounjaro $23.0 billion, Zepbound $13.5 billion
Full-year revenue reached $65.2 billion, up 45%. Tirzepatide's two brands produced $36.5 billion between them, more than any single drug in the world.
- Business
FDA approves the Rybelsus to Ozempic tablets name change, orphaning an established search term
The proprietary name change meant a brand term with years of accumulated search volume began pointing at a product being phased out. Novo Nordisk stopped shipping Rybelsus to wholesalers in May 2026 and inventory began running out from July 2026, though the FDA prescribing information remains a single combined Rybelsus and Ozempic tablets document. Ranking Rybelsus pages went stale and the equivalent Ozempic tablets queries had almost no established answer.
- Competition
Lilly and Novo Nordisk issue sharply diverging 2026 guidance
Lilly forecast 2026 revenue of $80 billion to $83 billion, above consensus, while Novo Nordisk braced for a sales decline, underlining Lilly's stronger position in obesity and diabetes.
- Business
Mounjaro and Zepbound hit $11.7 billion in a single quarter
Fourth-quarter results showed the two brands more than doubling year over year and Lilly guiding well above Novo Nordisk for 2026. The company also said it did not expect its coming pill to cannibalize injectable sales.
- Business
Novo Nordisk introduces the Ozempic pill for the US market
Novo Nordisk announced the Ozempic tablet branding and said the product would reach US pharmacies in the second quarter of 2026. Patients on Rybelsus would need a new prescription written under the Ozempic name and NDC code.
- Research
Study links GLP-1 receptor agonists to blunted thirst signaling
A secondary analysis of 54 euvolemic participants in the European Journal of Endocrinology found a GLP-1 receptor agonist inhibited the vasopressin system, with a median 12% reduction in copeptin versus placebo, and cited prior work showing reduced fluid intake and urine output on long-term treatment. It supplies the mechanism behind the clinical advice to drink on a schedule rather than on thirst.
- Business
Lilly quietly drops three pipeline programs, including a gene therapy
Disclosures alongside earnings showed the company cutting non-core assets, including one from its $1 billion Prevail acquisition, as it concentrated resources on cardiometabolic and immunology.
- Business
Full-year 2025 results: sales DKK 309.1 billion, first guided sales decline for 2026
Sales grew 10% at constant exchange rates but operating profit fell 1% to DKK 127.7 billion after restructuring costs. Novo Nordisk guided to a 2026 adjusted sales decline of 5% to 13% at constant exchange rates, its first guided contraction of the GLP-1 era.
- Business
Novo Nordisk forecasts its first annual sales decline in nine years
Novo Nordisk guided to a 2026 sales drop of 5% to 13% at constant exchange rates, far worse than the roughly 1.4% decline analysts expected, citing "unprecedented" US pricing pressure from the most-favored-nation deal and competition. Full-year 2025 sales had risen 10% at constant currencies to DKK 309 billion.
- Compounding
Judge dismisses Eli Lilly's case against Willow Health with prejudice
A federal judge in the Central District of California threw out Lilly's Lanham Act false-advertising claims at the pleading stage and denied leave to amend, the first clean defense win among the 2025 telehealth suits.
- Competition
Pfizer's monthly GLP-1 hits its Phase 2b endpoint in VESPER-3
PF'3944, now berobenatide, produced 10% and 12.3% placebo-adjusted weight loss at week 28 on the two monthly maintenance regimens selected for Phase 3, with no plateau observed.
- Culture
Analysts trim obesity-drug market forecasts by about 30%
Reuters reported Wall Street cutting 2030 obesity-drug forecasts by roughly 30% on price erosion, with Goldman Sachs at about $105 billion (down from $130 billion) and the $150 billion target sliding from 2030 to 2035 for some analysts.
- Research
CagriSema beats semaglutide on blood sugar and weight in REIMAGINE 2
Novo Nordisk reported that CagriSema cut HbA1c by 1.91 percentage points and produced 14.2% weight loss at week 68 in adults with type 2 diabetes, beating semaglutide across all tested doses. Novo said it would discuss a diabetes regulatory pathway with authorities after further readouts.
- Research
Claims analysis shows tirzepatide is displacing first-time CPAP starts
In the six months after the December 2024 OSA approval, new tirzepatide starts among people with OSA rose 16 percent. Only 4 percent of people with OSA who started tirzepatide began CPAP within six months, compared with 22 percent of those who did not. Primary care wrote about 84 percent of the prescriptions; sleep medicine wrote 0.2 percent.
- Research
REST trial begins recruiting: the first randomized test of tapering versus stopping
A Mount Sinai Hospital team in Toronto began recruiting for REST (Recovery Effects after Semaglutide Termination), registered as NCT07294950. It is the first randomized trial designed specifically to compare gradual semaglutide dose reduction against abrupt discontinuation, measuring weight, cardiometabolic profile and the hormones governing energy balance, with completion scheduled for May 2029. Until REST reports, every claim about tapering in this class is extrapolation from pharmacology.
- Safety
Zepbound's suicidal ideation warning removed and its severe gastrointestinal section updated
The Zepbound label's revision history records both changes in February 2026: Suicidal Behavior and Ideation removed, and Severe Gastrointestinal Adverse Reactions (5.2) updated. The same month, the Wegovy label recorded the identical suicidality removal. Mounjaro was unaffected because it never carried the warning.
- Business
Second and third generic Saxenda products reach US pharmacies
Cipla USA lists a weight-management liraglutide under ANDA217234 as first marketed 2026-02-25 and Orbicular lists one as first marketed 2026-02-26, ending Teva's six-month monopoly on generic liraglutide 3 mg. Biocon Pharma follows on 2026-03-27.
- FDA & regulation
Suicidal behavior and ideation section removed from the Saxenda label
The February 2026 label revision removes the Suicidal Behavior and Ideation subsection (5.9) from Saxenda and the corresponding generic labels. A pharmacovigilance analysis published later that year notes that neither US nor European regulators have confirmed a causal relationship between GLP-1 drugs and suicidality.
- Research
Truveta records show tirzepatide outperforming semaglutide outside of trials
In 2,396 US patients on treatment for six months, tirzepatide produced 11.15% weight loss versus 8.83% for semaglutide, an adjusted difference of -2.32 percentage points (95% CI -3.17 to -1.48) — despite more semaglutide patients being on high doses.
- Safety
Court dismisses Lilly's complaint against a compounded tirzepatide telehealth seller
The Central District of California granted Willow Health Services' motion to dismiss Lilly's first amended complaint. The opinion also records that Lilly holds regulatory exclusivity for tirzepatide until at least May 2027 and that Mounjaro and Zepbound are the only FDA-approved tirzepatide medicines, both injectable only.
- Compounding
FDA proposes a rule on liposomal compounding aimed at GLP-1 copies
The FDA issued a proposed rule that would prohibit compounding using liposomal delivery, the approach behind the Hims & Hers oral product. Comments questioned both the language and the agency's statutory authority.
- Research
SURPASS-SWITCH subgroup analysis finds consistent benefit across patient types
Switching from dulaglutide to tirzepatide produced greater HbA1c and weight reductions in every prespecified subgroup tested, including by age, diabetes duration, baseline dulaglutide dose, BMI, ethnicity and sex. HbA1c gains were larger at higher baseline HbA1c and lower BMI.
- Competition
AstraZeneca signs an obesity deal with China's CSPC worth up to $18.5 billion
AstraZeneca paid $1.2 billion upfront for global rights outside China to CSPC's once-monthly injectable weight management portfolio, covering eight programs including the GLP-1/GIP agonist SYH2082.
- Research
EU declines a separate HFpEF indication for tirzepatide but adds the SUMMIT data to the label
The European Medicines Agency acknowledged that tirzepatide reduced heart failure hospitalizations and improved quality of life but noted it did not reduce cardiovascular deaths and that a weight-independent effect was not established. Because those patients are already covered by the weight management indication, a separate HFpEF indication was judged unnecessary.
- FDA & regulation
FDA approves renaming the R2 oral semaglutide from Rybelsus to Ozempic tablets
Novo Nordisk renamed the reformulated oral semaglutide product from Rybelsus to Ozempic tablets, in strengths of 1.5 mg, 4 mg and 9 mg for type 2 diabetes. The change was meant to signal that oral and injectable Ozempic are both diabetes products. The change applies to the United States only; Rybelsus continues under its own name in other markets.
- Prices
Lilly commits $3.5 billion to a Pennsylvania injectable obesity-drug plant
The Lehigh Valley site, Lilly's fourth new US location under the $27 billion pledge, will make injectable weight-loss therapies including retatrutide and is expected to be operational in 2031. Pennsylvania committed more than $100 million in incentives.
- Policy
Lilly's chief executive calls Medicare coverage a potential 'game changer' for the pill launch
David Ricks told CNBC that the Medicare access created by the November 2025 pricing deal mattered more to the orforglipron launch than the list price, because it opened a population that had been excluded by statute for two decades.
- Safety
MHRA strengthens pancreatitis warnings for tirzepatide and the whole incretin class
The UK regulator updated product information for all GLP-1 and dual GLP-1/GIP receptor agonists, naming tirzepatide, to highlight rare necrotizing and fatal acute pancreatitis. Between 2007 and October 2025 it had received 1,296 Yellow Card pancreatitis reports across the class, 19 fatal and 24 necrotizing, against roughly 25.4 million packs dispensed over five years. Prescribers were told to ask about privately prescribed GLP-1 use, which may not appear in a patient's record.
- FDA & regulation
CHMP refuses an EU heart failure indication but accepts the SUMMIT data into the label
The CHMP declined to add a separate HFpEF indication to Mounjaro (EMEA/H/C/005620/II/38) and agreed only to put the SUMMIT trial information into the EU product information. The FDA had already prompted Lilly to withdraw the equivalent US application in May 2025.
- Business
President says Eli Lilly plans six new US manufacturing plants
Reuters reported the President saying Lilly would build six new US plants, expanding on the company's previously announced $27 billion four-site program and $50 billion total US manufacturing plan.
- Prices
KFF: Medicare Advantage insurers denied 4.1 million prior authorization requests in 2024, and 80.7 percent of appeals succeeded
KFF's analysis of CMS data found Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024 and denied 7.7 percent of them, but only 11.5 percent of denials were appealed and 80.7 percent of those appeals overturned the denial.
- Business
Novo Nordisk's US GLP-1 ad spend reported at nearly $500 million for nine months
MediaRadar data reported by Reuters showed $316 million spent on Wegovy and $169 million on Ozempic in the first nine months of 2025, up 54% and 44% year over year and more than double Eli Lilly's comparable spending.
- Policy
CMS selects 15 more drugs for the next negotiation round
CMS announced an additional set of Part D and Part B drugs for price negotiation in January 2026, continuing the annual expansion of the program. The accumulating list steadily widens the share of Medicare spending under negotiated prices.
- Competition
Sun Pharma wins Indian approval for a generic semaglutide injection
Sun Pharmaceutical said India's drug regulator approved its generic semaglutide injection for chronic weight management, ahead of the Indian patent expiry in March. Several Indian makers lined up launches at steep discounts to the originator.
- Culture
Lilly releases a short film reframing obesity care around health, not appearance
The film continued the company's move away from weight-loss imagery in its advertising, a response to criticism that GLP-1 marketing fuels the cosmetic use the company says it opposes.
- FDA & regulation
EU adds the pediatric indication and SURMOUNT-5 data to Mounjaro
A single Commission decision date covers the pediatric extension and the head-to-head labeling variation.
- FDA & regulation
Zepbound KwikPen Instructions for Use issued ahead of the device's US launch
Lilly issued the FDA-approved Instructions for Use for the Zepbound KwikPen (ZEPKP-0002-IFU-20260121). It introduced a priming step required before every weekly injection, not only the first, a dose-window icon that must be visible before the needle is withdrawn, and an explicit instruction not to count clicks when dialing the dose. Pen needles are not included with the device.
- FDA & regulation
FDA approves the Mounjaro KwikPen and the Zepbound KwikPen
Both four-dose single-patient-use pens were approved on the same day, more than two years after filing, in six strengths each. The label added a new Warnings and Precautions section 5.10 telling patients never to share a KwikPen even if the needle is changed.
- Research
SURMOUNT-MAINTAIN completes, testing a step-down dose instead of stopping
The 112-week phase 3b trial at 20 US sites finished. It randomized 378 of 441 enrolled participants at week 60 to continue maximum tolerated tirzepatide, drop to 5 mg, or switch to placebo — the first randomized test of dose reduction rather than discontinuation.
- Compounding
FDA warning letter to Genogenix over unapproved GLP-1 peptides
One of a run of letters to research-chemical sellers listing tirzepatide and other GLP-1 peptides under research-use-only labeling.
- Prices
KFF: 13 state Medicaid programs cover GLP-1s for obesity
KFF published its updated Medicaid analysis naming Delaware, Kansas, Massachusetts, Michigan, Minnesota, Missouri, Mississippi, North Carolina, Rhode Island, Tennessee, Utah, Virginia and Wisconsin as the states covering GLP-1s for obesity under fee-for-service as of January 2026, and reported that Medicaid GLP-1 prescriptions rose from about 1 million in 2019 to over 8 million in 2024 with gross spending rising from about $1 billion to almost $9 billion.
- Safety
FDA warning letter to Boothwyn Pharmacy over compounded GLP-1 conditions
The letter, published February 10, cited insanitary conditions and products that did not meet their stated strength, quality or purity, underscoring the agency's safety concerns about compounded GLP-1 supply.
- Culture
Jefferies estimates GLP-1s could save US airlines $580 million in fuel
A Jefferies analysis calculated that lighter passengers could cut jet fuel costs for American, Delta, Southwest and United by as much as $580 million a year, the most-shared illustration of how far the GLP-1 economy reaches.
- FDA & regulation
Reports say the FDA's new voucher program is running behind on Lilly's pill
Trade press reported that decisions under the Commissioner's National Priority Voucher pilot, including orforglipron, were slipping past their promised timelines. Lilly told investors in January it now expected a second-quarter decision.
- Research
SURMOUNT post hoc analysis finds no increase in depression risk on tirzepatide
Pooling SURMOUNT-1, -2 and -3, researchers found PHQ-9 depression scores fell slightly more on tirzepatide than placebo by week 72, and fewer people shifted into a more severe category (18.2 versus 24.3 percent). Suicidal ideation was reported by 0.6 percent in each group. Participants with known major psychiatric illness were excluded.
- Research
SURMOUNT-OSA mediation analysis separates weight effects from sleep apnea effects
Improvements in inflammation, insulin resistance and triglycerides were mediated independently by changes in sleep apnea metrics, while blood pressure change tracked weight loss. The authors conclude that treating both the breathing disorder and the obesity is needed for full cardiometabolic benefit.
- FDA & regulation
FDA approves Orbicular's generic Victoza, later sold by Cipla
ANDA217590 was approved on 2026-01-14. Products under it are marketed by Orbicular as NDC 81607-018 and by Cipla USA as NDC 69097-920, the first liraglutide products to appear in Medicare data at under $200 per claim.
- Research
Tirzepatide associated with lower dementia risk than semaglutide or SGLT2 inhibitors
A target trial emulation in adults with type 2 diabetes found tirzepatide associated with a lower two-year dementia risk than semaglutide (hazard ratio 0.69) and than SGLT2 inhibitors (0.66), with Bell's palsy used as a falsification endpoint. The authors described the findings as hypothesis-generating and noted residual confounding remains plausible.
- Research
FDA asks drugmakers to drop the suicidal thoughts warning from GLP-1 labels
After pooling 91 placebo-controlled trials covering 107,910 patients, the FDA found no increased risk of suicidal ideation or behavior and requested removal of the warning from Saxenda, Wegovy and Zepbound labels.
- Research
Obesity Association publishes 2026 pharmacologic treatment standards ranking every approved drug
The ADA's Obesity Association division publishes 'Pharmacologic Treatment of Obesity in Adults' with a Grade A recommendation to offer obesity medications as part of initial treatment. It maps drug choice to the weight reduction needed: 10% or more points to tirzepatide or semaglutide, 5% to 10% to phentermine-topiramate, and smaller targets to naltrexone-bupropion, liraglutide, phentermine alone or orlistat.
- Search trends
FDA asks for removal of the suicidal ideation warning, stranding a generation of tirzepatide side-effect pages
FDA's January 13, 2026 request named the three products whose labeling carried the language: Saxenda, Wegovy and Zepbound. Mounjaro, as a diabetes label, never carried a suicidal ideation warning. Any Zepbound side-effect page describing that warning became inaccurate, and most of them still are; pages that attribute the warning to Mounjaro were wrong before the change as well.
- Business
Doustdar sets out 2026 priorities at the J.P. Morgan Healthcare Conference
The CEO named commercial execution and direct-to-patient expansion, pipeline progression and financial discipline as his three priorities, and said obesity 'acts a lot more as a consumer business than a traditional medication.'
- Compounding
Alabama settles with a clinic over unapproved weight-loss drugs
The Alabama Attorney General settles a lawsuit against a Cullman clinic for administering dangerous unapproved weight-loss drugs, an example of state-level enforcement running parallel to FDA's.
- Business
Lilly and NVIDIA open a joint AI lab after building a drug-discovery supercomputer
The companies said the system was the most powerful dedicated to pharmaceutical research, funded out of the revenue Lilly's incretins had generated.
- Business
2026 framed as the year of the obesity pill
With the Wegovy pill on pharmacy shelves and Eli Lilly's orforglipron months from a decision, coverage described 2026 as the year oral GLP-1s would test whether convenience and lower cash prices could broaden the market. Analysts expected pills to attract patients seeking modest weight loss rather than replacing injections.
- Research
Zepbound plus Taltz beats Taltz alone in psoriatic arthritis
In a first-of-its-kind phase 3b trial, adding tirzepatide to Lilly's own immunology drug improved joint and skin outcomes in adults with psoriatic arthritis and obesity. It was the first randomized evidence that an incretin can improve an inflammatory disease outcome when added to standard therapy.
- Research
BMJ meta-analysis quantifies weight regain after stopping obesity drugs
A synthesis of 37 studies and 9,341 participants found weight returns at about 0.4 kg per month after any weight-management medication is stopped, with cardiometabolic gains projected to fade within roughly 1.4 years. Regain was faster after a drug than after a behavioral program.
- FDA & regulation
FDA approves multi-dose tirzepatide vials for both brands
Mounjaro supplement S-041 and Zepbound supplement S-037 added the multiple-dose single-patient-use vial: 2.4 mL holding four weekly 0.6 mL doses in all six strengths, using a preserved formulation with phenol, benzyl alcohol and glycerin.
- FDA & regulation
Zepbound multi-dose vial Instructions for Use issued, with a 30-day or four-dose in-use limit
Lilly issued the FDA-approved Instructions for Use for the Zepbound multi-dose vial (ZEP-0001-MDV-IFU-20260107). The document sets a 0.6 mL per-injection volume, distinct from the 0.5 mL single-dose vial, and establishes the in-use rule that has since been the most-asked storage question for the presentation: discard after a total of 30 days at room temperature, 30 days after first use, or after four weekly doses, whichever comes first, even if medicine remains.
- Science
An Arrowhead RNA drug roughly doubles tirzepatide's weight loss in an early trial
Combining Arrowhead's RNA interference candidate with tirzepatide produced markedly greater weight loss than tirzepatide alone in a small study, one of several combination results that reframed tirzepatide as a backbone therapy rather than an endpoint.
- Business
Lilly pays Nimbus up to $1.3 billion for another oral obesity drug
The deal covered a preclinical small molecule for obesity, Lilly's second with the AI-driven biotech. It showed the company building a pipeline of pills behind orforglipron before the first one was even approved.
- Compounding
Wegovy pill launches in the United States at $149 a month for cash payers
Novo Nordisk launched the Wegovy pill at more than 70,000 US pharmacies, pricing the 1.5 mg and 4 mg doses at $149 per month for cash payers and the 9 mg and 25 mg doses at $299. Commercially insured patients could pay as little as $25 a month with the savings offer.
- Business
Wegovy pill launches in the US, the first oral GLP-1 approved for obesity
Novo Nordisk launched oral semaglutide 25 mg for weight management across more than 70,000 pharmacies and nine telehealth partners at self-pay prices of $149 to $299 a month. It recorded 3,071 prescriptions in its first four days and became the strongest GLP-1 volume launch in US history.
- Safety
FAERS analysis finds a probable tirzepatide optic neuropathy signal
An analysis of FAERS from January 2022 to June 2025 identified 28 ischemic optic neuropathy cases with tirzepatide as primary suspect, reporting odds ratio 2.599, meeting Evans criteria for a probable drug-event association. The authors paired the finding with Google Trends data showing an exponential rise in tirzepatide search interest, a reporting-bias caveat they raise themselves.
- Competition
FDA grants breakthrough therapy designation to pemvidutide in MASH
Altimmune's glucagon/GLP-1 dual agonist received breakthrough status based on 24-week Phase 2b data showing MASH resolution without worsening of fibrosis.
- Prices
GoodRx matches Novo's cash price for the Wegovy pill
GoodRx said the newly approved Wegovy pill was available at $149 per month for the two lowest doses at more than 70,000 pharmacies through its platform. The company also began connecting users to prescribers through GoodRx for Weight Loss.
- Prices
California, New Hampshire, Pennsylvania and South Carolina Medicaid programs end GLP-1 obesity coverage
Four state Medicaid programs eliminated coverage of GLP-1s for obesity treatment effective January 1, 2026, citing budget pressure. KFF's October 2025 survey had counted 16 covering states; with these cuts and North Carolina's reinstatement, the count stood at 13 in January 2026.
- Business
Semaglutide exclusivity begins expiring outside the United States
Canadian data protection lapsed in January 2026, with Indian, Chinese and Brazilian patents following in March. Together the first wave of markets covers roughly 40% of the world's population. Generic semaglutide launched in India during the first quarter.
- Prices
Harvard Pilgrim excludes all weight-loss drugs; BCBS of Massachusetts and BCBS of Michigan narrow coverage
Harvard Pilgrim Health Care excluded all weight-loss drugs including GLP-1s effective January 1, 2026, with employers over 100 employees able to buy coverage back and members required to complete a six-month behavioral modification program unless already on therapy. Blue Cross Blue Shield of Massachusetts stopped covering GLP-1s for obesity for employers with fewer than 100 employees, and Blue Cross Blue Shield of Michigan dropped weight-loss GLP-1 coverage.
- Prices
North Dakota becomes the first state to require ACA Marketplace and small-group plans to cover GLP-1s
Individual ACA plans and small-group employer plans in North Dakota began covering GLP-1 and GIP drugs under an updated essential health benefit benchmark plan that CMS approved in 2023. The benchmark language covers the drugs as therapy for prevention of diabetes and treatment of insulin resistance, metabolic syndrome or morbid obesity, which is why carriers in the state commonly apply a BMI 40 threshold.
- Prices
CMS Interoperability and Prior Authorization rule turnaround times take effect
Under CMS-0057-F, Medicare Advantage, Medicaid and CHIP, and Marketplace QHP issuers must decide standard prior authorization requests within 7 calendar days and expedited requests within 72 hours, and must give a specific denial reason. The rule excludes drugs covered under the pharmacy benefit, which is where almost all GLP-1 prior authorizations sit.
- Prices
Express Scripts and Optum Rx set their 2026 tirzepatide formulary positions
The Express Scripts National Preferred Formulary lists the Zepbound pen as covered and excludes Zepbound vials. Optum Rx's Premium formulary puts the Zepbound auto-injector at Tier 2 with prior authorization and marks the Zepbound solution, the vial, as excluded. Both cover Mounjaro for type 2 diabetes with prior authorization.
- Prices
Kansas State Employee Health Plan raises its GLP-1 BMI threshold to 35
Effective January 1, 2026, the Kansas SEHP limits weight-management GLP-1 coverage to members with a BMI of 35 or higher for all prescriptions issued or renewed after that date, with Wegovy preferred and Zepbound non-preferred unless the member has tried and failed a preferred product.
- Search trends
Lilly raises US list prices for Mounjaro and Zepbound while cash prices fall
List and cash prices moved in opposite directions, which is genuinely confusing and generates a steady stream of 'why does it say $1,086 when I paid $299' searches. Explaining the gap between list price and what anyone actually pays is one of the most useful things a cost page can do.
- Prices
Massachusetts GIC requires Vida Health prescribing for weight-loss GLP-1 coverage
From January 1, 2026, any Group Insurance Commission member on an active-employee or non-Medicare plan had to be prescribed weight-loss medication by a Vida Health provider for it to be covered under CVS pharmacy benefits, with a 90-day grace period through the end of March 2026 for existing users.
- Prices
Medicare Part D out-of-pocket cap rises to $2,100
The Inflation Reduction Act cap on annual out-of-pocket Part D spending moved to $2,100 for 2026, with a further increase to $2,400 set for 2027.
- Policy
Negotiated Medicare prices take effect for the first 10 drugs
The first round of Inflation Reduction Act negotiated prices took effect on January 1, 2026, covering 10 Part D drugs. Semaglutide was in the second round, with its negotiated price scheduled for January 1, 2027.
- Search trends
Employer coverage cuts drive a surge in insurance-denial and appeal searches
A wave of employer plans narrowing or dropping weight-loss drug coverage at the January plan year produced high-engagement community threads about losing Wegovy coverage. Search demand shifted toward denial, appeal and cash-pay alternatives, with no ranking page offering a usable appeal process walkthrough.
- FDA & regulation
Suicidal behavior and ideation warning removed from the Wegovy label
FDA issued a Drug Safety Communication on January 13, 2026 reporting that a review of 91 placebo-controlled trials covering 107,910 participants found no increased risk of suicidal behavior or ideation with GLP-1 medicines, and asked the sponsors of Saxenda, Wegovy and Zepbound to remove the warning. The Wegovy label's Recent Major Changes list records the removal as 01/2026; Zepbound's records 02/2026.
- Prices
New Jersey becomes the 26th state to enact an anti-copay-accumulator law
Drug Channels reported that New Jersey's law took the number of states requiring copay assistance to count toward patient cost-sharing limits to 26, covering an estimated 17 percent of the US commercial market, or more than 34 million people, for 2025. These laws do not apply to self-funded employer plans.
- Business
Reformulated Rybelsus is renamed to reduce patient confusion
Novo Nordisk said renaming the reformulated oral product from Rybelsus to Ozempic tablets was intended to make clear that both oral and injectable Ozempic treat type 2 diabetes, while Wegovy covers weight management. Patients still needed a new prescription to switch.
- Research
TIRTLE1 published: the first randomized trial of tirzepatide in type 1 diabetes
Twenty-four adults with type 1 diabetes and a BMI above 30 were randomized to 12 weeks of low-dose tirzepatide or placebo. Weight fell 10.3 kg versus 0.7 kg, HbA1c fell 0.4 percentage points more than placebo, and total daily insulin fell 35 percent relative to placebo. A 2026 systematic review rated the overall certainty of evidence in this area as low to very low.
- Competition
China approves Sciwind's ecnoglutide for type 2 diabetes
Sciwind Biosciences' weekly GLP-1 receptor agonist was cleared by China's NMPA for type 2 diabetes, followed by a chronic weight management approval in March 2026. Verdiva Bio holds rights outside China and is developing a weekly oral version.
- FDA & regulation
Health Canada clears Rybelsus for cardiovascular risk reduction
Health Canada approved Rybelsus to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or are at high risk. The clearance followed the US approval of the same indication in October 2025.
- Business
Wegovy 7.2 mg approved in the United Kingdom
UK regulators cleared the higher-dose semaglutide injection ahead of the US approval, with the EU following in February 2026.